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1.  INTRODUCTION 
1.1. Heterocyclic compounds 
Heterocycles are an important class of compounds, making up more than half 
of all known organic compounds1. Heterocycles are present in a wide variety of drugs, 
most vitamins, many natural products, biomolecules, and biologically active 
compounds, including antitumor, antibiotic, anti-inflammatory, antidepressant, 
antimalarial, anti-HIV, antimicrobial, antibacterial, antifungal, antiviral, antidiabetic, 
herbicidal, fungicidal, and insecticidal agents. Also, they have been frequently found 
as a key structural unit in synthetic pharmaceuticals and agrochemicals2. Some of 
these compounds exhibit a significant solvatochromic, photochromic, and biochemi-
luminescence properties.  
Most of the heterocycles possess important applications in materials science 
such as dyestuff, fluorescent sensor, brightening agents, information storage, plastics, 
and analytical reagents. In addition, they have applications in supra molecular and 
polymer chemistry, especially in conjugated polymers. 
The medicinal chemists, the true utility of heterocyclic structures is the ability 
to synthesize one library based on one core scaffold and to screen it against a variety 
of different receptors, yielding several active compounds. Almost unlimited 
combinations of fused heterocyclic structures can be designed, resulting in novel 
polycyclic frameworks with the most diverse physical, chemical and biological 
properties.  
Therefore, efficient methodologies resulting in polycyclic structures from 
biologically active heterocyclic templates are always of interest to both organic and 
medicinal chemists3. The primary objective of medicinal chemistry is the design and 
discovery of new drug compounds. 
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1.2. Drug discovery and development process 
Drug discovery and development process (figure 1.1) is one of the most 
challenging and difficult process because this process is often a matter of life and 
death for patients; their cures are in the hands of scientists and clinicians who 
discover, develop, and administer medications for prevention, management, and cure 
of disease, injuries, and other disorders4. But it takes about 12 - 15 years from 
discovery to the approved medication and requires an investment of about billion 
dollars.  
From more than a million screened molecules only few compounds is 
investigated in late stage clinical trials and is finally made available for patients4. 
There are several stages involved in the drug discovery process. They are 
• Target identification and validation 
• Assay development 
• Lead identification 
• Lead optimization 
• Preclinical development 
• Clinical development 
o Phase I 
o Phase II 
o Phase III 
• Regulatory approval 
• Life cycle management  
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Figure 1.1: Drug discovery and development process 
1.5. Quantitative Structure Activity Relationship 
QSAR involves the derivation of mathematical formulae which relates the 
biological activities of a group of compounds to their measurable physiochemical 
parameters. These parameters have major influence on the drugs activity. QSAR 
derived equation take the general form: 
Biological activity = function 
(parameters) 
 Activity is expressed as log (1/c). C is the minimum concentration required 
to cause defined biological response. Activities used in QSAR include chemical 
measurements and biological assays. Quantitative structure-activity relationships have 
long been considered a vital component of drug discovery and development, providing 
insight into the role of molecular properties in the biological activity of similar and 
unrelated compounds. QSAR includes all statistical methods, by which biological 
activities (most often expressed by logarithms of equipotent molar activities) are 
related with structural elements (Free Wilson analysis), physicochemical properties 
(Hansch analysis), or fields (3D QSAR). The CoMFA analyses provided a number of 
insights into the mechanism of agonist binding5,6. 
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1.5.1. Molecular Descriptors used in QSAR 
Molecular descriptors can be defined as a numerical representation of 
chemical information encoded within a molecular structure via mathematical 
procedure. This mathematical representation has to be invariant to the molecule’s size 
and number of atoms to allow model building with statistical methods7. 
The information content of structure descriptors depends on two major factors: 
(1) The molecular representation of compounds. 
(2) The algorithm which is used for the calculation of the descriptor. 
There are various molecular descriptors used in QSAR, these are 
1. Hydrophobic parameter 
o Partition coefficient ; log P 
o Hansch’s substitution constant; π 
o Hydrophobic fragmental constant; f, f’ 
o Distribution coefficient; log D 
o Apparent log P 
o Capacity factor in HPLC; log k’ , log k’W 
o Solubility parameter; log S  
• Electronic parameter 
o Hammett constant; σ, σ +, σ - 
o Taft’s inductive (polar) constant; σ* 
o Swain and Lupton field parameter 
o Ionization constant; pKa , ∆pKa 
o Chemical shifts: IR, NMR 
• Steric parameter 
o Taft’s steric parameter; Es 
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o Molar volume; MV 
o Van der waals radius 
o Van der waals volume 
o Molar refractivity; MR 
o Parachor 
o Sterimol 
• Quantum chemical descriptors 
o Atomic net charge; Qσ, Qπ 
o Superdelocalizability 
o Energy of highest occupied molecular orbital; EHOMO 
o Energy of lowest unoccupied molecular orbital; ELUMO 
1.5.2. 3D-QSAR 
Three-dimensional quantitative structure-activity relationships (3D-QSAR) 
involve the analysis of the quantitative relationship between the biological activity of 
a set of compounds and their three-dimensional properties using statistical correlation 
methods. 3D-QSAR uses probe-based sampling within a molecular lattice to 
determine three-dimensional properties of molecules (particularly steric and 
electrostatic values) and can then correlate these 3D descriptors with biological 
activity. 
1.6. Physiochemical parameter 
The term physicochemical properties refers to the influence of the organic 
functional groups within a molecule on its acid-base properties, water solubility, 
partition coefficient, crystal structure, stereochemistry, ionization constant (pKa), 
lipophilicity and chemical stability. All these properties influence the absorption, 
distribution, metabolism excretion (ADME) and toxicity of the molecule. To design 
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better medicinal agents, the medicinal chemist needs to understand the relative 
contributions that each functional group makes to the overall physicochemical 
properties of the molecule. Studies of this type involve modification of the molecule 
in a systematic fashion and determination of how these changes affect biological 
activity. 
The physicochemical properties of a drug molecule are dependent not only on 
what functional groups are present in the molecule but also on the spatial arrangement 
of these groups. This becomes an especially important factor when a molecule is 
subjected to an asymmetric environment, such as the human body. Because proteins 
and other biological macromolecules are asymmetric in nature, how a particular drug 
molecule interacts with these macromolecules is determined by the three-dimensional 
orientation of the organic functional groups that are present. If crucial functional 
groups are not occupying the proper spatial region surrounding the molecule, then 
productive bonding interactions with the biological macromolecule (receptor) will not 
be possible, potentially negating the desired pharmacological effect. If however, these 
functional groups are in the proper three-dimensional orientation, the drug can 
produce a very strong interaction with its receptor. It therefore is very important for 
the medicinal chemist developing a new molecular entity for therapeutic use8,9. 
1.7. Molecular Docking10 - 13 
 When the structure of the target is known (available), usually from X-ray 
crystallography, the most commonly used virtual screening method is molecular 
docking. Molecular docking can also be used to test possible hypotheses before 
conducting costly laboratory experiments. Molecular docking programs try to predict 
how a drug candidate binds to a protein target without performing a laboratory 
experiment. Molecular docking software consists of two core components. 
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 A search algorithm (sometimes called an optimization algorithm). The 
search algorithm is responsible for finding the best conformations of the 
ligand3 and protein system. A conformation is the position and orientation 
of the ligand relative to the protein. In flexible docking a conformation 
also contains information about the internal flexible structure of the ligand 
– and in some cases about the internal flexible structure of the protein. 
Since the number of possible conformations is extremely large, it is not 
possible to test all of them, therefore sophisticated search techniques have 
to be applied. Examples of some commonly used methods are Genetic 
Algorithms and Monte Carlo simulations. 
 An evaluation function (sometimes called a score function). This is a 
function providing a measure of how strongly a given ligand will interact 
with a particular protein. Energy force fields are often used as evaluation 
functions. These force fields calculate the energy contribution from 
different terms such as the known electrostatic forces between the atoms 
in the ligand and in the protein, forces arising from deformation of the 
ligand, pure electron-shell repulsion between atoms and effect from the 
solvent in which the interaction takes place. 
 
An example of a drug candidate ( grey color) binding to a target (black color). The 
small filled circles represent solvent (water) molecules. 
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1.8. Molecular Docking Softwares 
 Molecular docking programs are widely used modeling tools for predicting 
ligand binding modes and structure based virtual screening.14 
 DOCK - University of California San Francisco. 
 AUTODOCK - Scripps Research Institute.  
 MOLEGRO VIRTUAL DOCKER  - Molegro APS, University of Aarhus, 
Denmark. 
 GRAMM - Centre of Bioinformatics, University of Kansas, USA. 
 HEX - University of Aberdeen, UK. 
1.9. Lipinski's Rule of Five 
 Lipinski's Rule of Five is a rule of thumb to evaluate drug likeness, or 
determine if a chemical compound with a certain pharmacological or biological 
activity has properties that would make it a likely orally active drug in humans. The 
rule was formulated by Christopher A. Lipinski in 1997, based on the observation that 
most medication drugs are relatively small and lipophilic molecules.15 
 The rule describes molecular properties important for a drug's 
pharmacokinetics in the human body, including their absorption, distribution, 
metabolism, and excretion ("ADME").  
 The rule is important for drug development where a pharmacologically active 
lead structure is optimized step-wise for increased activity and selectivity, as well as 
drug-like properties as described by Lipinski's rule. The modification of the molecular 
structure often leads to drugs with higher molecular weight, more rings, more 
rotatable bonds, and a higher lipophilicity.  
 The ‘Rule of 5’ 16 states that poor absorption or permeation of orally 
administered drugs are more likely when. 
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1) There are more than 5 H-bond donors (expressed as the sum of OHs 
and NHs) 
2) The Molecular Weight is over 500 Daltons 
3) The Log P is over 5 (or MLogP is over 4.15) 
4) There are more than 10 H-bond acceptors (expressed as the sum of Ns 
and Os) 
5) Compound classes that are substrates for biological transporters are 
exceptions to the rule. 
To evaluate drug likeness better, the rules have spawned many extensions 
• Partition coefficient log P in -0.4 to +5.6 range 
• Molar refractivity from 40 to 130 
• Molecular weight from 160 to 500 
• Number of atoms from 20 to 70 includes H-bond donors [e.g.OHs and 
NHs] and H-bond acceptors [e.g.; Ns and Os]. 
• Polar surface area no greater than 140 Ǻ 
Exception to the ‘Rule of 5’: 
Compound classes that are substrates for biological transporters: 
 Antibiotics 
 Fungicides-Protozoacides -antiseptics 
 Vitamins 
 Cardiac glycosides. 
1.10. Nitorgen Based Heterocycles 
 The nitrogen based heterocycles were involved at the very beginning of life 
in the genesis of DNA and plays an essential role in many living systems. The nucleic 
acid based adenine; guanine, cytosine and thymine are derivatives of the aromatic  
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nitrogen heterocycles.  
1.11. Benzimidazole 
 Benzimidazole is a heterocyclic aromatic organic compound. This bicyclic 
compound consists of the fusion of benzene and imidazole. Benzimidazole, in an 
extension of the well-elaborated imidazole system, has been used as carbon skeletons 
for  N-heterocyclic carbenes. The NHCs are usually used as ligands for transition 
metal complexes. They are often prepared by deprotonating an N,N'-disubstituted 
benzimidazolium salt at the 2-position with a base.17 
  Benzimidazole, as the name implies is a bicyclic ring system in which 
benzene has been fused to the 4 and 5 position of the hetero cycle (imidazole). A basis 
for interest in the benzimidazole ring system as a nucleus from which to develop 
potential chemotherapeutic agents was established in the 1950’s when it was found 
that 5,6,-dimethyl-l-(alpha-D-ribofuranosyl) benzimidazole was an integral part of the 
structure of the vitamin B12.18 
1.12. Chemistry of Benzimidazoles 
 Benzimidazole is a white to slightly beige solid; melting at 172 °C, boils at 
360 °C, slightly soluble in water, soluble in ethanol. It is a dicyclic compound having 
imidazole ring (containing two nitrogen atoms at nonadjacent positions) fused to 
benzene. Benzimidazole and its derivatives are used in organic synthesis and 
vermicides or fungicides as they inhibit the action of certain microorganisms. 
Examples of benzimidazole class fungicides include benomyl, carbendazim, 
chlorfenazole, cypendazole, debacarb, fuberidazole, furophanate, mecarbinzid, 
rabenzazole, thiabendazole, thiophanate. Benzimidazole structure is the nucleus in 
some drugs such as proton pump inhibitors and anthelmintic agents. 
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Product Identification: 
 CAS NO :  51-17-2 
       EINECS NO :  200-081-4 
       FORMULA :  C7H6N2 
       MOL WT :  118.14 
       SYNONYMS :  1H-Benzimidazole; 1,3-benzodiazole; benzoglyoxaline;  
                                      azindole; N,N'-methylenyl-o-phenylenediamine;  
     3-azaindole; o-benzimidazole; benzoimidazole; BZI;  
      1,3-diazaindene; 
Physical and Chemical Properties: 
Physical state    :  Slightly Beige Powder 
Melting point    :  172 °C 
Boiling point    :  360 °C 
Specific gravity        :  1 
Solubility in water   :  Slightly 
Auto ignition    :  538 °C 
Nfpa ratings    :  Health- 2 ; Flammability- 1; Reactivity- 0 
Flash point    :  143 °C 
Stability    :  Stable under normal temperatures and 
conditions 
1.13. Benzimidazole from Natural Sources 
 The most prominent benzimidazole compound in nature is N-ribosyl-
dimethylbenzimidazole, which serves as an axial ligand for cobalt in vitamin B12. 
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1.14. Preparation of Benz
 The synthetic pathway to the various benzimidazole usually proceeds 
through two steps; first the construction of benzene ring containing the desired 
substituents and 1-2 diamine grouping followed by the ring closer of the 1
diaminobenzene (o-phenylenediamine) derivative to construct the imidazole ring. In 
many cases this ring closure is the final step in the synthesis of the desired 
benzimidazole. However in the other instances this ring closure is followed by 
extensive derivatization of th
 The usual synthesis involves condensation of
phenylenediamine with
N
N
By altering the carboxylic acid used, this 
substituted benzimidazoles.
NH2
NH2
 
 
Vitamin B12 
imidazole 
e ring system of the existing exocyclic substituents.
 formic acid or the equivalent trimethyl orthoformate
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∆
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 Generally, the synthesis of benzimidazoles involves the treatment of 1,2-
phenylenediamine either with carboxylic acids under strongly acidic conditions or 
with aldehydes under oxidative conditions.21,22 
NH2
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 Synthetic approaches to 2-substituted benzimidazoles from 2-nitroanilines as 
starting material have been reported. 
NO2
NH2
SnCl2. 2H2O
R2CO2H
N
N
H
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R1 R1
 
1.15. Chromene 
 
Among the widespread heterocyclic compounds, oxygen heterocycles occupy 
a distinct position because of their wide natural abundance and broad biological as 
well as pharmaceutical significance23. In these particular classes of O-heterocycles, 
‘chromene’ heterocyclic scaffolds represent a privileged structural motif well-
distributed in natural products with a broad spectrum of potent biological activities. 
The word chromones is derived from the Greek word chroma, meaning “color”, 
Chapter 1 Introduction 
 
Dept. of Pharmaceutical chemistry, JKKNCP.  
 
Page | 24
which indicates that many chromone derivatives exhibit a broad variation of colors.  
The compound in which benzene ring is fused to a 4H pyran ring is known as 4H-
chromene (4H-l -benzopyran). Chromene constitute the basic backbone of various 
types of polyphenols and widely found in natural alkaloids, tocopherols, flavonoids, 
and anthocyanins.  The benzopyran nucleus include some structural skeletons such as 
chromane, 2H-chromene and 4H-chromene (figure 1.4) 
 
Figure 1.4. Structural skeletons of chromene 
1.16. Natural occurrence and pharmacological activity of chromone and its 
derivatives 
  Chromones are a group of naturally occurring compounds that are ubiquitous 
in nature, especially in plants, such as flavones and isoflavones. Flavones and 
isoflavones have been of interest for many years, as they have shown a broad range of 
biological activities, which are not limited to antioxidant24, anti-inflammatory25 and 
antiviral effects26. Figure 1.5 shows natural and synthetic chromone heterocyclic 
compounds. On the other hand, chromen ring acts as an essential chromophore in 
recent drug discovery. 
Chromone was obtained from the flower of Wisteria sinensis that exhibit 
organoleptic property. An additional naturally occurring chromone was uvafzlelin that 
isolated from the stems of Uvaria ufielii which shows broad spectrum of antimicrobial 
activity against gram-positive and acid-fast bacteria.  Vitamin E was an evident 
example for the naturally occurring chromone, which possess antioxidant activity. 
Conrauinone A was a naturally occurring fused ring chromone, has been isolated from 
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the bark of the tree Millettia conraui and potentially utilized for the treatment of 
intestinal parasites. Another natural compound was Erysenegalensein C which has 
been extracted from the bark of Erythrina senegalensis and found potential use in the 
treatment of stomach pain, female infertility and gonorrhea. A number of 
biologically-active chromones have been isolated from Piper gaudichaudianum and 
from P. aduncum and these chromones have been shown to exhibit anti-fungal and 
antitumor properties27. 
 
Figure 1.5. Natural and synthetic chromone containing heterocyclic compounds 
The rigid bicyclic chromone fragment has been classified as a privileged 
structure in drug discovery, due to its use in a wide variety of pharmacologically 
active compounds such as anticancer, anti-HIV, antibacterial and anti-inflammatory 
agents28. Presence of chromene-based structure in a molecule is often associated with 
its capacity to prevent diseases. Few naturally occurring chromene exhibit 
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antimicrobial, antitumor, antiviral and mutagenic, antiproliferative and central 
nervous system (CNS) activities29. Some chromones are sex pheromones. Numerous 
synthetic derivatives of naturally occurring chromene have found use in 
pharmaceuticals, particularly as antifungal and antimicrobial agents. Certain 2- amino 
chromene derivatives are used in cosmetics and pigments industry30. Several 
chromone derivatives have also been reported to act as kinase inhibitors, to bind to 
benzodiazepine receptors and as efficient agents in the treatment of cystic fibrosis31. 
Some chromene derivatives might prove useful synthetic intermediates for the 
synthesis of certain naturally occurring substances, such as Miroestrol32.  A key 
feature is that the lipophilic nature of the benzopyran derivatives helps to cross the 
cell membrane easily. Chromene derivatives are also plays important role in the 
production of highly effective fluorescent dyes for synthetic fibers, daylight 
fluorescent pigments and electro photographic and electroluminescent devices.  
1.17. Cancer 
Among various diseases, cancer has become a big threat to human beings 
globally.  Cancer is also known as a malignant tumor or malignant neoplasm, which is 
a group of diseases involving abnormal cell growth with the potential to invade or 
spread to other parts of the body33. Not all tumors are cancerous; benign tumors do 
not spread to other parts of the body. Cancer results from a series of molecular events 
that fundamentally alter the normal properties of cells. In cancer cells the normal 
control systems that prevent cell overgrowth and the invasion of other tissues are 
disabled. These altered cells divide and grow in the presence of signals that normally 
inhibit cell growth. Therefore they no longer require special signals to induce cell 
growth and division. As these cells grow they develop new characteristics, including 
changes in cell structure, decreased cell adhesion, and production of new enzymes. 
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These heritable changes allow the cell and its progeny to divide and grow, even in the 
presence of normal cells that typically inhibit the growth of nearby cells. Such 
changes allow the cancer cells to spread and invade other tissues34. 
Six characteristics of cancer have been proposed: 
o Self-sufficiency in growth signaling 
o Insensitivity to anti-growth signals 
o Evasion of apoptosis 
o Enabling of a limitless replicative potential 
o Induction and sustainment of angiogenesis 
o Activation of metastasis and invasion of tissue. 
Cancer is a leading cause of death group worldwide and accounted for 7.4 
million deaths (around 13% of all deaths) in 200435. More than 70% of all cancer 
deaths occurred in low- and middle-income countries. Deaths from cancer worldwide 
are projected to continue rising, with an estimated 11.5 million deaths in 203036. 
 Globally, the five most common cancers considered in both sexes such as 
• Lung (1,824,701; 13%),   
• Breast (1,676,633; 11.9%),   
• Colorectal (1,360,602; 9.7%),   
• Prostate (1,111,689; 7.9%), and  
• Cervix uteri (527,624; 3.7%). 
The estimated five most common cancers in men is listed below and death due to 
these cancers as 2,769,670. 
• Lung (16.7%),   
• Prostate (15%),  
• Colorectum (10%),  
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• Stomach (8.5%) and  
• Liver (7.5%)  
In women, the five most common cancers is listed below, and these cancers with a 
total of 3,721,266 cases. Death due to these cancers was 1,675,069.  
• Breast (25.2%),  
• Colorectum (9.2%),  
• Lung (8.8%),  
• Cervix uteri (7.9%), and  
• Corus uteri (4.8%)  
1.17.1. Lung cancer 
Lung cancer happens when the cells in lungs start to grow in an uncontrolled 
way and form tumors. Tumors are lumps of tissue made up of abnormal cells. Lung 
cancer that starts in the lung is called primary lung cancer; if the cancer started in 
another part of the body and metastasizes to the lung, it is called secondary lung 
cancer. 
1.17.2. Causes of Lung cancer 
Primary lung cancer is caused by the out-of-control growth of cells that do not 
die in the normal cell pattern. The cause of lung cancer may not always be known. 
Carcinogens are those things that can cause cancer. Normal cells in the lung can be 
affected by carcinogens in the environment, genetic factors, or a combination of those 
factors. Exposure to carcinogens may form molecules in the body called free radicals 
which damage cells and alter the DNA of the cell. This damage may cause cancer. 
Environmental factors include things such as smoking, secondhand smoke, radon gas, 
air pollutants, asbestos, heavy metals, and chronic dust exposure. Genetic factors may 
include an inherited (passed from parent to child) or a genetic mutation.  
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 Lung cancers are generally divided into five types, which are based on how it looks 
under the microscope.  
• Non-small cell lung cancer 
• Small cell lung cancer 
• Mesothelioma 
• Carcinoid 
• Sarcoma 
Among these NSCLC and SCLC represent about 96% of all lung cancers. 
These two types of lung cancer are I dentified by the size of abnormal cells and the 
way the cancer spreads in the body. 
  Small cell cancer (SCLC) tends to grow more quickly than non-small cell 
cancer. Because it grows more quickly, SCLC is often found when it has spread 
outside of the lung.  
1.17.3. Stages of small cell lung cancer 
Small cell lung cancer is staged as ‘limited’ or ‘extensive’. ‘Limited’ means 
that it is only in one lung. ‘Extensive’ means that is has spread to other parts of body. 
1.17.4. Stages of non-small cell lung cancer 
Non-small cell lung cancer has four stages – one to four. These tell how much 
it has spread to other parts of your body. Stage four is the most widely spread, or 
advanced. 
 
Stage 1 
The cancer is only in lungs and is not in any of lymph glands 
(part of the immune system which helps the body fight infection). 
Stage 2 
Stage 2A 
 
 
The cancer is small but cancer cells have spread to the lymph 
glands nearest to affected lung.  
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Stage 2B 
The cancer is slightly larger and has spread to the lymph glands 
nearest affected lungs. Or, the cancer cells have spread to another 
area such as chest wall. 
Stage 3 
 
Stage 3A 
 
 
 
Stage 3B 
 
Cancer cells have spread to the lymph glands furthest away from 
your affected lung. Or, the cancer is in the lymph glands nearest 
to your affected lung, and cancer cells have spread to either your 
chest wall or the middle of chest. 
The cancer cells have spread to the lymph glands in the other side 
of chest or to the lymph glands above collarbone. Or, there is 
more than one tumour in lung. Or, the tumor has grown into 
another area in chest such as heart or gullet. Or, there is fluid 
around lungs that contains cancer cells. 
 
Stage 4 The cancer has spread to another part of body such as liver or 
bones. 
The symptoms of lung cancer can include: 
o Coughing up blood 
o A persistent cough 
o Breathlessness 
o Wheezing 
o Hoarseness 
o Chest or shoulder pain 
o Tiredness 
o Weight loss 
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1.17.5. Treatment of Lung Cancer 
Possible treatments for lung cancer include surgery, chemotherapy, radiation 
therapy, targeted therapy or a combination of these. 
Lung cancer treatments fall into two 
Local therapy: Surgery and radiation therapy are local therapies. They remove or 
destroy cancer tumors in the lungs. If lung cancer has spread to other parts of the 
body, such as other organs or bones, the doctors may use one of these local therapies 
to control the disease in those specific areas as well. 
Systemic therapy: Chemotherapy and targeted therapies are systemic therapies. 
These drugs enter the bloodstream to destroy or control cancer everywhere in the 
body. Systemic therapy is taken by mouth or given through a vein in the arm or a port 
that is inserted in chest (intravenous). 
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2. REVIEW OF LITRATURE 
1. El-Sayed Ali et al., studied “Synthesis of some new 4-oxo-4H-chromene 
derivatives bearing nitrogen heterocyclic systems as antifungal agents”.37 
 
2. Batista et al., studied “Natural chromenes and chromene derivatives as 
potential anti-trypanosomal agents”. 38  
 
3. Dyrager et al., studied “Design, synthesis, and biological evaluation of 
chromone-based p38 MAP kinase inhibitors”.39 
 
4. Al-Said et al., studied “Dapson in heterocyclic chemistry, part VIII: synthesis, 
molecular docking and anticancer activity of some novel sulfonyl 
biscompounds carrying biologically active 1, 3-dihydropyridine, chromene 
and chromenopyridine moieties”40. 
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5. Azab et al., studied “Microwave-assisted synthesis of novel 2H-chromene 
derivatives bearing phenyl thiazolidinones and their biological activity 
assessment”.41 
 
6. Mohamed et al., studied “Green chemistry: new synthesis of substituted 
chromenes and benzochromenes via three-component reaction utilizing 
rochelle salt as novel green catalyst”.42 
 
7. Keri et al., describes the “Chromones as a privileged scaffold in drug 
discovery: A review”. The present review focuses on the pharmacological 
profile of chromone derivatives in the current literature with an update of 
recent research findings on this nucleus and the perspectives that they hold for 
future research.43 
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8. Vichai et al., studied on “Sulforhodamine B colorimetric assay for 
cytotoxicity Screening”. The sulforhodamine B (SRB) assay is used for cell 
density determination, based on the measurement of cellular protein content. 
The method described here has been optimized for the toxicity screening of 
compounds to adherent cells in a 96-well format. After an incubation period, 
cell monolayer are fixed with 10% (wt/vol) trichloroacetic acid and stained for 
30 min, after which the excess dye is removed by washing repeatedly with 1% 
(vol/vol) acetic acid. The protein-bound dye is dissolved in 10 mM Tris base 
solution for OD determination at 510 nm using a microplate reader. The 
results are linear over a 20-fold range of cell numbers and the sensitivity is 
comparable to those of fluorometric methods. The method not only allows a 
large number of samples to be tested within a few days, but also requires only 
simple equipment and inexpensive reagents. The SRB assay is therefore an 
efficient and highly cost-effective method for screening.44 
9. Mohamed et al., synthesized various (2- substituted phenyl) 
benzimidazoles45. 
N
N
N
R
R
X
 
R=CH3, CH2CH3, Ph 
10. Chari et al., reported the synthesis of benzimidazoles through the coupling of 
aldehydes with ortho phenylenediamine by using highly acidic nanoporous 
aluminosilicate with 3D structure and cage-type porous as the catalyst46. 
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N
H
N
Ar
 
11. Kamal et al., reported the synthesis of 2-aryl-1-aryl-methyl-1H-
benzimidazoles by using ceric(IV) ammonium nitrate as catalyst47. 
N
N
Ar
Ar
 
12. Salehi et al., synthesized 2-aryl-1-arylmethyl-1H-1, 3-benzimidazoles by 
using silica sulfuric acid as catalyst48. 
N
H
N
R2
R1
R1
 
13. Alajarin et al., reported the synthesis of pyrido [1, 2-a] benzimidazole 
derivatives42. 
N
N
Ar
H
R1 R2
 
14. Jesudason et al. synthesized N-Mannich bases of benzimidazole derivatives49. 
 
N
N
R2
R1
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R1 = H, CH3, -CH=CH-C6H5 
R2 = -N(CH3)2, -N(C2H5)2, -N(C6H5)2 
15. Pawar et al., Synthesized various N-alkyl and N-acyl derivatives of 2-(4-
thiazolyl)-1H-benzimidazoles and screened for their antifungal and 
antibacterial activities50. 
N
N
R
N
S
 
16. Yunhe et al., synthesized some benzimidazole derivatives and screened for 
antibacterial activity against Staphylococcus aureus and Escherichia coli51. 
 
 
 
 
 
 
 
17. Sivakumar et al. synthesized some novel 2-(6-fluorochroman-2-yl)-1-
alkyl/acyl/aroyl-1H-benzimidazoles and screened for antibacterial activity 
against Salmonella typhimurium53. 
 
N
N
O F
R
 
N
N
Cl
Cl
NH
R2R1N
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18. Ramya  et al., synthesized some novel 5-(nitro/bromo)-styryl-2-
benzimidazoles and screened in vitro anti-tubercular activity against 
Mycobacterium Tuberculosis  H37 Rv, anti-bacterial activity against 
Staphylococcus aureus, Escherichia coli, Enterococcus faecalis, Klebsiella 
pneumoniae bacterial strains and anti-fungal activity against Candida albicans 
and Asperigillus fumigatus fungal strains54. 
N
N
H
H
H
R
R1
 
19. David et al. synthesized some novel benzimidazole derivatives and screened 
for their in vitro (rat tunica muscularis mucosae) and in vivo tests (Bezold–
Jarisch reflex in rat and gastrointestinal motility and spontaneous motility in 
mice) 55. 
20. Maria et al. synthesized new benzimidazole-4-carboxamides and 
Carboxylates and screened for serotonergic 5-HT4 and 5-HT3 receptor 
antagonistic property56. 
N
NH
X
O
YR
 
R= H, Cl 
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3. AIM & OBJECTIVE 
Aim: 
The main aim of this proposed research work is to design and synthesize a 
novel class of (E)-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one 
derivatives and  characterization by using  IR, 1H NMR, 13C NMR, and mass 
spectroscopy. Further these novel set of compounds will be screened for various 
pharmacological activities. 
 Objective: 
• Design and synthesize (E)-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl) vinyl)-4H-
chromen-4-one derivatives. 
• Develop the efficient methodologies for accomplishing their synthesis. 
• Elucidate the structure of synthesized molecule by IR, 1H NMR, 13C NMR, 
and mass spectroscopy. 
• Perform the quantitative structure activity relationship (QSAR) of newly 
synthesized bioactive compounds. 
• Molecular docking studies for newly designed compounds using 
AUTODOCK software 
• Biological evaluation of newly synthesize compounds such as, In vitro Anti 
cancer activity 
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4. SCHEME OF THE WORK 
 
Step 1: 
 
 
 
 
 
Step 2: 
 
 
 
 
Step 3: 
 
 
(E)-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one Derivatives 
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Table 4.1: chemical structure of newly designed molecule 
 
 
Sl. No Compound code R 
1 R1 6-Cl 
2 R2 7-F 
3 R3 6-CH3 
4 R4 -H 
5 R5 6,7-Cl 
6 R6 6-F 
7 R7 6-OCH3 
8 R8 6-Br 
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5. EXPERIMENTAL SECTION 
5.1. Materials and methods 
All the chemicals were purchased from sigma Aldrich U.S.A. Analytical TLC 
was performed on Precoated sheets of silica gel G/UV-254 of 0.2mm thickness 
(Macherey-Nagel, Germany) using analytical grade solvent and visualized with iodine 
spray (10% w/w I2 in silica gel) or UV light. We also used bioinformatics tools, 
biological databases like PDB (Protein Data Bank) and software’s like Autodock and 
ACD ChemSketch. The PDB (Protein Data Bank) is the single worldwide archive of 
Structural data of Biological macromolecules, established in Brookhaven National 
Laboratories (BNL). It contains Structural information of the macromolecules 
determined by X-ray crystallographic, NMR methods etc. Auto Dock is an automated 
docking tool. It is designed to predict how small molecules, such as substrates, bind to 
a receptor of known 3D structures. Argus lab also one of the automated docking tool. 
5.2. Equipment and analytical instrument 
Melting point was determined in capillary tubes and is uncorrected. IR spectra 
were taken as KBr pellets for solids on Perkin Elmer Spectrum FT-IR. 1H NMR 
(400MHz) and 13C NMR (100 MHz) spectra were recorded in DMSO-d6 solution 
with TMS as an internal standard on Bruker instrument. Spin multiplicities are given 
as s (singlet), d (doublet), t (triplet) and m (multiplet). Coupling constant (J) is given 
in hertz. Mass spectra were recorded on a thermo Finnigan LCQ Advantage MAX 
6000 ESI spectrometer. 
5.3. General procedure for the synthesis of title compounds 
Step 1: Synthesis of 2-methyl-1H-benzo[d]imidazole 
 Place 5.43g of o-phenylene diamine, 20ml of water and 5.4g of acetic acid in 
RBF. 
 Reflux in a water bath for 45 minutes. 
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 Cool and add 10% ammonia solution slowly with constant shaking. 
 Filter the precipitated product. 
 Recrystallise it from 10% aqueous ethanol and activated charcoal. 
 
 
Step 2: 2-methyl-5-nitro-1H-benzo[d]imidazole 
 2-methyl-1H-benzo[d]imidazole adds 5 mL of Con. HNO3, 5 mL of Con 
H2SO4 and reflux for 30 mints. 
 After that pour the reaction mixture into cold water and shack vigorously. The 
yellow colour of 2-methyl-5-nitro-1H-benzo[d]imidazole was precipitated out. 
 
Step 3: (E)-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one 
Derivatives 
 1mmole of 2-methyl-1H-benzo[d]imidazole and add 1mmole of various 
substituted chromen 3 carboldehyde dissolved in ethanol. 
 Add 10 mL of Glacial Acetic acid and reflux for 1 hr.  
 The completion of reaction monitor by using TLC using ethyl acetate and 
petroleum ether (50:50) as mobile phase.  
 Upon completion of reaction, the reaction mixture was filtered, washed with 
acetic acid or ethanol and dry using vacuum. 
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(E)-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one Derivatives 
  
Sl. No Compound code R 
1 R1 6-Cl 
2 R2 7-F 
3 R3 6-CH3 
4 R4 -H 
5 R5 6,7-Cl 
6 R6 6-F 
7 R7 6-OCH3 
8 R8 6-Br 
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6. CHARECTERIZATION OF TITLE COMPOUNDS 
6.1. Spectral data for synthesized compound 
6.1.1. IR spectral data 
 
 
Figure.6.1. IR Spectra for compound R1 
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Figure.6.2. IR Spectra for compound R2 
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Figure.6.3. IR Spectra for compound R3 
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Figure.6.4. IR Spectra for compound R4 
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Figure.6.5. IR Spectra for compound R5 
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Figure.6.6. IR Spectra for compound R6 
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Figure.6.7. IR Spectra for compound R7 
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Figure.6.8. IR Spectra for compound R8 
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6.1.2. NMR spectral data 
 
 
 
 
 
Figure.6.9. 1H NMR spectrum of compound R1 
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Figure.6.10. 13C NMR spectrum of compound R1 
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Figure.6.11. 1H NMR spectrum of compound R7 
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Figure.6.12. 13C NMR spectrum of compound R7 
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6.1.3. Mass Spectra 
 
 
Figure 6.13: Mass Spectra of Compound R1 
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Figure 6.13: Mass Spectra of Compound R4 
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6.2. CHARACTERIZATION OF TITLE COMPOUNDS 
6.2.1. (E)-6-chloro-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one 
(R1) 
 
 
C18H10ClN3O4; MP: 218-2200C; Orange solid; 1H NMR (400 MHz, DMSO) δ 8.39 (s, 
1H), 8.07 (d, J = 7.1 Hz, 1H), 8.10 (m, 2H), 7.86 – 7.77 (m, 3H) 6.39 – 6.37 (d, 1H), 
6.65 (s, 1H), 5.0 (s, NH). 13NMR (101 MHz, DMSO) δ 178.5, 163.2, 155.3, 144.3, 145.0, 
141.5, 139.8, 136.4, 145.0, 130. 6, 129.0, 128.8, 125.5, 125.3, 119.6, 118.6, 116.1, 112.2. 
IR (KBr): 3158, 3095, 1634, 1644, 724; ESI-MS: m/z 367.74; Elemental Analysis: C, 
58.79; H, 2.74; Cl, 9.64; N, 11.43; O, 17.40.  
 
6.2.2. (E)-7-fluoro-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one 
(R2) 
 
 
 
C18H10FN3O4; MP: 210-2120C; Yellow solid; 1H NMR (400 MHz, DMSO) δ 8.39 (s, 
1H), 8.17 (d, J = 7.1 Hz, 1H), 8.10 (m, 2H), 7.56 – 7.67 (m, 3H) 6.36 – 6.31 (d, 1H), 
6.65 (s, 1H), 5.0 (s, NH). 13NMR (101 MHz, DMSO) δ 178.5, 163.2, 155.3, 144.3, 145.0, 
141.5, 139.8, 136.4, 145.0, 130. 6, 128.7, 128.8, 125.5, 125.3, 119.6, 117.6, 116.1, 111.2. 
IR (KBr): 3157, 3095, 1644, 1317, 1124, 824, 726; ESI-MS: m/z 351; Elemental 
Analysis: C, 61.54; H, 2.87; F, 5.41; N, 11.96; O, 18.22. 
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6.2.3. (E)-6-methyl-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-
one (R3) 
 
 
C19H13N3O4; MP: 200-2020C; Orange solid; 1H NMR (400 MHz, DMSO) δ 8.29 (s, 1H), 
8.07 (d, J = 7.1 Hz, 1H), 8.10 (m, 2H), 7.56 – 7.67 (m, 3H) 6.36 – 6.31 (d, 1H), 6.65 (s, 
1H), 5.0 (s, NH), 2.33 (T, 3H). 13NMR (101 MHz, DMSO) δ 178.5, 163.2, 155.3, 144.3, 
145.0, 141.5, 139.8, 136.4, 145.0, 130. 6, 128.7, 128.8, 125.5, 125.3, 119.6, 117.6, 116.1, 
111.2. 20.98 IR (KBr): 3158, 3095, 2940, 1644, 1435, 1374, 834, 637; ESI-MS: m/z 347; 
Elemental Analysis: C, 65.70; H, 3.77; N, 12.10; O, 18.43. 
 
6.2.4. (E)-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one (R4) 
 
 
C18H11N3O4; MP: 220-2220C; Orange solid; 1H NMR (400 MHz, DMSO) δ 8.29 (s, 2H), 
8.07 (d, J = 7.1 Hz, 2H), 8.10 (m, 2H), 7.67 (s, 1H), 7.56 – 7.47 (m, 4H),  6.36 – 6.31 (d, 
2H), 6.65 (s, 2H), 5.0 (s, NH),. 13NMR (101 MHz, DMSO) δ 178.5, 163.2, 155.3, 144.3, 
145.0, 141.5, 139.8, 136.4, 145.0, 130. 6, 128.7, 128.8, 125.5, 125.3, 119.6, 118.2, 
115.90, 111.2.IR (KBr): 3159, 1641, 1499, 1215, 824, 725, 637; ESI-MS: m/z 333; 
Elemental Analysis: C, 64.86; H, 3.33; N, 12.61; O, 19.20. 
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6.2.5. (E)-6,7-dichloro-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-
4-one (R5) 
 
 
C18H9Cl2N3O4; MP: 221-2230C; Orange solid; 1H NMR (400 MHz, DMSO) δ 8.49 (s, 2H), 
8.37 (d, J = 7.1 Hz, 2H), 8.14 (m, 2H), 7.77 (s, 1H), 7.46 – 7.37 (m, 3H),  6.36 – 6.31 (d, 
2H), 6.55 (s, 2H), 5.2 (s, NH),. 13NMR (101 MHz, DMSO) δ 178.5, 163.2, 155.3, 144.3, 
145.0, 141.5, 139.8, 136.4, 145.0, 130. 6, 128.7, 128.8, 125.5, 125.3, 119.6, 118.2, 
115.90, 115.2.IR (KBr): 1644, 1468, 1336, 824, 725, 637; ESI-MS: m/z 402; Elemental 
Analysis: C, 53.75; H, 2.26; Cl, 17.63; N, 10.45; O, 15.91. 
 
6.2.6. (E)-6-fluoro-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one 
(R6) 
 
 
C18H10FN3O4; MP: 210-2120C; Yellow solid; 1H NMR (400 MHz, DMSO) δ 8.39 (s, 
1H), 8.17 (d, J = 7.1 Hz, 1H), 8.10 (m, 2H), 7.56 – 7.67 (m, 3H) 6.36 – 6.31 (d, 1H), 
6.65 (s, 1H), 5.0 (s, NH). 13NMR (101 MHz, DMSO) δ 178.5, 163.2, 155.3, 144.3, 145.0, 
141.5, 139.8, 136.4, 145.0, 130. 6, 128.7, 128.8, 125.5, 125.3, 119.6, 117.6, 116.1, 111.2. 
IR (KBr): 3157, 3095, 1644, 1317, 1124, 824, 726; ESI-MS: m/z 351; Elemental 
Analysis: C, 61.54; H, 2.87; F, 5.41; N, 11.96; O, 18.22. 
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6.2.7. (E)-6-methoxy-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-
one (R7) 
 
 
C19H13N3O5: MP: 216-2180C; Orange solid; 1H NMR (400 MHz, DMSO) δ 8.39 (s, 1H), 
8.17 (d, J = 7.1 Hz, 1H), 8.10 (m, 2H), 7.56 – 7.67 (m, 3H) 6.36 – 6.31 (d, 1H), 6.65 (s, 
2H), 5.0 (s, NH) 3.90 (m, 3H). 13NMR (101 MHz, DMSO) δ 178.5, 163.2, 155.3, 144.3, 
145.0, 141.5, 139.8, 136.4, 145.0, 130. 6, 128.7, 128.8, 125.5, 125.3, 119.6, 117.6, 116.1, 
111.2. IR (KBr): 3157, 3011, 2980, 2927, 1644, 1574, 1156, 1317, 937, 637; ESI-MS: 
m/z 363; Elemental Analysis: C, 62.81; H, 3.61; N, 11.57; O, 22.02.  
 
6.2.8. (E)-6-bromo-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-
one (R8) 
 
 
C18H10BrN3O4; MP: 218-2200C; Orange solid; 1H NMR (400 MHz, DMSO) δ 8.49 (s, 
1H), 8.27 (d, J = 7.1 Hz, 1H), 8.20 (m, 2H), 7.56 – 7.67 (m, 3H) 6.36 – 6.31 (d, 1H), 
6.65 (s, 1H), 5.0 (s, NH). 13NMR (101 MHz, DMSO) δ 179.01, 163.2, 155.3, 144.3, 
145.0, 141.5, 139.8, 136.4, 145.0, 130. 6, 128.7, 128.8, 125.5, 125.3, 119.6, 117.6, 116.1, 
111.2. IR (KBr): 3157, 3095, 1644, 1317, 1124, 824, 726; ESI-MS: m/z 412; Elemental 
Analysis: C, 52.45; H, 2.45; Br, 19.39; N, 10.19; O, 15.53. 
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7. PRELIMINARY QSAR STUDIES 
Table.7.1. Physico-chemical properties of synthesized compound 
 
Com 
code Structure 
Molecular 
Formula 
Mol 
weight 
Melting 
point Appearance 
R1 
 
 
C18H10ClN3O4 367 218-2200C Orange solid 
R2 
 
C18H10FN3O4 351 
210-
2120C Yellow solid 
R3 
 
 
 
C19H13N3O4 347 
200-
2020C Orange solid 
R4 
 
 
 
C18H11N3O4 333 
220-
2220C Orange solid 
R5 
 
 
 
C18H9Cl2N3O4 402 220-2220C Orange solid 
R6 
 
 
 
C18H10FN3O4 351 
219-
2210C Orange solid 
R7 
 
 
 
C19H13N3O5 363 
216-
2180C Orange solid 
R8  C18H10BrN3O4 412 218- Orange solid 
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2200C 
Table.7.2. Solubility data of synthesized compounds 
 
 
Compound 
code Water Acetone Chloroform DMSO Ethanol Methanol 
Ethyl 
acetate 
R1 - ++ +++ +++ + ++ + 
R2 - ++ +++ +++ + ++ + 
R3 - ++ +++ +++ + ++ + 
R4 - ++ +++ +++ + ++ + 
R5 - ++ +++ +++ ++ ++ + 
R6 - ++ +++ +++ + ++ + 
R7 - ++ ++ +++ + ++ + 
R8 - ++ ++ +++ + ++ + 
 
+++ = Freely soluble; ++ = Soluble; + = Slightly soluble; - = Insoluble 
 
Table7.3. QSAR studies of synthesized compounds 
 
Compound 
Code 
Log P TPSA 
N 
atoms 
n ON 
N 
OHNH 
N 
Violation 
N rotb Volume 
R1 3.48 104.72 25 7 1 0 3 275.57 
R2 4.13 104.72 26 7 1 0 3 289.10 
R3 4.47 104.72 27 7 1 0 3 302.64 
R4 2.64 104.72 26 7 1 0 3 280.50 
R5 3.62 104.72 26 7 1 0 3 280.50 
R6 4.26 104.72 26 7 1 0 3 293.45 
R7 3.90 104.72 26 7 1 0 3 292.13 
R8 3.51 113.95 27 8 1 0 4 301.11 
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Table. 7.4. Lipinski rule for title compounds 
 
Compound 
code 
Molecular 
Weight 
No. of H 
bond 
donor 
No. of H 
bond 
Acceptor 
TPSA 
No. of 
Rotatable 
Bond 
Log P 
R1 367 0 7 104.72 3 3.48 
R2 351 0 7 104.72 3 4.13 
R3 347 0 7 104.72 3 4.47 
R4 333 0 7 104.72 3 2.64 
R5 402 0 7 104.72 3 3.62 
R6 351 0 7 104.72 3 4.26 
R7 363 0 8 104.72 3 3.90 
R8 412 0 7 113.95 4 3.51 
 
 
 
 
Table.7.5. Drug likeness score for title compounds 
 
Compound 
Code 
GPCR 
Ligand 
Ion 
channel 
modulator 
Kinase 
inhibitor 
Nuclear 
Receptor 
ligand 
Protease 
Inhibitor 
Enzyme 
Inhibitor 
R1 
-0.16 -0.32 -0.11 -0.22 -0.65 -0.07 
R2 -0.16 -0.32 -0.12 -0.23 -0.65 -0.10 
R3 -0.13 -0.25 -0.16 -0.18 -0.62 -0.07 
R4 -0.13 -0.32 -0.08 -0.18 -0.65 -0.07 
R5 -0.07 -0.27 -0.05 -0.22 -0.62 -0.06 
R6 -0.28 -0.42 -0.16 -0.36 -0.76 -0.16 
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R7 -0.20 -0.39 -0.16 -0.23 -0.68 -0.12 
R8 -0.19 -0.37 -0.12 -0.20 -0.67 -0.10 
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8. DOCKING STUDY 
8.1. Docking Studies of Synthesized Compound on Various Enzymes  
8.1.1. Introduction 
In the field of molecular modeling, docking is a method which predicts the 
preferred orientation of one molecule to second when bound to each other to form a 
stable complex and it is also key tool in structural molecular biology and computer 
assisted drug design. Docking is frequently used to predict the binding orientation of 
small molecule drug candidates to their protein targets in order to in turn predict the 
affinity and activity of the small molecule57. The small molecule, known as ligand 
usually fits within the proteins cavity which is predicted by search algorithm. These 
protein cavities become active when come in contact with any external compounds and 
are thus called as active sites. Hence docking plays an important role in the rational 
design in drugs58.  
Docking is a method which predicts the preferred orientation of one molecule to a 
second molecule when bound to each other to form a stable complex in three 
dimensional spaces. In cell biology, the function protein is a result of its interaction with 
other proteins as well as other molecule components. So if we could predict how protein 
interacts with other molecules, we could possibly inhibit the function. Thus the result of 
docking was extremely beneficial in finding drugs which are effective against particular 
disease. The knowledge of the preferred orientation in turn may be used to predict the 
strength of association or binding affinity between two molecules using scoring function. 
There is much commercially available docking software each using a different 
combination of searching method and algorithm and scoring function. These are 
• GOLD (Genetic Optimization for Ligand Docking) 
• Glide 
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• Drug Discovery 
• Auto dock 1.5.4 
Among these in my research work i have used auto dock software to calculate the free 
energy binding of ligand towards various target enzymes. 
  8.1.2. AUTODOCK 1.5.4 
Autodock is a software suite to develop in Scripps Research Institute. This 
software is used for modeling flexible small molecule such as drug molecule binding to 
receptor proteins. The current version of Autodcok uses genetic algorithm for the 
conformational search and is a suitable method for the docking studies. Scripps Research 
Institute has developed a Graphical User Interface (GUI) using Python 2.5 language, and 
it is called Autodock Tool (ADT). ADT is used to prepare, run and analyze the docking 
stimulation, in addition to its several features necessary for modeling studies.  
8.1.3. Major steps involved in molecular docking 
Step I – Building the receptor 
In this step the 3D structure of the receptor should be downloaded from PDB and 
modified. This should include removal of water molecules from the cavity, stabilizing 
charges, filling in the missing residue, generation of side chain etc., according to the 
parameters available. After modification the receptor should be biologically active and 
stable. 
Step II – Identification of active site 
After the receptor is build, the active site within the receptor should be identified. 
The receptor may have many active sites but the one of the interest should be selected.  
Step III – Ligand preparation  
Ligand can be obtain from various databases like ZINC, PubChem or can be 
sketched using tools like chemsketch. While selecting the ligand, the Lipinski rule of 5 
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should be applied.  The rule is very important for drug development where the 
pharmacologically active lead structure is optimized stepwise for increased activity and 
selectivity as well as drug like properties.  
 Step IV – Docking 
This is a last step, where the ligand is docked into receptor and the interaction are 
checked. The scoring function generates depending on which ligand with best fit was 
selected.  
8.2. MAP Kinase as target Enzyme 
Over the last decade, the pursuit of p38a MAP kinase inhibitors has received an 
extraordinary level of attention in the pharmaceutical industry and in the medicinal 
chemistry community. A unique combination of well-established pharmacology, clinical 
efficacy and the opportunity to utilize structure-based drug design has made this a highly 
attractive target for therapeutic intervention. There is overwhelming evidence indicating 
that p38a plays a dominant role in regulating the production of pro-inflammatory 
cytokines, such as tumor necrosis factor and interleukin-1. Blocking this kinase may 
offer an effective therapy for treating many inflammatory diseases. 
However great number of heterocyclic compounds display interesting anti-
inflammatory and anti-cancer especially benzimidazole and 4H–chromen–4–one 
derivatives having important role in this concern. Compounds containing benzimidazole 
rings, which are formed via the fusion of imidazole and benzene rings, have been used 
extensively for pharmaceutical purposes. 1H-Benzimidazole rings exhibit remarkable 
number of biologically activities due to their nitrogen content, which comprise the active 
substrate of several drugs. Benzimidazole derivatives possessing wide range biological 
activities like antibacterial, antifunga, anticancer, anti-HIV, anti-tubercular. Presence of 
chromene-based structure in a molecule is often associated with its capacity to prevent 
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diseases. Chromone containing compound exhibit anticancer, anti-HIV, antibacterial, 
anti-inflammatory agents, antimicrobial, antitumor, antiviral and mutagenic, anti-
proliferative and central nervous system activities. Both the derivatives produced various 
biological activities individually. Hence we are planned to incorporate both the nucleus 
by chemical reaction. The designed compound were evaluated for their molecular 
properties by the “Lipinski’s rule of 5” and further their ability to bind in the active site 
region of MAP Kinase identified using molecular docking approach. 
8.3. Molecular docking study  
In order to gain more insight on the binding mode of the compounds with MAP 
Kinase docking studies using Auto Dock 4.0.1 were carried out. Top scoring molecules 
from the largest cluster were considered for interaction studies. The crystallographic 
structure of MAP kinase, which is retrieved from the RCSB Protein Data Bank (PDB 
code 1CM8) serves as docking receptor, and all the designed compounds are selected as 
ligand molecules. Before docking the screened ligands in to the protein active site, the 
protein was prepared by deleting the substrate cofactor as well as the crystallographically 
observed water molecules and then protein was defined for generating the grid. All 
molecules were drawn using ChemDraw Ultra 8.0 tool and energy minimized using 
Chem 3D Ultra 8.0 software.  
8.5. Auto Dock 4.0.1 procedure 
Automated docking was used to locate the appropriate binding orientations and 
conformations of various inhibitors into the 1CM8 binding pocket. To perform the task, 
the powerful genetic algorithm method implemented in the program Auto Dock 4.0.1 
was employed. Grid maps were generated by AutoGrid program. Each grid was centered 
at the crystal structure of the corresponding 1G2A and 2GT1 separately. Lamarckian 
Genetic Algorithm was employed as the docking algorithm. The grid dimensions were 
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60 Å X 60 Å X 60 Å with points separated by 0.375 Å. For all ligands, random starting 
positions, random orientations and torsions were used. During docking, grid parameters 
were specified for x, y and z axes as 38.808, 30.946 and 42.249 respectively. The 
Docking parameters Number of Genetic Algorithm (GA) runs: 25, Population size: 150, 
Maximum number of evaluation: 2,500,000, Maximum number of generation: 27,000 
were used for this study. The structure with the lowest binding free energy and the most 
cluster members was chosen for the optimum docking conformation. 
Table 8.1: Energy minimization table of Ligand and MAP kinase 
Interaction 
Code 
Binding 
Energy 
(Kcal/mol) 
 
Inhibition 
Constant 
Vdw. 
Desolvation 
Energy 
Intermol 
Energy 
Ligand 
efficiency 
Electrostatic 
Energy 
Total 
internal 
R1 -7.79 2.04 -7.66 -8.96 -0.31 -1.3 1.19 
R2 -7.95 6.75 -7.83 -8.25 -0.27 -0.42 0.32 
R3 -7.28 6.42 -6.95 -8.28 -0.26 -1.33 -0.44 
R4 -6.41 20.04 -7.48 -7.6 -0.25 -0.12 -.044 
R5 -7.19 5.36 -8.71 -8.38 -0.28 -0.32 -0.42 
R6 -7.76 2.05 -7.73 -8.95 -0.3 -1.23 -0.41 
R7 -7.35 4.1 -8.71 -8.54 -0.28 0.17 -0.44 
R8 -6.58 14.98 -7.89 -8.07 -0.24 -0.19 -0.43 
Diclofenac -7.18 14.32 -8.98 -9.02 -0.32 -0.18 -0.32 
Imatinib  -7.27 53.99 -11.29 -11.65 -0.43 -0.19 -0.54 
 
8.6. Docking Analysis 
The newly designed molecules are energy minimized and the resulting molecules 
are considered for docking analysis using Auto Dock 4.0.1. Auto Dock is employed to 
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study the docking molecules within active site region of 1CM8 and the H-bond 
interaction. Docked scores of newly designed molecules along with inhibition constant, 
Vdw. Desolvation Energy, ligand efficacy and electrostatic energy and hydrogen bonds 
are represented in Table 8.1. and table 8.2. respectively. Among the studied compounds, 
compound R1 have highest binding score (-7.79 K Cal/mol with one hydrogen bond) 
when compared with standard drugs such as Diclofenac -7.18 K Cal/mol (for anti-
inflammatory) and Imatinib -7.27 K Cal/mol (for Anti-cancer) followed by compound 
R6 with score of -7.76 K Cal/mol with one hydrogen bond, compound R5 with score of  
-7.19 K Cal/mol with one hydrogen bond, compound R3 have score of –7.28 with two 
hydrogen bond and lastly compound R4 with score of -6.41 K Cal/mol with one 
hydrogen bond. The docked molecule with MAP Kinase was visualized in Chimara 
software and the docking pose of compounds showed in figure 2 – 5. Docking results 
show that all the designed molecules have similar orientations in the binding pocket of 
MAP Kinase enzyme.  
Table 8.2: Hydrogen bond and hydrophobic interaction of ligand against target enzyme 
MAP kinase 
 
Compound 
code 
No. of 
Hydrogen 
bonds formed 
Amino acid 
involved in H 
bond interaction 
H bond 
distance 
Amino acid 
involved in 
vander waals 
interaction 
R1 1 Agr 82 2.93 
His 80, His 83, Lys 
139, Arg 142, Tyr 
143, Val 323, Gln 
324 
R2 Nil Nil Nil 
Gly 117, Met 120, 
Pro 156, Gly 157, 
Glu 218, Gly 222. 
R3 2 1. Lys 118 2. Lys 121 
2.771 
2.753 
Gly 117, Lys 118, 
Met 120, Glu 218 
R4 1 Asn 119 2.836 
Leu 193, Leu 253, 
Phe 249, Apg 252, 
Leu 294 
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R5 1 THR 242 2.75 
His 80, Arg 82, 
His 83, Lys 139, 
Val 323, Gln 324 
R6 1 TYR 143 3.327 
His 80, Arg 82, 
His 83, Lys 139, 
Arg 142, Tyr 143, 
Val 323, Gln 324 
R7 Nil Nil Nil 
Arg 142, Phe 249, 
Met 120, Glu 218, 
Tyr 143, Val 323 
R8 1 Arg 252 2.67 
Leu 253, Phe 249, 
Apg 252, Gln 254, 
Leu 294. 
Diclofenac Nil Nil Nil Met 120, Glu 218, Val 323, Gln 324. 
Imatinib Nil Nil Nil 
His 80, Arg 82, 
Arg 142, Glu 218, 
Val 323, Gln 324 
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Figure 8.1: Docking pose of compound R1 against MAP Kinase as Target Enzyme 
 
 
Figure 8.2: Docking pose of compound R2 against MAP Kinase as Target Enzyme 
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Figure 8.3: Docking pose of compound R3 against MAP Kinase as Target Enzyme 
 
 
 
Figure 8.4: Docking pose of compound R4 against MAP Kinase as Target Enzyme 
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Figure 8.5: Docking pose of compound R5 against MAP Kinase as Target Enzyme 
 
 
 
Figure 8.6: Docking pose of compound R6 against MAP Kinase as Target Enzyme 
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Figure 8.7: Docking pose of compound R7 against MAP Kinase as Target Enzyme 
 
 
 
Figure 8.8: Docking pose of compound R8 against MAP Kinase as Target Enzyme 
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Figure 8.9: Docking pose of standard drug (Imatinib) against MAP Kinase as Target 
Enzyme 
 
 
 
Figure 8.10: Docking pose of standard drug (Diclofenac) against MAP Kinase as Target 
Enzyme 
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9. IN-VITRO ANTICANCER ACTIVITY 
9.1. Introduction  
Cancers are a large family of diseases which involve abnormal cell growth with 
the potential to invade or spread to other parts of the body. They form a subset of 
neoplasms. A neoplasm or tumor is a group of cells that have undergone unregulated 
growth, and will often form a mass or lump, but may be distributed diffusely. 
Six characteristics of cancer have been proposed: 
• Self-sufficiency in growth signaling 
• Insensitivity to anti-growth signals 
• Evasion of apoptosis 
• Enabling of a limitless replicative potential 
• Induction and sustainment of angiogenesis 
• Activation of metastasis and invasion of tissue. 
The progression from normal cells to cells that can form a discernible mass to 
outright cancer involves multiple steps known as malignant progression. 
The great majority of cancers, some 90–95% of cases, are due to environmental 
factors. The remaining 5–10% is due to inherited genetics. Environmental, as used by 
cancer researchers, means any cause that is not inherited genetically, such as lifestyle, 
economic and behavioral factors, and not merely pollution. Common environmental 
factors that contribute to cancer death include tobacco (25–30%), diet and obesity (30–
35%), infections (15–20%), radiation (both ionizing and non ionizing, up to 10%), stress, 
lack of physical activity, and environmental pollutants. 
 
 
9.2. Anticancer Drug Development 
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Around the world, tremendous resources are being invested in prevention, 
diagnosis, and treatment of cancer. Cancer is the second leading cause of death in Europe 
and North America. Discovery and development of anticancer agents are the key focus 
of several pharmaceutical companies as well as nonprofit government and non-
government organizations, like the National Cancer Institute (NCI) in the United States, 
the European Organization for Research and Treatment of Cancer (EORTC), and the 
British Cancer Research Campaign (CRC). 
Identification of cytotoxic compounds led the development of anticancer 
therapeutics for several decades. Advances in cancer treatment, however, continued to be 
limited by the identification of unique biochemical aspects of malignancies that could be 
exploited to selectively target tumor cells. Schwartsmann et al. noted in 1988 that of over 
600,000 compounds screened by then, less than 40 agents were routinely used in the 
clinic. The recent growth in molecular sciences and the advances in genomics and 
proteomics have generated several potential new drug targets, leading to changes in the 
paradigms of anticancer drug discovery toward molecularly targeted therapeutics. These 
shifting paradigms have not only resulted in the greater involvement of biological 
scientists in the drug discovery process but also required changes in the screening and 
clinical evaluation of drug candidates. Both small and large molecular compounds 
continue to be investigated as anticancer agents. 
The discovery and development of anticancer drugs, especially cytotoxic agents, 
differ significantly from the drug development process for any other indication. The 
unique challenges and opportunities in working with these agents are reflected in each 
stage of the drug development process. This chapter will highlight the unique aspects of 
anticancer drug discovery and development. 
9.3. In-Vitro Anticancer Activity by SRB Assay 
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In order to study the anti tumor activity of new compound, it is important to 
determine the cytotoxicity concentration of the compound. Cytotoxicity tests define the 
upper limit of the extract concentration, which is non toxic to the cell line. After the 
addition of the drug, cell death and cell viability was estimated. The result is confirmed 
by additional metabolic intervention experiment such as SRB assay. 
9.3.1. Materials Required SRB Assay 
1. Monolayer culture in log phase 
2. Drug extracts (different concentration) 
3. 0.45 filter 
4. 5mL sterile storage vials 
5. Tissue paper, Marker pen, Spirit, Cotton, and Gloves 
6. 1mL, 2mL pipettes, Micropipettes and tips 
7. Discarding Jar with 1% Hypochlorite solution 
9.3.2. SRB Assay introduction 
The sulforhodamine B (SRB) assay, which was developed in 1990, remains one 
of the most widely used methods for in vitro cytotoxicity screening. The assay relies on 
the ability of SRB to bind to protein components of cells that have been fixed to tissue 
culture plates by trichloroacetic acid (TCA). SRB is a bright-pink aminoxanthene dye 
with two sulfonic groups that bind to basic amino-acid residues under mild acidic 
conditions, and dissociate under basic conditions. As the binding of SRB is 
stoichiometric, the amount of dye extracted from stained cells is directly proportional to 
the cell mass. 
The strong intensity of SRB staining allows the assay to be carried out in a 96-
well format showed that the assay can detect densities as low as 1,000–2,000 cells per 
well. The SRB method has proven to be practical, because after the TCA-fixed and SRB-
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stained cell monolayers are dried they can be stored indefinitely. Color extracted from 
SRB-stained cells is also stable. With its high level of sensitivity, adaptability to the 96-
well format and endpoint stability, the SRB assay is well suited to large-scale screening 
applications, as well as research.  
This assay has been widely used for drug-toxicity testing against different types 
of cancerous and non-cancerous cell lines. Other cell-growth assays have been employed 
to assess drug efficacy against both intracellular pathogens and host cells simultaneously 
in co-cultures and it is possible to use the SRB method for this purpose. In addition, the 
SRB method has also been shown to be effective for in vitro testing of cancer cell 
sensitivity to radiation, and for the study of interactions between radiotherapy and 
chemotherapy, with sensitivity comparable to that of the standard clonogenic assay. 
The application of the SRB assay is limited to manual or semiautomatic 
screening due to the multiple washing and drying steps, which, at present, are not 
amenable to automation. This method nevertheless provides an efficient and sensitive 
tool for screening, especially for use in less well-equipped laboratories.  
Calculate the percentage of cell-growth inhibition using the formulae below. For primary 
screening, we use a threshold of 50% cell-growth inhibition as a cut-off for compound 
toxicity against cell lines. However, the threshold can be varied according to toxicity 
criteria defined by the investigators. For IC50 determination, plot a dose–response curve 
between the compound concentration and percent growth inhibition. IC50 values can be 
derived using curve-fitting methods with statistical analysis software or IC50 calculation 
software. 
 
9.3.3. EXPERIMENTAL PROCEDURE FOR SRB ASSAY 
• The cell lines were grown in RPMI 1640 medium containing 10% fetal bovine 
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serum and 2 mM L-glutamine. For present screening experiment, cells were 
inoculated into 96 well microtiter plates in 100 µL at plating densities as shown 
in the study details above, depending on the doubling time of individual cell 
lines. After cell inoculation, the microtiter plates were incubated at 37° C, 5 % 
CO2, 95 % air and 100 % relative humidity for 24 h prior to addition of 
experimental drugs.  
• Experimental drugs were initially solubilize in dimethyl sulfoxide at 100mg/ml 
and diluted to 1mg/ml using water and stored frozen prior to use. At the time of 
drug addition, an aliquote of frozen concentrate (1mg/ml) was thawed and diluted 
to 100 µg/ml, 200 µg/ml, 400 µg/ml and 800 µg/ml with complete medium 
containing test article. Aliquots of 10 µl of these different drug dilutions were 
added to the appropriate micro titer wells already containing 90 µl of medium, 
resulting in the required final drug concentrations i.e.10 µg/ml, 20 µg/ml, 40 
µg/ml, 80 µg/ml.  
• After compound addition, plates were incubated at standard conditions for 48 
hours and assay was terminated by the addition of cold TCA. Cells were fixed in 
situ by the gentle addition of 50 µl of cold 30 % (w/v) TCA (final concentration, 
10 % TCA) and incubated for 60 minutes at 4°C. The supernatant was discarded; 
the plates were washed five times with tap water and air dried. Sulforhodamine B 
(SRB) solution (50 µl) at 0.4 % (w/v) in 1 % acetic acid was added to each of the 
wells, and plates were incubated for 20 minutes at room temperature. After 
staining, unbound dye was recovered and the residual dye was removed by 
washing five times with 1 % acetic acid. The plates were air dried. Bound stain 
was subsequently eluted with 10 mM trizma base, and the absorbance was read 
on an plate reader at a wavelength of 540 nm with 690 nm reference wavelength.  
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• Percent growth was calculated on a plate-by-plate basis for test wells relative to 
control wells. Percent Growth was expressed as the ratio of average absorbance 
of the test well to the average absorbance of the control wells * 100.  
• Using the six absorbance measurements [time zero (Tz), control growth (C), and 
test growth in the presence of drug at the four concentration levels (Ti)], the 
percentage growth was calculated at each of the drug concentration levels. 
Percentage growth inhibition was calculated as:  
[Ti/C] x 100 % 
• In this study Adriamycin used as standard drug. The table 9.1 shows the SRB 
Assay of tested compounds against Human Lung Cancer Cell Line A-549. And 
the table 9.2 represents the LC50, TGI and GI50 values of the tested compound. 
• The Figure 9.2 represented the drug treated human cancer cell line A-549. 
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Table 9.1. The SRB Assay of tested compounds against Human Lung Cancer Cell Line 
A-549 
Code 
Human Lung Cancer Cell Line A-549 
% Control Growth 
 Drug Concentrations (µg/ml) 
Experiment 1 Experiment 2 Experiment 3 Average Values 
10 20 40 80 10 20 40 80 10 20 40 80 10 20 40 80 
R1 86.7 96.7 62.5 18.3 101.9 113.2 84.1 34.7 93.2 92.4 42.5 12.8 93.9 100.8 63.0 21.9 
R2 91.2 89.5 85.6 95.3 101.3 104.9 112.6 93.0 90.8 92.4 88.9 95.2 94.4 95.6 95.7 94.5 
R5 91.2 87.6 75.6 66.9 102.7 104.9 104.3 56.3 90.1 90.6 61.2 49.9 94.7 94.3 80.4 57.7 
R6  96.2 88.5 77.0 33.5 110.4 111.7 98.6 51.0 96.2 102.0 81.7 33.5 100.9 100.7 85.8 39.4 
R7 94.9 85.6 80.0 43.3 104.8 97.6 102.6 75.1 93.6 111.8 82.3 96.2 97.8 98.3 88.3 71.5 
ADR 10.0 5.1 -8.4 -1.2 8.4 5.0 10.4 6.1 4.7 2.6 -3.1 5.4 7.7 4.2 -0.4 3.4 
 
Table 9.2.  LC50, TGI and GI50 values of the tested compoun 
sample coode 
Drug concentrations (µg/ml) calculated from graph 
LC50 TGI GI50* 
R1 NE >80 55.1 
R2 NE >80 >80 
R5 NE >80 >80 
R6 NE >80 71.9 
R7 NE >80 >80 
ADR NE <10 <10 
 
Figure 9.2 Drug treated human cancer cell line A-549 
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10. RESULT AND DISCUSSION 
10.1. Synthetic methodology 
A series of novel class of (E)-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-
chromen-4-one Derivatives were synthesized by  using of 2-methyl-1H-
benzo[d]imidazole,   substituted chromone-3-carbaldehyde in presence of GAA. 
10.2. Characterization of synthesized compound 
 The purity of synthesized compounds was confirmed by Melting Point and TLC 
using Ethyl Acetate: Petroleum Ether (50:50) as solvent system. 
 The structures of synthesized compounds were confirmed by FT-IR, 1H-NMR, 
13C-NMR and Mass spectral analysis the result was correlated with the 
expected structure. 
10.3. Preliminary QSAR study: 
 The physic chemical character of title compounds were evaluated and given in 
the table 7.1. 
 Solubility parameters of synthesized compounds were tested, using various 
organic solvents and the result was tabulated in Table 7.2. 
 The synthesized compounds were subject to Preliminary QSAR studies by using 
MOLINSPIRATION software and the results are given in the Table7.3. All the 
synthesized compounds obey Lipinski rule of 5. 
10.4. Docking study 
 The docking study of the synthesized compound was carried out by using 
AUTODOCK software version 4.2 working system against target enzyme MAP 
Kinase as per the literature survey. 
 The docking result of the synthesized compounds showed binding score in active 
site of MAP Kinase between 7.0 and 7.90 K Cal/mol. 
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 Compounds R1, R2, R6, and R7 were found to have significant binding score 
against target enzyme MAP Kinase, compared to standard drugs such as 
Imatinib and Diclofenac.  
10.5. In vitro Anti-cancer Activity 
 Synthesized compounds R1, R2, R3, R6 and R7 were evaluated for 
anticancer activity by SRB assay method against Human Cancer Cell line 
A-549. 
 All tested compound exhibit moderate to good percentage of growth 
inhibition of Human Lung Cancer Cell Line A-549 when compared with 
the control drug Adriamycin.  
 
During the last twenty years, the study of the biological activities of chromene 
derivatives has been the aim of many scientists.59 Chromene-based natural and synthetic 
compounds have contributed substantially to the development of therapeutics as anti-
neoplastic agents against various human malignancies. Sesilin, tephrosin, calanone and 
acronycine are some of the chromene derivatives with a very good anti-cancer activity. 
An important breakthrough in the development of 4H-chromenes as anti-cancer agents 
was given by the discovery of MAP Kinase protein.  Imidazole and benzimidazole nuclei 
are the important and well known pharmacophores in drug discovery.60,61. There is a 
continual increase on the incidence of cancer and it is considered to be the leading cause 
of morbidity and mortality.62 Recently, considerable attention has been drawn on the 
search for novel anticancer drugs in order to improve survival rates and wellbeing. 
Benzimidazole derivatives are being explored in pharmaceutical industries and 
substituted benzimidazole derivatives have also been found in the diverse therapeutic 
applications such as in anti-ulcers, anti-hypertensives, anti-virals, anti-fungals, anti-
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cancers and anti-histaminics.63 On the other hand, such benzimidazole derivatives are 
condensed with other heterocycles like pyrazole, thiadiazole, triazole, thiazole, coumarin 
and 2-azetidinone moieties which have shown diverse pharmacological activities.64-71 
We targeted MAP Kinase protein for anticancer activity by benzimidazole containing 
4H- chromen-4-one Derivatives. We  designed some novel (E)-2-(2-(5-nitro-1H-
benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one Derivatives on the basis reaction 
between 2-methyl-1H-benzo[d]imidazole,   substituted chromone-3-carbaldehyde in 
presence of GAA and the synthesized compound were characterized by IR, 1H NMR, 13C 
NMR, Mass spectrometry and Elementary Analysis. The structures of the synthesized 
compounds were studied using Autodock software against different target enzymes. The 
docking results showed that Compounds R2, R3, R6, and R7 were found to have 
significant binding score against target enzyme MAP Kinase compared to standard drug 
Imatinib. Synthesized compound were evaluated for their in-vitro anti cancer activity by 
SRB assay method against Human Cancer Cell line A-549. From the result the 
compound R1 and R6 allowed only 21.9 and 39.4 of % cell growth at the concentration 
of 80µg/mL. Whereas other compounds has showed 57-94% 0f %cell growth. From the 
results the substitution on the Coumarin nucleus alter the biological activity. The un-
substituted (R4) and Flouro (R6) and Chloro (R1) substituted Coumarin derivatives were 
found to be potent by producing biological activity.  
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11. CONCLUSION 
 The present study deals with designing of some novel (E)-2-(2-(5-nitro-1H-
benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one Derivatives on the basis reaction 
between 2-methyl-1H-benzo[d]imidazole,   substituted chromone-3-carbaldehyde 
in presence of GAA. 
 The synthesized compound were characterized by IR, 1H NMR, 13C NMR, Mass 
spectrometry and Elementary Analysis. 
 Preliminary QSAR study was carried out for the synthesized compounds. All the 
compounds obey the Lipnski rule of 5. 
 Solubility characters of synthesized compounds were carried out by using various 
solvents. The tested compounds are freely soluble in DMSO, soluble in 
Chloroform and Methanol, slightly soluble in Acetone, Ethyl Acetate and Ethanol 
and Insoluble in Water. 
 The structures of the synthesized compounds were studied using Autodock 
software against different target enzymes. The docking results showed that 
Compounds R2, R3, R6, and R7 were found to have significant binding score 
against target enzyme MAP Kinase compared to standard drug Imatinib.  
 Synthesized compound were evaluated for their in-vitro anti cancer activity by SRB 
assay method against Human Cancer Cell line A-549. From the result the compound 
R1 and R6 allowed only 21.9 and 39.4 of % cell growth at the concentration of 
80µg/mL. Whereas other compounds has showed 57-94% 0f %cell growth. 
 From the above, it may conclude that the substitution on the Coumarin nucleus 
alter the biological activity. The un-substituted (R4) and Flouro (R6) and Chloro 
(R1) substituted Coumarin derivatives were found to be potent by producing 
biological activity.        
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1.  INTRODUCTION 
1.1. Heterocyclic compounds 
Heterocycles are an important class of compounds, making up more than half 
of all known organic compounds1. Heterocycles are present in a wide variety of drugs, 
most vitamins, many natural products, biomolecules, and biologically active 
compounds, including antitumor, antibiotic, anti-inflammatory, antidepressant, 
antimalarial, anti-HIV, antimicrobial, antibacterial, antifungal, antiviral, antidiabetic, 
herbicidal, fungicidal, and insecticidal agents. Also, they have been frequently found 
as a key structural unit in synthetic pharmaceuticals and agrochemicals2. Some of 
these compounds exhibit a significant solvatochromic, photochromic, and biochemi-
luminescence properties.  
Most of the heterocycles possess important applications in materials science 
such as dyestuff, fluorescent sensor, brightening agents, information storage, plastics, 
and analytical reagents. In addition, they have applications in supra molecular and 
polymer chemistry, especially in conjugated polymers. 
The medicinal chemists, the true utility of heterocyclic structures is the ability 
to synthesize one library based on one core scaffold and to screen it against a variety 
of different receptors, yielding several active compounds. Almost unlimited 
combinations of fused heterocyclic structures can be designed, resulting in novel 
polycyclic frameworks with the most diverse physical, chemical and biological 
properties.  
Therefore, efficient methodologies resulting in polycyclic structures from 
biologically active heterocyclic templates are always of interest to both organic and 
medicinal chemists3. The primary objective of medicinal chemistry is the design and 
discovery of new drug compounds. 
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1.2. Drug discovery and development process 
Drug discovery and development process (figure 1.1) is one of the most 
challenging and difficult process because this process is often a matter of life and 
death for patients; their cures are in the hands of scientists and clinicians who 
discover, develop, and administer medications for prevention, management, and cure 
of disease, injuries, and other disorders4. But it takes about 12 - 15 years from 
discovery to the approved medication and requires an investment of about billion 
dollars.  
From more than a million screened molecules only few compounds is 
investigated in late stage clinical trials and is finally made available for patients4. 
There are several stages involved in the drug discovery process. They are 
• Target identification and validation 
• Assay development 
• Lead identification 
• Lead optimization 
• Preclinical development 
• Clinical development 
o Phase I 
o Phase II 
o Phase III 
• Regulatory approval 
• Life cycle management  
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Figure 1.1: Drug discovery and development process 
1.5. Quantitative Structure Activity Relationship 
QSAR involves the derivation of mathematical formulae which relates the 
biological activities of a group of compounds to their measurable physiochemical 
parameters. These parameters have major influence on the drugs activity. QSAR 
derived equation take the general form: 
Biological activity = function 
(parameters) 
 Activity is expressed as log (1/c). C is the minimum concentration required 
to cause defined biological response. Activities used in QSAR include chemical 
measurements and biological assays. Quantitative structure-activity relationships have 
long been considered a vital component of drug discovery and development, providing 
insight into the role of molecular properties in the biological activity of similar and 
unrelated compounds. QSAR includes all statistical methods, by which biological 
activities (most often expressed by logarithms of equipotent molar activities) are 
related with structural elements (Free Wilson analysis), physicochemical properties 
(Hansch analysis), or fields (3D QSAR). The CoMFA analyses provided a number of 
insights into the mechanism of agonist binding5,6. 
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1.5.1. Molecular Descriptors used in QSAR 
Molecular descriptors can be defined as a numerical representation of 
chemical information encoded within a molecular structure via mathematical 
procedure. This mathematical representation has to be invariant to the molecule’s size 
and number of atoms to allow model building with statistical methods7. 
The information content of structure descriptors depends on two major factors: 
(1) The molecular representation of compounds. 
(2) The algorithm which is used for the calculation of the descriptor. 
There are various molecular descriptors used in QSAR, these are 
1. Hydrophobic parameter 
o Partition coefficient ; log P 
o Hansch’s substitution constant; π 
o Hydrophobic fragmental constant; f, f’ 
o Distribution coefficient; log D 
o Apparent log P 
o Capacity factor in HPLC; log k’ , log k’W 
o Solubility parameter; log S  
• Electronic parameter 
o Hammett constant; σ, σ +, σ - 
o Taft’s inductive (polar) constant; σ* 
o Swain and Lupton field parameter 
o Ionization constant; pKa , ∆pKa 
o Chemical shifts: IR, NMR 
• Steric parameter 
o Taft’s steric parameter; Es 
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o Molar volume; MV 
o Van der waals radius 
o Van der waals volume 
o Molar refractivity; MR 
o Parachor 
o Sterimol 
• Quantum chemical descriptors 
o Atomic net charge; Qσ, Qπ 
o Superdelocalizability 
o Energy of highest occupied molecular orbital; EHOMO 
o Energy of lowest unoccupied molecular orbital; ELUMO 
1.5.2. 3D-QSAR 
Three-dimensional quantitative structure-activity relationships (3D-QSAR) 
involve the analysis of the quantitative relationship between the biological activity of 
a set of compounds and their three-dimensional properties using statistical correlation 
methods. 3D-QSAR uses probe-based sampling within a molecular lattice to 
determine three-dimensional properties of molecules (particularly steric and 
electrostatic values) and can then correlate these 3D descriptors with biological 
activity. 
1.6. Physiochemical parameter 
The term physicochemical properties refers to the influence of the organic 
functional groups within a molecule on its acid-base properties, water solubility, 
partition coefficient, crystal structure, stereochemistry, ionization constant (pKa), 
lipophilicity and chemical stability. All these properties influence the absorption, 
distribution, metabolism excretion (ADME) and toxicity of the molecule. To design 
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better medicinal agents, the medicinal chemist needs to understand the relative 
contributions that each functional group makes to the overall physicochemical 
properties of the molecule. Studies of this type involve modification of the molecule 
in a systematic fashion and determination of how these changes affect biological 
activity. 
The physicochemical properties of a drug molecule are dependent not only on 
what functional groups are present in the molecule but also on the spatial arrangement 
of these groups. This becomes an especially important factor when a molecule is 
subjected to an asymmetric environment, such as the human body. Because proteins 
and other biological macromolecules are asymmetric in nature, how a particular drug 
molecule interacts with these macromolecules is determined by the three-dimensional 
orientation of the organic functional groups that are present. If crucial functional 
groups are not occupying the proper spatial region surrounding the molecule, then 
productive bonding interactions with the biological macromolecule (receptor) will not 
be possible, potentially negating the desired pharmacological effect. If however, these 
functional groups are in the proper three-dimensional orientation, the drug can 
produce a very strong interaction with its receptor. It therefore is very important for 
the medicinal chemist developing a new molecular entity for therapeutic use8,9. 
1.7. Molecular Docking10 - 13 
 When the structure of the target is known (available), usually from X-ray 
crystallography, the most commonly used virtual screening method is molecular 
docking. Molecular docking can also be used to test possible hypotheses before 
conducting costly laboratory experiments. Molecular docking programs try to predict 
how a drug candidate binds to a protein target without performing a laboratory 
experiment. Molecular docking software consists of two core components. 
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 A search algorithm (sometimes called an optimization algorithm). The 
search algorithm is responsible for finding the best conformations of the 
ligand3 and protein system. A conformation is the position and orientation 
of the ligand relative to the protein. In flexible docking a conformation 
also contains information about the internal flexible structure of the ligand 
– and in some cases about the internal flexible structure of the protein. 
Since the number of possible conformations is extremely large, it is not 
possible to test all of them, therefore sophisticated search techniques have 
to be applied. Examples of some commonly used methods are Genetic 
Algorithms and Monte Carlo simulations. 
 An evaluation function (sometimes called a score function). This is a 
function providing a measure of how strongly a given ligand will interact 
with a particular protein. Energy force fields are often used as evaluation 
functions. These force fields calculate the energy contribution from 
different terms such as the known electrostatic forces between the atoms 
in the ligand and in the protein, forces arising from deformation of the 
ligand, pure electron-shell repulsion between atoms and effect from the 
solvent in which the interaction takes place. 
 
An example of a drug candidate ( grey color) binding to a target (black color). The 
small filled circles represent solvent (water) molecules. 
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1.8. Molecular Docking Softwares 
 Molecular docking programs are widely used modeling tools for predicting 
ligand binding modes and structure based virtual screening.14 
 DOCK - University of California San Francisco. 
 AUTODOCK - Scripps Research Institute.  
 MOLEGRO VIRTUAL DOCKER  - Molegro APS, University of Aarhus, 
Denmark. 
 GRAMM - Centre of Bioinformatics, University of Kansas, USA. 
 HEX - University of Aberdeen, UK. 
1.9. Lipinski's Rule of Five 
 Lipinski's Rule of Five is a rule of thumb to evaluate drug likeness, or 
determine if a chemical compound with a certain pharmacological or biological 
activity has properties that would make it a likely orally active drug in humans. The 
rule was formulated by Christopher A. Lipinski in 1997, based on the observation that 
most medication drugs are relatively small and lipophilic molecules.15 
 The rule describes molecular properties important for a drug's 
pharmacokinetics in the human body, including their absorption, distribution, 
metabolism, and excretion ("ADME").  
 The rule is important for drug development where a pharmacologically active 
lead structure is optimized step-wise for increased activity and selectivity, as well as 
drug-like properties as described by Lipinski's rule. The modification of the molecular 
structure often leads to drugs with higher molecular weight, more rings, more 
rotatable bonds, and a higher lipophilicity.  
 The ‘Rule of 5’ 16 states that poor absorption or permeation of orally 
administered drugs are more likely when. 
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1) There are more than 5 H-bond donors (expressed as the sum of OHs 
and NHs) 
2) The Molecular Weight is over 500 Daltons 
3) The Log P is over 5 (or MLogP is over 4.15) 
4) There are more than 10 H-bond acceptors (expressed as the sum of Ns 
and Os) 
5) Compound classes that are substrates for biological transporters are 
exceptions to the rule. 
To evaluate drug likeness better, the rules have spawned many extensions 
• Partition coefficient log P in -0.4 to +5.6 range 
• Molar refractivity from 40 to 130 
• Molecular weight from 160 to 500 
• Number of atoms from 20 to 70 includes H-bond donors [e.g.OHs and 
NHs] and H-bond acceptors [e.g.; Ns and Os]. 
• Polar surface area no greater than 140 Ǻ 
Exception to the ‘Rule of 5’: 
Compound classes that are substrates for biological transporters: 
 Antibiotics 
 Fungicides-Protozoacides -antiseptics 
 Vitamins 
 Cardiac glycosides. 
1.10. Nitorgen Based Heterocycles 
 The nitrogen based heterocycles were involved at the very beginning of life 
in the genesis of DNA and plays an essential role in many living systems. The nucleic 
acid based adenine; guanine, cytosine and thymine are derivatives of the aromatic  
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nitrogen heterocycles.  
1.11. Benzimidazole 
 Benzimidazole is a heterocyclic aromatic organic compound. This bicyclic 
compound consists of the fusion of benzene and imidazole. Benzimidazole, in an 
extension of the well-elaborated imidazole system, has been used as carbon skeletons 
for  N-heterocyclic carbenes. The NHCs are usually used as ligands for transition 
metal complexes. They are often prepared by deprotonating an N,N'-disubstituted 
benzimidazolium salt at the 2-position with a base.17 
  Benzimidazole, as the name implies is a bicyclic ring system in which 
benzene has been fused to the 4 and 5 position of the hetero cycle (imidazole). A basis 
for interest in the benzimidazole ring system as a nucleus from which to develop 
potential chemotherapeutic agents was established in the 1950’s when it was found 
that 5,6,-dimethyl-l-(alpha-D-ribofuranosyl) benzimidazole was an integral part of the 
structure of the vitamin B12.18 
1.12. Chemistry of Benzimidazoles 
 Benzimidazole is a white to slightly beige solid; melting at 172 °C, boils at 
360 °C, slightly soluble in water, soluble in ethanol. It is a dicyclic compound having 
imidazole ring (containing two nitrogen atoms at nonadjacent positions) fused to 
benzene. Benzimidazole and its derivatives are used in organic synthesis and 
vermicides or fungicides as they inhibit the action of certain microorganisms. 
Examples of benzimidazole class fungicides include benomyl, carbendazim, 
chlorfenazole, cypendazole, debacarb, fuberidazole, furophanate, mecarbinzid, 
rabenzazole, thiabendazole, thiophanate. Benzimidazole structure is the nucleus in 
some drugs such as proton pump inhibitors and anthelmintic agents. 
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Product Identification: 
 CAS NO :  51-17-2 
       EINECS NO :  200-081-4 
       FORMULA :  C7H6N2 
       MOL WT :  118.14 
       SYNONYMS :  1H-Benzimidazole; 1,3-benzodiazole; benzoglyoxaline;  
                                      azindole; N,N'-methylenyl-o-phenylenediamine;  
     3-azaindole; o-benzimidazole; benzoimidazole; BZI;  
      1,3-diazaindene; 
Physical and Chemical Properties: 
Physical state    :  Slightly Beige Powder 
Melting point    :  172 °C 
Boiling point    :  360 °C 
Specific gravity        :  1 
Solubility in water   :  Slightly 
Auto ignition    :  538 °C 
Nfpa ratings    :  Health- 2 ; Flammability- 1; Reactivity- 0 
Flash point    :  143 °C 
Stability    :  Stable under normal temperatures and 
conditions 
1.13. Benzimidazole from Natural Sources 
 The most prominent benzimidazole compound in nature is N-ribosyl-
dimethylbenzimidazole, which serves as an axial ligand for cobalt in vitamin B12. 
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1.14. Preparation of Benz
 The synthetic pathway to the various benzimidazole usually proceeds 
through two steps; first the construction of benzene ring containing the desired 
substituents and 1-2 diamine grouping followed by the ring closer of the 1
diaminobenzene (o-phenylenediamine) derivative to construct the imidazole ring. In 
many cases this ring closure is the final step in the synthesis of the desired 
benzimidazole. However in the other instances this ring closure is followed by 
extensive derivatization of th
 The usual synthesis involves condensation of
phenylenediamine with
N
N
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 Generally, the synthesis of benzimidazoles involves the treatment of 1,2-
phenylenediamine either with carboxylic acids under strongly acidic conditions or 
with aldehydes under oxidative conditions.21,22 
NH2
NH2
N
N
H N
N
H
Us
ing
 
ca
rbo
xy
lic
 
ac
ids
un
de
r 
st
ro
ng
 
ac
idi
c 
co
nd
itio
n U
sing
 aldehydes
under
 oxidative
 conditions
 
 Synthetic approaches to 2-substituted benzimidazoles from 2-nitroanilines as 
starting material have been reported. 
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1.15. Chromene 
 
Among the widespread heterocyclic compounds, oxygen heterocycles occupy 
a distinct position because of their wide natural abundance and broad biological as 
well as pharmaceutical significance23. In these particular classes of O-heterocycles, 
‘chromene’ heterocyclic scaffolds represent a privileged structural motif well-
distributed in natural products with a broad spectrum of potent biological activities. 
The word chromones is derived from the Greek word chroma, meaning “color”, 
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which indicates that many chromone derivatives exhibit a broad variation of colors.  
The compound in which benzene ring is fused to a 4H pyran ring is known as 4H-
chromene (4H-l -benzopyran). Chromene constitute the basic backbone of various 
types of polyphenols and widely found in natural alkaloids, tocopherols, flavonoids, 
and anthocyanins.  The benzopyran nucleus include some structural skeletons such as 
chromane, 2H-chromene and 4H-chromene (figure 1.4) 
 
Figure 1.4. Structural skeletons of chromene 
1.16. Natural occurrence and pharmacological activity of chromone and its 
derivatives 
  Chromones are a group of naturally occurring compounds that are ubiquitous 
in nature, especially in plants, such as flavones and isoflavones. Flavones and 
isoflavones have been of interest for many years, as they have shown a broad range of 
biological activities, which are not limited to antioxidant24, anti-inflammatory25 and 
antiviral effects26. Figure 1.5 shows natural and synthetic chromone heterocyclic 
compounds. On the other hand, chromen ring acts as an essential chromophore in 
recent drug discovery. 
Chromone was obtained from the flower of Wisteria sinensis that exhibit 
organoleptic property. An additional naturally occurring chromone was uvafzlelin that 
isolated from the stems of Uvaria ufielii which shows broad spectrum of antimicrobial 
activity against gram-positive and acid-fast bacteria.  Vitamin E was an evident 
example for the naturally occurring chromone, which possess antioxidant activity. 
Conrauinone A was a naturally occurring fused ring chromone, has been isolated from 
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the bark of the tree Millettia conraui and potentially utilized for the treatment of 
intestinal parasites. Another natural compound was Erysenegalensein C which has 
been extracted from the bark of Erythrina senegalensis and found potential use in the 
treatment of stomach pain, female infertility and gonorrhea. A number of 
biologically-active chromones have been isolated from Piper gaudichaudianum and 
from P. aduncum and these chromones have been shown to exhibit anti-fungal and 
antitumor properties27. 
 
Figure 1.5. Natural and synthetic chromone containing heterocyclic compounds 
The rigid bicyclic chromone fragment has been classified as a privileged 
structure in drug discovery, due to its use in a wide variety of pharmacologically 
active compounds such as anticancer, anti-HIV, antibacterial and anti-inflammatory 
agents28. Presence of chromene-based structure in a molecule is often associated with 
its capacity to prevent diseases. Few naturally occurring chromene exhibit 
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antimicrobial, antitumor, antiviral and mutagenic, antiproliferative and central 
nervous system (CNS) activities29. Some chromones are sex pheromones. Numerous 
synthetic derivatives of naturally occurring chromene have found use in 
pharmaceuticals, particularly as antifungal and antimicrobial agents. Certain 2- amino 
chromene derivatives are used in cosmetics and pigments industry30. Several 
chromone derivatives have also been reported to act as kinase inhibitors, to bind to 
benzodiazepine receptors and as efficient agents in the treatment of cystic fibrosis31. 
Some chromene derivatives might prove useful synthetic intermediates for the 
synthesis of certain naturally occurring substances, such as Miroestrol32.  A key 
feature is that the lipophilic nature of the benzopyran derivatives helps to cross the 
cell membrane easily. Chromene derivatives are also plays important role in the 
production of highly effective fluorescent dyes for synthetic fibers, daylight 
fluorescent pigments and electro photographic and electroluminescent devices.  
1.17. Cancer 
Among various diseases, cancer has become a big threat to human beings 
globally.  Cancer is also known as a malignant tumor or malignant neoplasm, which is 
a group of diseases involving abnormal cell growth with the potential to invade or 
spread to other parts of the body33. Not all tumors are cancerous; benign tumors do 
not spread to other parts of the body. Cancer results from a series of molecular events 
that fundamentally alter the normal properties of cells. In cancer cells the normal 
control systems that prevent cell overgrowth and the invasion of other tissues are 
disabled. These altered cells divide and grow in the presence of signals that normally 
inhibit cell growth. Therefore they no longer require special signals to induce cell 
growth and division. As these cells grow they develop new characteristics, including 
changes in cell structure, decreased cell adhesion, and production of new enzymes. 
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These heritable changes allow the cell and its progeny to divide and grow, even in the 
presence of normal cells that typically inhibit the growth of nearby cells. Such 
changes allow the cancer cells to spread and invade other tissues34. 
Six characteristics of cancer have been proposed: 
o Self-sufficiency in growth signaling 
o Insensitivity to anti-growth signals 
o Evasion of apoptosis 
o Enabling of a limitless replicative potential 
o Induction and sustainment of angiogenesis 
o Activation of metastasis and invasion of tissue. 
Cancer is a leading cause of death group worldwide and accounted for 7.4 
million deaths (around 13% of all deaths) in 200435. More than 70% of all cancer 
deaths occurred in low- and middle-income countries. Deaths from cancer worldwide 
are projected to continue rising, with an estimated 11.5 million deaths in 203036. 
 Globally, the five most common cancers considered in both sexes such as 
• Lung (1,824,701; 13%),   
• Breast (1,676,633; 11.9%),   
• Colorectal (1,360,602; 9.7%),   
• Prostate (1,111,689; 7.9%), and  
• Cervix uteri (527,624; 3.7%). 
The estimated five most common cancers in men is listed below and death due to 
these cancers as 2,769,670. 
• Lung (16.7%),   
• Prostate (15%),  
• Colorectum (10%),  
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• Stomach (8.5%) and  
• Liver (7.5%)  
In women, the five most common cancers is listed below, and these cancers with a 
total of 3,721,266 cases. Death due to these cancers was 1,675,069.  
• Breast (25.2%),  
• Colorectum (9.2%),  
• Lung (8.8%),  
• Cervix uteri (7.9%), and  
• Corus uteri (4.8%)  
1.17.1. Lung cancer 
Lung cancer happens when the cells in lungs start to grow in an uncontrolled 
way and form tumors. Tumors are lumps of tissue made up of abnormal cells. Lung 
cancer that starts in the lung is called primary lung cancer; if the cancer started in 
another part of the body and metastasizes to the lung, it is called secondary lung 
cancer. 
1.17.2. Causes of Lung cancer 
Primary lung cancer is caused by the out-of-control growth of cells that do not 
die in the normal cell pattern. The cause of lung cancer may not always be known. 
Carcinogens are those things that can cause cancer. Normal cells in the lung can be 
affected by carcinogens in the environment, genetic factors, or a combination of those 
factors. Exposure to carcinogens may form molecules in the body called free radicals 
which damage cells and alter the DNA of the cell. This damage may cause cancer. 
Environmental factors include things such as smoking, secondhand smoke, radon gas, 
air pollutants, asbestos, heavy metals, and chronic dust exposure. Genetic factors may 
include an inherited (passed from parent to child) or a genetic mutation.  
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 Lung cancers are generally divided into five types, which are based on how it looks 
under the microscope.  
• Non-small cell lung cancer 
• Small cell lung cancer 
• Mesothelioma 
• Carcinoid 
• Sarcoma 
Among these NSCLC and SCLC represent about 96% of all lung cancers. 
These two types of lung cancer are I dentified by the size of abnormal cells and the 
way the cancer spreads in the body. 
  Small cell cancer (SCLC) tends to grow more quickly than non-small cell 
cancer. Because it grows more quickly, SCLC is often found when it has spread 
outside of the lung.  
1.17.3. Stages of small cell lung cancer 
Small cell lung cancer is staged as ‘limited’ or ‘extensive’. ‘Limited’ means 
that it is only in one lung. ‘Extensive’ means that is has spread to other parts of body. 
1.17.4. Stages of non-small cell lung cancer 
Non-small cell lung cancer has four stages – one to four. These tell how much 
it has spread to other parts of your body. Stage four is the most widely spread, or 
advanced. 
 
Stage 1 
The cancer is only in lungs and is not in any of lymph glands 
(part of the immune system which helps the body fight infection). 
Stage 2 
Stage 2A 
 
 
The cancer is small but cancer cells have spread to the lymph 
glands nearest to affected lung.  
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Stage 2B 
The cancer is slightly larger and has spread to the lymph glands 
nearest affected lungs. Or, the cancer cells have spread to another 
area such as chest wall. 
Stage 3 
 
Stage 3A 
 
 
 
Stage 3B 
 
Cancer cells have spread to the lymph glands furthest away from 
your affected lung. Or, the cancer is in the lymph glands nearest 
to your affected lung, and cancer cells have spread to either your 
chest wall or the middle of chest. 
The cancer cells have spread to the lymph glands in the other side 
of chest or to the lymph glands above collarbone. Or, there is 
more than one tumour in lung. Or, the tumor has grown into 
another area in chest such as heart or gullet. Or, there is fluid 
around lungs that contains cancer cells. 
 
Stage 4 The cancer has spread to another part of body such as liver or 
bones. 
The symptoms of lung cancer can include: 
o Coughing up blood 
o A persistent cough 
o Breathlessness 
o Wheezing 
o Hoarseness 
o Chest or shoulder pain 
o Tiredness 
o Weight loss 
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1.17.5. Treatment of Lung Cancer 
Possible treatments for lung cancer include surgery, chemotherapy, radiation 
therapy, targeted therapy or a combination of these. 
Lung cancer treatments fall into two 
Local therapy: Surgery and radiation therapy are local therapies. They remove or 
destroy cancer tumors in the lungs. If lung cancer has spread to other parts of the 
body, such as other organs or bones, the doctors may use one of these local therapies 
to control the disease in those specific areas as well. 
Systemic therapy: Chemotherapy and targeted therapies are systemic therapies. 
These drugs enter the bloodstream to destroy or control cancer everywhere in the 
body. Systemic therapy is taken by mouth or given through a vein in the arm or a port 
that is inserted in chest (intravenous). 
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1. El-Sayed Ali et al., studied “Synthesis of some new 4-oxo-4H-chromene 
derivatives bearing nitrogen heterocyclic systems as antifungal agents”.37 
 
2. Batista et al., studied “Natural chromenes and chromene derivatives as 
potential anti-trypanosomal agents”. 38  
 
3. Dyrager et al., studied “Design, synthesis, and biological evaluation of 
chromone-based p38 MAP kinase inhibitors”.39 
 
4. Al-Said et al., studied “Dapson in heterocyclic chemistry, part VIII: synthesis, 
molecular docking and anticancer activity of some novel sulfonyl 
biscompounds carrying biologically active 1, 3-dihydropyridine, chromene 
and chromenopyridine moieties”40. 
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5. Azab et al., studied “Microwave-assisted synthesis of novel 2H-chromene 
derivatives bearing phenyl thiazolidinones and their biological activity 
assessment”.41 
 
6. Mohamed et al., studied “Green chemistry: new synthesis of substituted 
chromenes and benzochromenes via three-component reaction utilizing 
rochelle salt as novel green catalyst”.42 
 
7. Keri et al., describes the “Chromones as a privileged scaffold in drug 
discovery: A review”. The present review focuses on the pharmacological 
profile of chromone derivatives in the current literature with an update of 
recent research findings on this nucleus and the perspectives that they hold for 
future research.43 
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8. Vichai et al., studied on “Sulforhodamine B colorimetric assay for 
cytotoxicity Screening”. The sulforhodamine B (SRB) assay is used for cell 
density determination, based on the measurement of cellular protein content. 
The method described here has been optimized for the toxicity screening of 
compounds to adherent cells in a 96-well format. After an incubation period, 
cell monolayer are fixed with 10% (wt/vol) trichloroacetic acid and stained for 
30 min, after which the excess dye is removed by washing repeatedly with 1% 
(vol/vol) acetic acid. The protein-bound dye is dissolved in 10 mM Tris base 
solution for OD determination at 510 nm using a microplate reader. The 
results are linear over a 20-fold range of cell numbers and the sensitivity is 
comparable to those of fluorometric methods. The method not only allows a 
large number of samples to be tested within a few days, but also requires only 
simple equipment and inexpensive reagents. The SRB assay is therefore an 
efficient and highly cost-effective method for screening.44 
9. Mohamed et al., synthesized various (2- substituted phenyl) 
benzimidazoles45. 
N
N
N
R
R
X
 
R=CH3, CH2CH3, Ph 
10. Chari et al., reported the synthesis of benzimidazoles through the coupling of 
aldehydes with ortho phenylenediamine by using highly acidic nanoporous 
aluminosilicate with 3D structure and cage-type porous as the catalyst46. 
Chapter 3 Aim and Objective 
Dept. of Pharmaceutical chemistry, JKKNCP.  
 
Page | 25
N
H
N
Ar
 
11. Kamal et al., reported the synthesis of 2-aryl-1-aryl-methyl-1H-
benzimidazoles by using ceric(IV) ammonium nitrate as catalyst47. 
N
N
Ar
Ar
 
12. Salehi et al., synthesized 2-aryl-1-arylmethyl-1H-1, 3-benzimidazoles by 
using silica sulfuric acid as catalyst48. 
N
H
N
R2
R1
R1
 
13. Alajarin et al., reported the synthesis of pyrido [1, 2-a] benzimidazole 
derivatives42. 
N
N
Ar
H
R1 R2
 
14. Jesudason et al. synthesized N-Mannich bases of benzimidazole derivatives49. 
 
N
N
R2
R1
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R1 = H, CH3, -CH=CH-C6H5 
R2 = -N(CH3)2, -N(C2H5)2, -N(C6H5)2 
15. Pawar et al., Synthesized various N-alkyl and N-acyl derivatives of 2-(4-
thiazolyl)-1H-benzimidazoles and screened for their antifungal and 
antibacterial activities50. 
N
N
R
N
S
 
16. Yunhe et al., synthesized some benzimidazole derivatives and screened for 
antibacterial activity against Staphylococcus aureus and Escherichia coli51. 
 
 
 
 
 
 
 
17. Sivakumar et al. synthesized some novel 2-(6-fluorochroman-2-yl)-1-
alkyl/acyl/aroyl-1H-benzimidazoles and screened for antibacterial activity 
against Salmonella typhimurium53. 
 
N
N
O F
R
 
N
N
Cl
Cl
NH
R2R1N
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18. Ramya  et al., synthesized some novel 5-(nitro/bromo)-styryl-2-
benzimidazoles and screened in vitro anti-tubercular activity against 
Mycobacterium Tuberculosis  H37 Rv, anti-bacterial activity against 
Staphylococcus aureus, Escherichia coli, Enterococcus faecalis, Klebsiella 
pneumoniae bacterial strains and anti-fungal activity against Candida albicans 
and Asperigillus fumigatus fungal strains54. 
N
N
H
H
H
R
R1
 
19. David et al. synthesized some novel benzimidazole derivatives and screened 
for their in vitro (rat tunica muscularis mucosae) and in vivo tests (Bezold–
Jarisch reflex in rat and gastrointestinal motility and spontaneous motility in 
mice) 55. 
20. Maria et al. synthesized new benzimidazole-4-carboxamides and 
Carboxylates and screened for serotonergic 5-HT4 and 5-HT3 receptor 
antagonistic property56. 
N
NH
X
O
YR
 
R= H, Cl 
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3. AIM & OBJECTIVE 
Aim: 
The main aim of this proposed research work is to design and synthesize a 
novel class of (E)-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one 
derivatives and  characterization by using  IR, 1H NMR, 13C NMR, and mass 
spectroscopy. Further these novel set of compounds will be screened for various 
pharmacological activities. 
 Objective: 
• Design and synthesize (E)-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl) vinyl)-4H-
chromen-4-one derivatives. 
• Develop the efficient methodologies for accomplishing their synthesis. 
• Elucidate the structure of synthesized molecule by IR, 1H NMR, 13C NMR, 
and mass spectroscopy. 
• Perform the quantitative structure activity relationship (QSAR) of newly 
synthesized bioactive compounds. 
• Molecular docking studies for newly designed compounds using 
AUTODOCK software 
• Biological evaluation of newly synthesize compounds such as, In vitro Anti 
cancer activity 
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4. SCHEME OF THE WORK 
 
Step 1: 
 
 
 
 
 
Step 2: 
 
 
 
 
Step 3: 
 
 
(E)-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one Derivatives 
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Table 4.1: chemical structure of newly designed molecule 
 
 
Sl. No Compound code R 
1 R1 6-Cl 
2 R2 7-F 
3 R3 6-CH3 
4 R4 -H 
5 R5 6,7-Cl 
6 R6 6-F 
7 R7 6-OCH3 
8 R8 6-Br 
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5. EXPERIMENTAL SECTION 
5.1. Materials and methods 
All the chemicals were purchased from sigma Aldrich U.S.A. Analytical TLC 
was performed on Precoated sheets of silica gel G/UV-254 of 0.2mm thickness 
(Macherey-Nagel, Germany) using analytical grade solvent and visualized with iodine 
spray (10% w/w I2 in silica gel) or UV light. We also used bioinformatics tools, 
biological databases like PDB (Protein Data Bank) and software’s like Autodock and 
ACD ChemSketch. The PDB (Protein Data Bank) is the single worldwide archive of 
Structural data of Biological macromolecules, established in Brookhaven National 
Laboratories (BNL). It contains Structural information of the macromolecules 
determined by X-ray crystallographic, NMR methods etc. Auto Dock is an automated 
docking tool. It is designed to predict how small molecules, such as substrates, bind to 
a receptor of known 3D structures. Argus lab also one of the automated docking tool. 
5.2. Equipment and analytical instrument 
Melting point was determined in capillary tubes and is uncorrected. IR spectra 
were taken as KBr pellets for solids on Perkin Elmer Spectrum FT-IR. 1H NMR 
(400MHz) and 13C NMR (100 MHz) spectra were recorded in DMSO-d6 solution 
with TMS as an internal standard on Bruker instrument. Spin multiplicities are given 
as s (singlet), d (doublet), t (triplet) and m (multiplet). Coupling constant (J) is given 
in hertz. Mass spectra were recorded on a thermo Finnigan LCQ Advantage MAX 
6000 ESI spectrometer. 
5.3. General procedure for the synthesis of title compounds 
Step 1: Synthesis of 2-methyl-1H-benzo[d]imidazole 
 Place 5.43g of o-phenylene diamine, 20ml of water and 5.4g of acetic acid in 
RBF. 
 Reflux in a water bath for 45 minutes. 
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 Cool and add 10% ammonia solution slowly with constant shaking. 
 Filter the precipitated product. 
 Recrystallise it from 10% aqueous ethanol and activated charcoal. 
 
 
Step 2: 2-methyl-5-nitro-1H-benzo[d]imidazole 
 2-methyl-1H-benzo[d]imidazole adds 5 mL of Con. HNO3, 5 mL of Con 
H2SO4 and reflux for 30 mints. 
 After that pour the reaction mixture into cold water and shack vigorously. The 
yellow colour of 2-methyl-5-nitro-1H-benzo[d]imidazole was precipitated out. 
 
Step 3: (E)-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one 
Derivatives 
 1mmole of 2-methyl-1H-benzo[d]imidazole and add 1mmole of various 
substituted chromen 3 carboldehyde dissolved in ethanol. 
 Add 10 mL of Glacial Acetic acid and reflux for 1 hr.  
 The completion of reaction monitor by using TLC using ethyl acetate and 
petroleum ether (50:50) as mobile phase.  
 Upon completion of reaction, the reaction mixture was filtered, washed with 
acetic acid or ethanol and dry using vacuum. 
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(E)-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one Derivatives 
  
Sl. No Compound code R 
1 R1 6-Cl 
2 R2 7-F 
3 R3 6-CH3 
4 R4 -H 
5 R5 6,7-Cl 
6 R6 6-F 
7 R7 6-OCH3 
8 R8 6-Br 
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6. CHARECTERIZATION OF TITLE COMPOUNDS 
6.1. Spectral data for synthesized compound 
6.1.1. IR spectral data 
 
 
Figure.6.1. IR Spectra for compound R1 
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Figure.6.2. IR Spectra for compound R2 
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Figure.6.3. IR Spectra for compound R3 
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Figure.6.4. IR Spectra for compound R4 
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Figure.6.5. IR Spectra for compound R5 
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Figure.6.6. IR Spectra for compound R6 
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Figure.6.7. IR Spectra for compound R7 
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Figure.6.8. IR Spectra for compound R8 
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6.1.2. NMR spectral data 
 
 
 
 
 
Figure.6.9. 1H NMR spectrum of compound R1 
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Figure.6.10. 13C NMR spectrum of compound R1 
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Figure.6.11. 1H NMR spectrum of compound R7 
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Figure.6.12. 13C NMR spectrum of compound R7 
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6.1.3. Mass Spectra 
 
 
Figure 6.13: Mass Spectra of Compound R1 
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Figure 6.13: Mass Spectra of Compound R4 
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6.2. CHARACTERIZATION OF TITLE COMPOUNDS 
6.2.1. (E)-6-chloro-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one 
(R1) 
 
 
C18H10ClN3O4; MP: 218-2200C; Orange solid; 1H NMR (400 MHz, DMSO) δ 8.39 (s, 
1H), 8.07 (d, J = 7.1 Hz, 1H), 8.10 (m, 2H), 7.86 – 7.77 (m, 3H) 6.39 – 6.37 (d, 1H), 
6.65 (s, 1H), 5.0 (s, NH). 13NMR (101 MHz, DMSO) δ 178.5, 163.2, 155.3, 144.3, 145.0, 
141.5, 139.8, 136.4, 145.0, 130. 6, 129.0, 128.8, 125.5, 125.3, 119.6, 118.6, 116.1, 112.2. 
IR (KBr): 3158, 3095, 1634, 1644, 724; ESI-MS: m/z 367.74; Elemental Analysis: C, 
58.79; H, 2.74; Cl, 9.64; N, 11.43; O, 17.40.  
 
6.2.2. (E)-7-fluoro-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one 
(R2) 
 
 
 
C18H10FN3O4; MP: 210-2120C; Yellow solid; 1H NMR (400 MHz, DMSO) δ 8.39 (s, 
1H), 8.17 (d, J = 7.1 Hz, 1H), 8.10 (m, 2H), 7.56 – 7.67 (m, 3H) 6.36 – 6.31 (d, 1H), 
6.65 (s, 1H), 5.0 (s, NH). 13NMR (101 MHz, DMSO) δ 178.5, 163.2, 155.3, 144.3, 145.0, 
141.5, 139.8, 136.4, 145.0, 130. 6, 128.7, 128.8, 125.5, 125.3, 119.6, 117.6, 116.1, 111.2. 
IR (KBr): 3157, 3095, 1644, 1317, 1124, 824, 726; ESI-MS: m/z 351; Elemental 
Analysis: C, 61.54; H, 2.87; F, 5.41; N, 11.96; O, 18.22. 
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6.2.3. (E)-6-methyl-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-
one (R3) 
 
 
C19H13N3O4; MP: 200-2020C; Orange solid; 1H NMR (400 MHz, DMSO) δ 8.29 (s, 1H), 
8.07 (d, J = 7.1 Hz, 1H), 8.10 (m, 2H), 7.56 – 7.67 (m, 3H) 6.36 – 6.31 (d, 1H), 6.65 (s, 
1H), 5.0 (s, NH), 2.33 (T, 3H). 13NMR (101 MHz, DMSO) δ 178.5, 163.2, 155.3, 144.3, 
145.0, 141.5, 139.8, 136.4, 145.0, 130. 6, 128.7, 128.8, 125.5, 125.3, 119.6, 117.6, 116.1, 
111.2. 20.98 IR (KBr): 3158, 3095, 2940, 1644, 1435, 1374, 834, 637; ESI-MS: m/z 347; 
Elemental Analysis: C, 65.70; H, 3.77; N, 12.10; O, 18.43. 
 
6.2.4. (E)-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one (R4) 
 
 
C18H11N3O4; MP: 220-2220C; Orange solid; 1H NMR (400 MHz, DMSO) δ 8.29 (s, 2H), 
8.07 (d, J = 7.1 Hz, 2H), 8.10 (m, 2H), 7.67 (s, 1H), 7.56 – 7.47 (m, 4H),  6.36 – 6.31 (d, 
2H), 6.65 (s, 2H), 5.0 (s, NH),. 13NMR (101 MHz, DMSO) δ 178.5, 163.2, 155.3, 144.3, 
145.0, 141.5, 139.8, 136.4, 145.0, 130. 6, 128.7, 128.8, 125.5, 125.3, 119.6, 118.2, 
115.90, 111.2.IR (KBr): 3159, 1641, 1499, 1215, 824, 725, 637; ESI-MS: m/z 333; 
Elemental Analysis: C, 64.86; H, 3.33; N, 12.61; O, 19.20. 
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6.2.5. (E)-6,7-dichloro-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-
4-one (R5) 
 
 
C18H9Cl2N3O4; MP: 221-2230C; Orange solid; 1H NMR (400 MHz, DMSO) δ 8.49 (s, 2H), 
8.37 (d, J = 7.1 Hz, 2H), 8.14 (m, 2H), 7.77 (s, 1H), 7.46 – 7.37 (m, 3H),  6.36 – 6.31 (d, 
2H), 6.55 (s, 2H), 5.2 (s, NH),. 13NMR (101 MHz, DMSO) δ 178.5, 163.2, 155.3, 144.3, 
145.0, 141.5, 139.8, 136.4, 145.0, 130. 6, 128.7, 128.8, 125.5, 125.3, 119.6, 118.2, 
115.90, 115.2.IR (KBr): 1644, 1468, 1336, 824, 725, 637; ESI-MS: m/z 402; Elemental 
Analysis: C, 53.75; H, 2.26; Cl, 17.63; N, 10.45; O, 15.91. 
 
6.2.6. (E)-6-fluoro-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one 
(R6) 
 
 
C18H10FN3O4; MP: 210-2120C; Yellow solid; 1H NMR (400 MHz, DMSO) δ 8.39 (s, 
1H), 8.17 (d, J = 7.1 Hz, 1H), 8.10 (m, 2H), 7.56 – 7.67 (m, 3H) 6.36 – 6.31 (d, 1H), 
6.65 (s, 1H), 5.0 (s, NH). 13NMR (101 MHz, DMSO) δ 178.5, 163.2, 155.3, 144.3, 145.0, 
141.5, 139.8, 136.4, 145.0, 130. 6, 128.7, 128.8, 125.5, 125.3, 119.6, 117.6, 116.1, 111.2. 
IR (KBr): 3157, 3095, 1644, 1317, 1124, 824, 726; ESI-MS: m/z 351; Elemental 
Analysis: C, 61.54; H, 2.87; F, 5.41; N, 11.96; O, 18.22. 
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6.2.7. (E)-6-methoxy-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-
one (R7) 
 
 
C19H13N3O5: MP: 216-2180C; Orange solid; 1H NMR (400 MHz, DMSO) δ 8.39 (s, 1H), 
8.17 (d, J = 7.1 Hz, 1H), 8.10 (m, 2H), 7.56 – 7.67 (m, 3H) 6.36 – 6.31 (d, 1H), 6.65 (s, 
2H), 5.0 (s, NH) 3.90 (m, 3H). 13NMR (101 MHz, DMSO) δ 178.5, 163.2, 155.3, 144.3, 
145.0, 141.5, 139.8, 136.4, 145.0, 130. 6, 128.7, 128.8, 125.5, 125.3, 119.6, 117.6, 116.1, 
111.2. IR (KBr): 3157, 3011, 2980, 2927, 1644, 1574, 1156, 1317, 937, 637; ESI-MS: 
m/z 363; Elemental Analysis: C, 62.81; H, 3.61; N, 11.57; O, 22.02.  
 
6.2.8. (E)-6-bromo-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-
one (R8) 
 
 
C18H10BrN3O4; MP: 218-2200C; Orange solid; 1H NMR (400 MHz, DMSO) δ 8.49 (s, 
1H), 8.27 (d, J = 7.1 Hz, 1H), 8.20 (m, 2H), 7.56 – 7.67 (m, 3H) 6.36 – 6.31 (d, 1H), 
6.65 (s, 1H), 5.0 (s, NH). 13NMR (101 MHz, DMSO) δ 179.01, 163.2, 155.3, 144.3, 
145.0, 141.5, 139.8, 136.4, 145.0, 130. 6, 128.7, 128.8, 125.5, 125.3, 119.6, 117.6, 116.1, 
111.2. IR (KBr): 3157, 3095, 1644, 1317, 1124, 824, 726; ESI-MS: m/z 412; Elemental 
Analysis: C, 52.45; H, 2.45; Br, 19.39; N, 10.19; O, 15.53. 
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7. PRELIMINARY QSAR STUDIES 
Table.7.1. Physico-chemical properties of synthesized compound 
 
Com 
code Structure 
Molecular 
Formula 
Mol 
weight 
Melting 
point Appearance 
R1 
 
 
C18H10ClN3O4 367 218-2200C Orange solid 
R2 
 
C18H10FN3O4 351 
210-
2120C Yellow solid 
R3 
 
 
 
C19H13N3O4 347 
200-
2020C Orange solid 
R4 
 
 
 
C18H11N3O4 333 
220-
2220C Orange solid 
R5 
 
 
 
C18H9Cl2N3O4 402 220-2220C Orange solid 
R6 
 
 
 
C18H10FN3O4 351 
219-
2210C Orange solid 
R7 
 
 
 
C19H13N3O5 363 
216-
2180C Orange solid 
R8  C18H10BrN3O4 412 218- Orange solid 
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2200C 
Table.7.2. Solubility data of synthesized compounds 
 
 
Compound 
code Water Acetone Chloroform DMSO Ethanol Methanol 
Ethyl 
acetate 
R1 - ++ +++ +++ + ++ + 
R2 - ++ +++ +++ + ++ + 
R3 - ++ +++ +++ + ++ + 
R4 - ++ +++ +++ + ++ + 
R5 - ++ +++ +++ ++ ++ + 
R6 - ++ +++ +++ + ++ + 
R7 - ++ ++ +++ + ++ + 
R8 - ++ ++ +++ + ++ + 
 
+++ = Freely soluble; ++ = Soluble; + = Slightly soluble; - = Insoluble 
 
Table7.3. QSAR studies of synthesized compounds 
 
Compound 
Code 
Log P TPSA 
N 
atoms 
n ON 
N 
OHNH 
N 
Violation 
N rotb Volume 
R1 3.48 104.72 25 7 1 0 3 275.57 
R2 4.13 104.72 26 7 1 0 3 289.10 
R3 4.47 104.72 27 7 1 0 3 302.64 
R4 2.64 104.72 26 7 1 0 3 280.50 
R5 3.62 104.72 26 7 1 0 3 280.50 
R6 4.26 104.72 26 7 1 0 3 293.45 
R7 3.90 104.72 26 7 1 0 3 292.13 
R8 3.51 113.95 27 8 1 0 4 301.11 
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Table. 7.4. Lipinski rule for title compounds 
 
Compound 
code 
Molecular 
Weight 
No. of H 
bond 
donor 
No. of H 
bond 
Acceptor 
TPSA 
No. of 
Rotatable 
Bond 
Log P 
R1 367 0 7 104.72 3 3.48 
R2 351 0 7 104.72 3 4.13 
R3 347 0 7 104.72 3 4.47 
R4 333 0 7 104.72 3 2.64 
R5 402 0 7 104.72 3 3.62 
R6 351 0 7 104.72 3 4.26 
R7 363 0 8 104.72 3 3.90 
R8 412 0 7 113.95 4 3.51 
 
 
 
 
Table.7.5. Drug likeness score for title compounds 
 
Compound 
Code 
GPCR 
Ligand 
Ion 
channel 
modulator 
Kinase 
inhibitor 
Nuclear 
Receptor 
ligand 
Protease 
Inhibitor 
Enzyme 
Inhibitor 
R1 
-0.16 -0.32 -0.11 -0.22 -0.65 -0.07 
R2 -0.16 -0.32 -0.12 -0.23 -0.65 -0.10 
R3 -0.13 -0.25 -0.16 -0.18 -0.62 -0.07 
R4 -0.13 -0.32 -0.08 -0.18 -0.65 -0.07 
R5 -0.07 -0.27 -0.05 -0.22 -0.62 -0.06 
R6 -0.28 -0.42 -0.16 -0.36 -0.76 -0.16 
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R7 -0.20 -0.39 -0.16 -0.23 -0.68 -0.12 
R8 -0.19 -0.37 -0.12 -0.20 -0.67 -0.10 
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8. DOCKING STUDY 
8.1. Docking Studies of Synthesized Compound on Various Enzymes  
8.1.1. Introduction 
In the field of molecular modeling, docking is a method which predicts the 
preferred orientation of one molecule to second when bound to each other to form a 
stable complex and it is also key tool in structural molecular biology and computer 
assisted drug design. Docking is frequently used to predict the binding orientation of 
small molecule drug candidates to their protein targets in order to in turn predict the 
affinity and activity of the small molecule57. The small molecule, known as ligand 
usually fits within the proteins cavity which is predicted by search algorithm. These 
protein cavities become active when come in contact with any external compounds and 
are thus called as active sites. Hence docking plays an important role in the rational 
design in drugs58.  
Docking is a method which predicts the preferred orientation of one molecule to a 
second molecule when bound to each other to form a stable complex in three 
dimensional spaces. In cell biology, the function protein is a result of its interaction with 
other proteins as well as other molecule components. So if we could predict how protein 
interacts with other molecules, we could possibly inhibit the function. Thus the result of 
docking was extremely beneficial in finding drugs which are effective against particular 
disease. The knowledge of the preferred orientation in turn may be used to predict the 
strength of association or binding affinity between two molecules using scoring function. 
There is much commercially available docking software each using a different 
combination of searching method and algorithm and scoring function. These are 
• GOLD (Genetic Optimization for Ligand Docking) 
• Glide 
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• Drug Discovery 
• Auto dock 1.5.4 
Among these in my research work i have used auto dock software to calculate the free 
energy binding of ligand towards various target enzymes. 
  8.1.2. AUTODOCK 1.5.4 
Autodock is a software suite to develop in Scripps Research Institute. This 
software is used for modeling flexible small molecule such as drug molecule binding to 
receptor proteins. The current version of Autodcok uses genetic algorithm for the 
conformational search and is a suitable method for the docking studies. Scripps Research 
Institute has developed a Graphical User Interface (GUI) using Python 2.5 language, and 
it is called Autodock Tool (ADT). ADT is used to prepare, run and analyze the docking 
stimulation, in addition to its several features necessary for modeling studies.  
8.1.3. Major steps involved in molecular docking 
Step I – Building the receptor 
In this step the 3D structure of the receptor should be downloaded from PDB and 
modified. This should include removal of water molecules from the cavity, stabilizing 
charges, filling in the missing residue, generation of side chain etc., according to the 
parameters available. After modification the receptor should be biologically active and 
stable. 
Step II – Identification of active site 
After the receptor is build, the active site within the receptor should be identified. 
The receptor may have many active sites but the one of the interest should be selected.  
Step III – Ligand preparation  
Ligand can be obtain from various databases like ZINC, PubChem or can be 
sketched using tools like chemsketch. While selecting the ligand, the Lipinski rule of 5 
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should be applied.  The rule is very important for drug development where the 
pharmacologically active lead structure is optimized stepwise for increased activity and 
selectivity as well as drug like properties.  
 Step IV – Docking 
This is a last step, where the ligand is docked into receptor and the interaction are 
checked. The scoring function generates depending on which ligand with best fit was 
selected.  
8.2. MAP Kinase as target Enzyme 
Over the last decade, the pursuit of p38a MAP kinase inhibitors has received an 
extraordinary level of attention in the pharmaceutical industry and in the medicinal 
chemistry community. A unique combination of well-established pharmacology, clinical 
efficacy and the opportunity to utilize structure-based drug design has made this a highly 
attractive target for therapeutic intervention. There is overwhelming evidence indicating 
that p38a plays a dominant role in regulating the production of pro-inflammatory 
cytokines, such as tumor necrosis factor and interleukin-1. Blocking this kinase may 
offer an effective therapy for treating many inflammatory diseases. 
However great number of heterocyclic compounds display interesting anti-
inflammatory and anti-cancer especially benzimidazole and 4H–chromen–4–one 
derivatives having important role in this concern. Compounds containing benzimidazole 
rings, which are formed via the fusion of imidazole and benzene rings, have been used 
extensively for pharmaceutical purposes. 1H-Benzimidazole rings exhibit remarkable 
number of biologically activities due to their nitrogen content, which comprise the active 
substrate of several drugs. Benzimidazole derivatives possessing wide range biological 
activities like antibacterial, antifunga, anticancer, anti-HIV, anti-tubercular. Presence of 
chromene-based structure in a molecule is often associated with its capacity to prevent 
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diseases. Chromone containing compound exhibit anticancer, anti-HIV, antibacterial, 
anti-inflammatory agents, antimicrobial, antitumor, antiviral and mutagenic, anti-
proliferative and central nervous system activities. Both the derivatives produced various 
biological activities individually. Hence we are planned to incorporate both the nucleus 
by chemical reaction. The designed compound were evaluated for their molecular 
properties by the “Lipinski’s rule of 5” and further their ability to bind in the active site 
region of MAP Kinase identified using molecular docking approach. 
8.3. Molecular docking study  
In order to gain more insight on the binding mode of the compounds with MAP 
Kinase docking studies using Auto Dock 4.0.1 were carried out. Top scoring molecules 
from the largest cluster were considered for interaction studies. The crystallographic 
structure of MAP kinase, which is retrieved from the RCSB Protein Data Bank (PDB 
code 1CM8) serves as docking receptor, and all the designed compounds are selected as 
ligand molecules. Before docking the screened ligands in to the protein active site, the 
protein was prepared by deleting the substrate cofactor as well as the crystallographically 
observed water molecules and then protein was defined for generating the grid. All 
molecules were drawn using ChemDraw Ultra 8.0 tool and energy minimized using 
Chem 3D Ultra 8.0 software.  
8.5. Auto Dock 4.0.1 procedure 
Automated docking was used to locate the appropriate binding orientations and 
conformations of various inhibitors into the 1CM8 binding pocket. To perform the task, 
the powerful genetic algorithm method implemented in the program Auto Dock 4.0.1 
was employed. Grid maps were generated by AutoGrid program. Each grid was centered 
at the crystal structure of the corresponding 1G2A and 2GT1 separately. Lamarckian 
Genetic Algorithm was employed as the docking algorithm. The grid dimensions were 
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60 Å X 60 Å X 60 Å with points separated by 0.375 Å. For all ligands, random starting 
positions, random orientations and torsions were used. During docking, grid parameters 
were specified for x, y and z axes as 38.808, 30.946 and 42.249 respectively. The 
Docking parameters Number of Genetic Algorithm (GA) runs: 25, Population size: 150, 
Maximum number of evaluation: 2,500,000, Maximum number of generation: 27,000 
were used for this study. The structure with the lowest binding free energy and the most 
cluster members was chosen for the optimum docking conformation. 
Table 8.1: Energy minimization table of Ligand and MAP kinase 
Interaction 
Code 
Binding 
Energy 
(Kcal/mol) 
 
Inhibition 
Constant 
Vdw. 
Desolvation 
Energy 
Intermol 
Energy 
Ligand 
efficiency 
Electrostatic 
Energy 
Total 
internal 
R1 -7.79 2.04 -7.66 -8.96 -0.31 -1.3 1.19 
R2 -7.95 6.75 -7.83 -8.25 -0.27 -0.42 0.32 
R3 -7.28 6.42 -6.95 -8.28 -0.26 -1.33 -0.44 
R4 -6.41 20.04 -7.48 -7.6 -0.25 -0.12 -.044 
R5 -7.19 5.36 -8.71 -8.38 -0.28 -0.32 -0.42 
R6 -7.76 2.05 -7.73 -8.95 -0.3 -1.23 -0.41 
R7 -7.35 4.1 -8.71 -8.54 -0.28 0.17 -0.44 
R8 -6.58 14.98 -7.89 -8.07 -0.24 -0.19 -0.43 
Diclofenac -7.18 14.32 -8.98 -9.02 -0.32 -0.18 -0.32 
Imatinib  -7.27 53.99 -11.29 -11.65 -0.43 -0.19 -0.54 
 
8.6. Docking Analysis 
The newly designed molecules are energy minimized and the resulting molecules 
are considered for docking analysis using Auto Dock 4.0.1. Auto Dock is employed to 
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study the docking molecules within active site region of 1CM8 and the H-bond 
interaction. Docked scores of newly designed molecules along with inhibition constant, 
Vdw. Desolvation Energy, ligand efficacy and electrostatic energy and hydrogen bonds 
are represented in Table 8.1. and table 8.2. respectively. Among the studied compounds, 
compound R1 have highest binding score (-7.79 K Cal/mol with one hydrogen bond) 
when compared with standard drugs such as Diclofenac -7.18 K Cal/mol (for anti-
inflammatory) and Imatinib -7.27 K Cal/mol (for Anti-cancer) followed by compound 
R6 with score of -7.76 K Cal/mol with one hydrogen bond, compound R5 with score of  
-7.19 K Cal/mol with one hydrogen bond, compound R3 have score of –7.28 with two 
hydrogen bond and lastly compound R4 with score of -6.41 K Cal/mol with one 
hydrogen bond. The docked molecule with MAP Kinase was visualized in Chimara 
software and the docking pose of compounds showed in figure 2 – 5. Docking results 
show that all the designed molecules have similar orientations in the binding pocket of 
MAP Kinase enzyme.  
Table 8.2: Hydrogen bond and hydrophobic interaction of ligand against target enzyme 
MAP kinase 
 
Compound 
code 
No. of 
Hydrogen 
bonds formed 
Amino acid 
involved in H 
bond interaction 
H bond 
distance 
Amino acid 
involved in 
vander waals 
interaction 
R1 1 Agr 82 2.93 
His 80, His 83, Lys 
139, Arg 142, Tyr 
143, Val 323, Gln 
324 
R2 Nil Nil Nil 
Gly 117, Met 120, 
Pro 156, Gly 157, 
Glu 218, Gly 222. 
R3 2 1. Lys 118 2. Lys 121 
2.771 
2.753 
Gly 117, Lys 118, 
Met 120, Glu 218 
R4 1 Asn 119 2.836 
Leu 193, Leu 253, 
Phe 249, Apg 252, 
Leu 294 
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R5 1 THR 242 2.75 
His 80, Arg 82, 
His 83, Lys 139, 
Val 323, Gln 324 
R6 1 TYR 143 3.327 
His 80, Arg 82, 
His 83, Lys 139, 
Arg 142, Tyr 143, 
Val 323, Gln 324 
R7 Nil Nil Nil 
Arg 142, Phe 249, 
Met 120, Glu 218, 
Tyr 143, Val 323 
R8 1 Arg 252 2.67 
Leu 253, Phe 249, 
Apg 252, Gln 254, 
Leu 294. 
Diclofenac Nil Nil Nil Met 120, Glu 218, Val 323, Gln 324. 
Imatinib Nil Nil Nil 
His 80, Arg 82, 
Arg 142, Glu 218, 
Val 323, Gln 324 
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Figure 8.1: Docking pose of compound R1 against MAP Kinase as Target Enzyme 
 
 
Figure 8.2: Docking pose of compound R2 against MAP Kinase as Target Enzyme 
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Figure 8.3: Docking pose of compound R3 against MAP Kinase as Target Enzyme 
 
 
 
Figure 8.4: Docking pose of compound R4 against MAP Kinase as Target Enzyme 
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Figure 8.5: Docking pose of compound R5 against MAP Kinase as Target Enzyme 
 
 
 
Figure 8.6: Docking pose of compound R6 against MAP Kinase as Target Enzyme 
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Figure 8.7: Docking pose of compound R7 against MAP Kinase as Target Enzyme 
 
 
 
Figure 8.8: Docking pose of compound R8 against MAP Kinase as Target Enzyme 
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Figure 8.9: Docking pose of standard drug (Imatinib) against MAP Kinase as Target 
Enzyme 
 
 
 
Figure 8.10: Docking pose of standard drug (Diclofenac) against MAP Kinase as Target 
Enzyme 
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9. IN-VITRO ANTICANCER ACTIVITY 
9.1. Introduction  
Cancers are a large family of diseases which involve abnormal cell growth with 
the potential to invade or spread to other parts of the body. They form a subset of 
neoplasms. A neoplasm or tumor is a group of cells that have undergone unregulated 
growth, and will often form a mass or lump, but may be distributed diffusely. 
Six characteristics of cancer have been proposed: 
• Self-sufficiency in growth signaling 
• Insensitivity to anti-growth signals 
• Evasion of apoptosis 
• Enabling of a limitless replicative potential 
• Induction and sustainment of angiogenesis 
• Activation of metastasis and invasion of tissue. 
The progression from normal cells to cells that can form a discernible mass to 
outright cancer involves multiple steps known as malignant progression. 
The great majority of cancers, some 90–95% of cases, are due to environmental 
factors. The remaining 5–10% is due to inherited genetics. Environmental, as used by 
cancer researchers, means any cause that is not inherited genetically, such as lifestyle, 
economic and behavioral factors, and not merely pollution. Common environmental 
factors that contribute to cancer death include tobacco (25–30%), diet and obesity (30–
35%), infections (15–20%), radiation (both ionizing and non ionizing, up to 10%), stress, 
lack of physical activity, and environmental pollutants. 
 
 
9.2. Anticancer Drug Development 
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Around the world, tremendous resources are being invested in prevention, 
diagnosis, and treatment of cancer. Cancer is the second leading cause of death in Europe 
and North America. Discovery and development of anticancer agents are the key focus 
of several pharmaceutical companies as well as nonprofit government and non-
government organizations, like the National Cancer Institute (NCI) in the United States, 
the European Organization for Research and Treatment of Cancer (EORTC), and the 
British Cancer Research Campaign (CRC). 
Identification of cytotoxic compounds led the development of anticancer 
therapeutics for several decades. Advances in cancer treatment, however, continued to be 
limited by the identification of unique biochemical aspects of malignancies that could be 
exploited to selectively target tumor cells. Schwartsmann et al. noted in 1988 that of over 
600,000 compounds screened by then, less than 40 agents were routinely used in the 
clinic. The recent growth in molecular sciences and the advances in genomics and 
proteomics have generated several potential new drug targets, leading to changes in the 
paradigms of anticancer drug discovery toward molecularly targeted therapeutics. These 
shifting paradigms have not only resulted in the greater involvement of biological 
scientists in the drug discovery process but also required changes in the screening and 
clinical evaluation of drug candidates. Both small and large molecular compounds 
continue to be investigated as anticancer agents. 
The discovery and development of anticancer drugs, especially cytotoxic agents, 
differ significantly from the drug development process for any other indication. The 
unique challenges and opportunities in working with these agents are reflected in each 
stage of the drug development process. This chapter will highlight the unique aspects of 
anticancer drug discovery and development. 
9.3. In-Vitro Anticancer Activity by SRB Assay 
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In order to study the anti tumor activity of new compound, it is important to 
determine the cytotoxicity concentration of the compound. Cytotoxicity tests define the 
upper limit of the extract concentration, which is non toxic to the cell line. After the 
addition of the drug, cell death and cell viability was estimated. The result is confirmed 
by additional metabolic intervention experiment such as SRB assay. 
9.3.1. Materials Required SRB Assay 
1. Monolayer culture in log phase 
2. Drug extracts (different concentration) 
3. 0.45 filter 
4. 5mL sterile storage vials 
5. Tissue paper, Marker pen, Spirit, Cotton, and Gloves 
6. 1mL, 2mL pipettes, Micropipettes and tips 
7. Discarding Jar with 1% Hypochlorite solution 
9.3.2. SRB Assay introduction 
The sulforhodamine B (SRB) assay, which was developed in 1990, remains one 
of the most widely used methods for in vitro cytotoxicity screening. The assay relies on 
the ability of SRB to bind to protein components of cells that have been fixed to tissue 
culture plates by trichloroacetic acid (TCA). SRB is a bright-pink aminoxanthene dye 
with two sulfonic groups that bind to basic amino-acid residues under mild acidic 
conditions, and dissociate under basic conditions. As the binding of SRB is 
stoichiometric, the amount of dye extracted from stained cells is directly proportional to 
the cell mass. 
The strong intensity of SRB staining allows the assay to be carried out in a 96-
well format showed that the assay can detect densities as low as 1,000–2,000 cells per 
well. The SRB method has proven to be practical, because after the TCA-fixed and SRB-
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stained cell monolayers are dried they can be stored indefinitely. Color extracted from 
SRB-stained cells is also stable. With its high level of sensitivity, adaptability to the 96-
well format and endpoint stability, the SRB assay is well suited to large-scale screening 
applications, as well as research.  
This assay has been widely used for drug-toxicity testing against different types 
of cancerous and non-cancerous cell lines. Other cell-growth assays have been employed 
to assess drug efficacy against both intracellular pathogens and host cells simultaneously 
in co-cultures and it is possible to use the SRB method for this purpose. In addition, the 
SRB method has also been shown to be effective for in vitro testing of cancer cell 
sensitivity to radiation, and for the study of interactions between radiotherapy and 
chemotherapy, with sensitivity comparable to that of the standard clonogenic assay. 
The application of the SRB assay is limited to manual or semiautomatic 
screening due to the multiple washing and drying steps, which, at present, are not 
amenable to automation. This method nevertheless provides an efficient and sensitive 
tool for screening, especially for use in less well-equipped laboratories.  
Calculate the percentage of cell-growth inhibition using the formulae below. For primary 
screening, we use a threshold of 50% cell-growth inhibition as a cut-off for compound 
toxicity against cell lines. However, the threshold can be varied according to toxicity 
criteria defined by the investigators. For IC50 determination, plot a dose–response curve 
between the compound concentration and percent growth inhibition. IC50 values can be 
derived using curve-fitting methods with statistical analysis software or IC50 calculation 
software. 
 
9.3.3. EXPERIMENTAL PROCEDURE FOR SRB ASSAY 
• The cell lines were grown in RPMI 1640 medium containing 10% fetal bovine 
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serum and 2 mM L-glutamine. For present screening experiment, cells were 
inoculated into 96 well microtiter plates in 100 µL at plating densities as shown 
in the study details above, depending on the doubling time of individual cell 
lines. After cell inoculation, the microtiter plates were incubated at 37° C, 5 % 
CO2, 95 % air and 100 % relative humidity for 24 h prior to addition of 
experimental drugs.  
• Experimental drugs were initially solubilize in dimethyl sulfoxide at 100mg/ml 
and diluted to 1mg/ml using water and stored frozen prior to use. At the time of 
drug addition, an aliquote of frozen concentrate (1mg/ml) was thawed and diluted 
to 100 µg/ml, 200 µg/ml, 400 µg/ml and 800 µg/ml with complete medium 
containing test article. Aliquots of 10 µl of these different drug dilutions were 
added to the appropriate micro titer wells already containing 90 µl of medium, 
resulting in the required final drug concentrations i.e.10 µg/ml, 20 µg/ml, 40 
µg/ml, 80 µg/ml.  
• After compound addition, plates were incubated at standard conditions for 48 
hours and assay was terminated by the addition of cold TCA. Cells were fixed in 
situ by the gentle addition of 50 µl of cold 30 % (w/v) TCA (final concentration, 
10 % TCA) and incubated for 60 minutes at 4°C. The supernatant was discarded; 
the plates were washed five times with tap water and air dried. Sulforhodamine B 
(SRB) solution (50 µl) at 0.4 % (w/v) in 1 % acetic acid was added to each of the 
wells, and plates were incubated for 20 minutes at room temperature. After 
staining, unbound dye was recovered and the residual dye was removed by 
washing five times with 1 % acetic acid. The plates were air dried. Bound stain 
was subsequently eluted with 10 mM trizma base, and the absorbance was read 
on an plate reader at a wavelength of 540 nm with 690 nm reference wavelength.  
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• Percent growth was calculated on a plate-by-plate basis for test wells relative to 
control wells. Percent Growth was expressed as the ratio of average absorbance 
of the test well to the average absorbance of the control wells * 100.  
• Using the six absorbance measurements [time zero (Tz), control growth (C), and 
test growth in the presence of drug at the four concentration levels (Ti)], the 
percentage growth was calculated at each of the drug concentration levels. 
Percentage growth inhibition was calculated as:  
[Ti/C] x 100 % 
• In this study Adriamycin used as standard drug. The table 9.1 shows the SRB 
Assay of tested compounds against Human Lung Cancer Cell Line A-549. And 
the table 9.2 represents the LC50, TGI and GI50 values of the tested compound. 
• The Figure 9.2 represented the drug treated human cancer cell line A-549. 
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Table 9.1. The SRB Assay of tested compounds against Human Lung Cancer Cell Line 
A-549 
Code 
Human Lung Cancer Cell Line A-549 
% Control Growth 
 Drug Concentrations (µg/ml) 
Experiment 1 Experiment 2 Experiment 3 Average Values 
10 20 40 80 10 20 40 80 10 20 40 80 10 20 40 80 
R1 86.7 96.7 62.5 18.3 101.9 113.2 84.1 34.7 93.2 92.4 42.5 12.8 93.9 100.8 63.0 21.9 
R2 91.2 89.5 85.6 95.3 101.3 104.9 112.6 93.0 90.8 92.4 88.9 95.2 94.4 95.6 95.7 94.5 
R5 91.2 87.6 75.6 66.9 102.7 104.9 104.3 56.3 90.1 90.6 61.2 49.9 94.7 94.3 80.4 57.7 
R6  96.2 88.5 77.0 33.5 110.4 111.7 98.6 51.0 96.2 102.0 81.7 33.5 100.9 100.7 85.8 39.4 
R7 94.9 85.6 80.0 43.3 104.8 97.6 102.6 75.1 93.6 111.8 82.3 96.2 97.8 98.3 88.3 71.5 
ADR 10.0 5.1 -8.4 -1.2 8.4 5.0 10.4 6.1 4.7 2.6 -3.1 5.4 7.7 4.2 -0.4 3.4 
 
Table 9.2.  LC50, TGI and GI50 values of the tested compoun 
sample coode 
Drug concentrations (µg/ml) calculated from graph 
LC50 TGI GI50* 
R1 NE >80 55.1 
R2 NE >80 >80 
R5 NE >80 >80 
R6 NE >80 71.9 
R7 NE >80 >80 
ADR NE <10 <10 
 
Figure 9.2 Drug treated human cancer cell line A-549 
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10. RESULT AND DISCUSSION 
10.1. Synthetic methodology 
A series of novel class of (E)-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-
chromen-4-one Derivatives were synthesized by  using of 2-methyl-1H-
benzo[d]imidazole,   substituted chromone-3-carbaldehyde in presence of GAA. 
10.2. Characterization of synthesized compound 
 The purity of synthesized compounds was confirmed by Melting Point and TLC 
using Ethyl Acetate: Petroleum Ether (50:50) as solvent system. 
 The structures of synthesized compounds were confirmed by FT-IR, 1H-NMR, 
13C-NMR and Mass spectral analysis the result was correlated with the 
expected structure. 
10.3. Preliminary QSAR study: 
 The physic chemical character of title compounds were evaluated and given in 
the table 7.1. 
 Solubility parameters of synthesized compounds were tested, using various 
organic solvents and the result was tabulated in Table 7.2. 
 The synthesized compounds were subject to Preliminary QSAR studies by using 
MOLINSPIRATION software and the results are given in the Table7.3. All the 
synthesized compounds obey Lipinski rule of 5. 
10.4. Docking study 
 The docking study of the synthesized compound was carried out by using 
AUTODOCK software version 4.2 working system against target enzyme MAP 
Kinase as per the literature survey. 
 The docking result of the synthesized compounds showed binding score in active 
site of MAP Kinase between 7.0 and 7.90 K Cal/mol. 
Chapter 9 Results and Discussion 
Dept. of Pharmaceutical chemistry, JKKNCP. Page | 79
 Compounds R1, R2, R6, and R7 were found to have significant binding score 
against target enzyme MAP Kinase, compared to standard drugs such as 
Imatinib and Diclofenac.  
10.5. In vitro Anti-cancer Activity 
 Synthesized compounds R1, R2, R3, R6 and R7 were evaluated for 
anticancer activity by SRB assay method against Human Cancer Cell line 
A-549. 
 All tested compound exhibit moderate to good percentage of growth 
inhibition of Human Lung Cancer Cell Line A-549 when compared with 
the control drug Adriamycin.  
 
During the last twenty years, the study of the biological activities of chromene 
derivatives has been the aim of many scientists.59 Chromene-based natural and synthetic 
compounds have contributed substantially to the development of therapeutics as anti-
neoplastic agents against various human malignancies. Sesilin, tephrosin, calanone and 
acronycine are some of the chromene derivatives with a very good anti-cancer activity. 
An important breakthrough in the development of 4H-chromenes as anti-cancer agents 
was given by the discovery of MAP Kinase protein.  Imidazole and benzimidazole nuclei 
are the important and well known pharmacophores in drug discovery.60,61. There is a 
continual increase on the incidence of cancer and it is considered to be the leading cause 
of morbidity and mortality.62 Recently, considerable attention has been drawn on the 
search for novel anticancer drugs in order to improve survival rates and wellbeing. 
Benzimidazole derivatives are being explored in pharmaceutical industries and 
substituted benzimidazole derivatives have also been found in the diverse therapeutic 
applications such as in anti-ulcers, anti-hypertensives, anti-virals, anti-fungals, anti-
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cancers and anti-histaminics.63 On the other hand, such benzimidazole derivatives are 
condensed with other heterocycles like pyrazole, thiadiazole, triazole, thiazole, coumarin 
and 2-azetidinone moieties which have shown diverse pharmacological activities.64-71 
We targeted MAP Kinase protein for anticancer activity by benzimidazole containing 
4H- chromen-4-one Derivatives. We  designed some novel (E)-2-(2-(5-nitro-1H-
benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one Derivatives on the basis reaction 
between 2-methyl-1H-benzo[d]imidazole,   substituted chromone-3-carbaldehyde in 
presence of GAA and the synthesized compound were characterized by IR, 1H NMR, 13C 
NMR, Mass spectrometry and Elementary Analysis. The structures of the synthesized 
compounds were studied using Autodock software against different target enzymes. The 
docking results showed that Compounds R2, R3, R6, and R7 were found to have 
significant binding score against target enzyme MAP Kinase compared to standard drug 
Imatinib. Synthesized compound were evaluated for their in-vitro anti cancer activity by 
SRB assay method against Human Cancer Cell line A-549. From the result the 
compound R1 and R6 allowed only 21.9 and 39.4 of % cell growth at the concentration 
of 80µg/mL. Whereas other compounds has showed 57-94% 0f %cell growth. From the 
results the substitution on the Coumarin nucleus alter the biological activity. The un-
substituted (R4) and Flouro (R6) and Chloro (R1) substituted Coumarin derivatives were 
found to be potent by producing biological activity.  
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11. CONCLUSION 
 The present study deals with designing of some novel (E)-2-(2-(5-nitro-1H-
benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one Derivatives on the basis reaction 
between 2-methyl-1H-benzo[d]imidazole,   substituted chromone-3-carbaldehyde 
in presence of GAA. 
 The synthesized compound were characterized by IR, 1H NMR, 13C NMR, Mass 
spectrometry and Elementary Analysis. 
 Preliminary QSAR study was carried out for the synthesized compounds. All the 
compounds obey the Lipnski rule of 5. 
 Solubility characters of synthesized compounds were carried out by using various 
solvents. The tested compounds are freely soluble in DMSO, soluble in 
Chloroform and Methanol, slightly soluble in Acetone, Ethyl Acetate and Ethanol 
and Insoluble in Water. 
 The structures of the synthesized compounds were studied using Autodock 
software against different target enzymes. The docking results showed that 
Compounds R2, R3, R6, and R7 were found to have significant binding score 
against target enzyme MAP Kinase compared to standard drug Imatinib.  
 Synthesized compound were evaluated for their in-vitro anti cancer activity by SRB 
assay method against Human Cancer Cell line A-549. From the result the compound 
R1 and R6 allowed only 21.9 and 39.4 of % cell growth at the concentration of 
80µg/mL. Whereas other compounds has showed 57-94% 0f %cell growth. 
 From the above, it may conclude that the substitution on the Coumarin nucleus 
alter the biological activity. The un-substituted (R4) and Flouro (R6) and Chloro 
(R1) substituted Coumarin derivatives were found to be potent by producing 
biological activity.        
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1.  INTRODUCTION 
1.1. Heterocyclic compounds 
Heterocycles are an important class of compounds, making up more than half 
of all known organic compounds1. Heterocycles are present in a wide variety of drugs, 
most vitamins, many natural products, biomolecules, and biologically active 
compounds, including antitumor, antibiotic, anti-inflammatory, antidepressant, 
antimalarial, anti-HIV, antimicrobial, antibacterial, antifungal, antiviral, antidiabetic, 
herbicidal, fungicidal, and insecticidal agents. Also, they have been frequently found 
as a key structural unit in synthetic pharmaceuticals and agrochemicals2. Some of 
these compounds exhibit a significant solvatochromic, photochromic, and biochemi-
luminescence properties.  
Most of the heterocycles possess important applications in materials science 
such as dyestuff, fluorescent sensor, brightening agents, information storage, plastics, 
and analytical reagents. In addition, they have applications in supra molecular and 
polymer chemistry, especially in conjugated polymers. 
The medicinal chemists, the true utility of heterocyclic structures is the ability 
to synthesize one library based on one core scaffold and to screen it against a variety 
of different receptors, yielding several active compounds. Almost unlimited 
combinations of fused heterocyclic structures can be designed, resulting in novel 
polycyclic frameworks with the most diverse physical, chemical and biological 
properties.  
Therefore, efficient methodologies resulting in polycyclic structures from 
biologically active heterocyclic templates are always of interest to both organic and 
medicinal chemists3. The primary objective of medicinal chemistry is the design and 
discovery of new drug compounds. 
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1.2. Drug discovery and development process 
Drug discovery and development process (figure 1.1) is one of the most 
challenging and difficult process because this process is often a matter of life and 
death for patients; their cures are in the hands of scientists and clinicians who 
discover, develop, and administer medications for prevention, management, and cure 
of disease, injuries, and other disorders4. But it takes about 12 - 15 years from 
discovery to the approved medication and requires an investment of about billion 
dollars.  
From more than a million screened molecules only few compounds is 
investigated in late stage clinical trials and is finally made available for patients4. 
There are several stages involved in the drug discovery process. They are 
• Target identification and validation 
• Assay development 
• Lead identification 
• Lead optimization 
• Preclinical development 
• Clinical development 
o Phase I 
o Phase II 
o Phase III 
• Regulatory approval 
• Life cycle management  
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Figure 1.1: Drug discovery and development process 
1.5. Quantitative Structure Activity Relationship 
QSAR involves the derivation of mathematical formulae which relates the 
biological activities of a group of compounds to their measurable physiochemical 
parameters. These parameters have major influence on the drugs activity. QSAR 
derived equation take the general form: 
Biological activity = function 
(parameters) 
 Activity is expressed as log (1/c). C is the minimum concentration required 
to cause defined biological response. Activities used in QSAR include chemical 
measurements and biological assays. Quantitative structure-activity relationships have 
long been considered a vital component of drug discovery and development, providing 
insight into the role of molecular properties in the biological activity of similar and 
unrelated compounds. QSAR includes all statistical methods, by which biological 
activities (most often expressed by logarithms of equipotent molar activities) are 
related with structural elements (Free Wilson analysis), physicochemical properties 
(Hansch analysis), or fields (3D QSAR). The CoMFA analyses provided a number of 
insights into the mechanism of agonist binding5,6. 
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1.5.1. Molecular Descriptors used in QSAR 
Molecular descriptors can be defined as a numerical representation of 
chemical information encoded within a molecular structure via mathematical 
procedure. This mathematical representation has to be invariant to the molecule’s size 
and number of atoms to allow model building with statistical methods7. 
The information content of structure descriptors depends on two major factors: 
(1) The molecular representation of compounds. 
(2) The algorithm which is used for the calculation of the descriptor. 
There are various molecular descriptors used in QSAR, these are 
1. Hydrophobic parameter 
o Partition coefficient ; log P 
o Hansch’s substitution constant; π 
o Hydrophobic fragmental constant; f, f’ 
o Distribution coefficient; log D 
o Apparent log P 
o Capacity factor in HPLC; log k’ , log k’W 
o Solubility parameter; log S  
• Electronic parameter 
o Hammett constant; σ, σ +, σ - 
o Taft’s inductive (polar) constant; σ* 
o Swain and Lupton field parameter 
o Ionization constant; pKa , ∆pKa 
o Chemical shifts: IR, NMR 
• Steric parameter 
o Taft’s steric parameter; Es 
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o Molar volume; MV 
o Van der waals radius 
o Van der waals volume 
o Molar refractivity; MR 
o Parachor 
o Sterimol 
• Quantum chemical descriptors 
o Atomic net charge; Qσ, Qπ 
o Superdelocalizability 
o Energy of highest occupied molecular orbital; EHOMO 
o Energy of lowest unoccupied molecular orbital; ELUMO 
1.5.2. 3D-QSAR 
Three-dimensional quantitative structure-activity relationships (3D-QSAR) 
involve the analysis of the quantitative relationship between the biological activity of 
a set of compounds and their three-dimensional properties using statistical correlation 
methods. 3D-QSAR uses probe-based sampling within a molecular lattice to 
determine three-dimensional properties of molecules (particularly steric and 
electrostatic values) and can then correlate these 3D descriptors with biological 
activity. 
1.6. Physiochemical parameter 
The term physicochemical properties refers to the influence of the organic 
functional groups within a molecule on its acid-base properties, water solubility, 
partition coefficient, crystal structure, stereochemistry, ionization constant (pKa), 
lipophilicity and chemical stability. All these properties influence the absorption, 
distribution, metabolism excretion (ADME) and toxicity of the molecule. To design 
Chapter 1 Introduction 
 
Dept. of Pharmaceutical chemistry, JKKNCP.  
 
Page | 16
better medicinal agents, the medicinal chemist needs to understand the relative 
contributions that each functional group makes to the overall physicochemical 
properties of the molecule. Studies of this type involve modification of the molecule 
in a systematic fashion and determination of how these changes affect biological 
activity. 
The physicochemical properties of a drug molecule are dependent not only on 
what functional groups are present in the molecule but also on the spatial arrangement 
of these groups. This becomes an especially important factor when a molecule is 
subjected to an asymmetric environment, such as the human body. Because proteins 
and other biological macromolecules are asymmetric in nature, how a particular drug 
molecule interacts with these macromolecules is determined by the three-dimensional 
orientation of the organic functional groups that are present. If crucial functional 
groups are not occupying the proper spatial region surrounding the molecule, then 
productive bonding interactions with the biological macromolecule (receptor) will not 
be possible, potentially negating the desired pharmacological effect. If however, these 
functional groups are in the proper three-dimensional orientation, the drug can 
produce a very strong interaction with its receptor. It therefore is very important for 
the medicinal chemist developing a new molecular entity for therapeutic use8,9. 
1.7. Molecular Docking10 - 13 
 When the structure of the target is known (available), usually from X-ray 
crystallography, the most commonly used virtual screening method is molecular 
docking. Molecular docking can also be used to test possible hypotheses before 
conducting costly laboratory experiments. Molecular docking programs try to predict 
how a drug candidate binds to a protein target without performing a laboratory 
experiment. Molecular docking software consists of two core components. 
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 A search algorithm (sometimes called an optimization algorithm). The 
search algorithm is responsible for finding the best conformations of the 
ligand3 and protein system. A conformation is the position and orientation 
of the ligand relative to the protein. In flexible docking a conformation 
also contains information about the internal flexible structure of the ligand 
– and in some cases about the internal flexible structure of the protein. 
Since the number of possible conformations is extremely large, it is not 
possible to test all of them, therefore sophisticated search techniques have 
to be applied. Examples of some commonly used methods are Genetic 
Algorithms and Monte Carlo simulations. 
 An evaluation function (sometimes called a score function). This is a 
function providing a measure of how strongly a given ligand will interact 
with a particular protein. Energy force fields are often used as evaluation 
functions. These force fields calculate the energy contribution from 
different terms such as the known electrostatic forces between the atoms 
in the ligand and in the protein, forces arising from deformation of the 
ligand, pure electron-shell repulsion between atoms and effect from the 
solvent in which the interaction takes place. 
 
An example of a drug candidate ( grey color) binding to a target (black color). The 
small filled circles represent solvent (water) molecules. 
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1.8. Molecular Docking Softwares 
 Molecular docking programs are widely used modeling tools for predicting 
ligand binding modes and structure based virtual screening.14 
 DOCK - University of California San Francisco. 
 AUTODOCK - Scripps Research Institute.  
 MOLEGRO VIRTUAL DOCKER  - Molegro APS, University of Aarhus, 
Denmark. 
 GRAMM - Centre of Bioinformatics, University of Kansas, USA. 
 HEX - University of Aberdeen, UK. 
1.9. Lipinski's Rule of Five 
 Lipinski's Rule of Five is a rule of thumb to evaluate drug likeness, or 
determine if a chemical compound with a certain pharmacological or biological 
activity has properties that would make it a likely orally active drug in humans. The 
rule was formulated by Christopher A. Lipinski in 1997, based on the observation that 
most medication drugs are relatively small and lipophilic molecules.15 
 The rule describes molecular properties important for a drug's 
pharmacokinetics in the human body, including their absorption, distribution, 
metabolism, and excretion ("ADME").  
 The rule is important for drug development where a pharmacologically active 
lead structure is optimized step-wise for increased activity and selectivity, as well as 
drug-like properties as described by Lipinski's rule. The modification of the molecular 
structure often leads to drugs with higher molecular weight, more rings, more 
rotatable bonds, and a higher lipophilicity.  
 The ‘Rule of 5’ 16 states that poor absorption or permeation of orally 
administered drugs are more likely when. 
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1) There are more than 5 H-bond donors (expressed as the sum of OHs 
and NHs) 
2) The Molecular Weight is over 500 Daltons 
3) The Log P is over 5 (or MLogP is over 4.15) 
4) There are more than 10 H-bond acceptors (expressed as the sum of Ns 
and Os) 
5) Compound classes that are substrates for biological transporters are 
exceptions to the rule. 
To evaluate drug likeness better, the rules have spawned many extensions 
• Partition coefficient log P in -0.4 to +5.6 range 
• Molar refractivity from 40 to 130 
• Molecular weight from 160 to 500 
• Number of atoms from 20 to 70 includes H-bond donors [e.g.OHs and 
NHs] and H-bond acceptors [e.g.; Ns and Os]. 
• Polar surface area no greater than 140 Ǻ 
Exception to the ‘Rule of 5’: 
Compound classes that are substrates for biological transporters: 
 Antibiotics 
 Fungicides-Protozoacides -antiseptics 
 Vitamins 
 Cardiac glycosides. 
1.10. Nitorgen Based Heterocycles 
 The nitrogen based heterocycles were involved at the very beginning of life 
in the genesis of DNA and plays an essential role in many living systems. The nucleic 
acid based adenine; guanine, cytosine and thymine are derivatives of the aromatic  
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nitrogen heterocycles.  
1.11. Benzimidazole 
 Benzimidazole is a heterocyclic aromatic organic compound. This bicyclic 
compound consists of the fusion of benzene and imidazole. Benzimidazole, in an 
extension of the well-elaborated imidazole system, has been used as carbon skeletons 
for  N-heterocyclic carbenes. The NHCs are usually used as ligands for transition 
metal complexes. They are often prepared by deprotonating an N,N'-disubstituted 
benzimidazolium salt at the 2-position with a base.17 
  Benzimidazole, as the name implies is a bicyclic ring system in which 
benzene has been fused to the 4 and 5 position of the hetero cycle (imidazole). A basis 
for interest in the benzimidazole ring system as a nucleus from which to develop 
potential chemotherapeutic agents was established in the 1950’s when it was found 
that 5,6,-dimethyl-l-(alpha-D-ribofuranosyl) benzimidazole was an integral part of the 
structure of the vitamin B12.18 
1.12. Chemistry of Benzimidazoles 
 Benzimidazole is a white to slightly beige solid; melting at 172 °C, boils at 
360 °C, slightly soluble in water, soluble in ethanol. It is a dicyclic compound having 
imidazole ring (containing two nitrogen atoms at nonadjacent positions) fused to 
benzene. Benzimidazole and its derivatives are used in organic synthesis and 
vermicides or fungicides as they inhibit the action of certain microorganisms. 
Examples of benzimidazole class fungicides include benomyl, carbendazim, 
chlorfenazole, cypendazole, debacarb, fuberidazole, furophanate, mecarbinzid, 
rabenzazole, thiabendazole, thiophanate. Benzimidazole structure is the nucleus in 
some drugs such as proton pump inhibitors and anthelmintic agents. 
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Product Identification: 
 CAS NO :  51-17-2 
       EINECS NO :  200-081-4 
       FORMULA :  C7H6N2 
       MOL WT :  118.14 
       SYNONYMS :  1H-Benzimidazole; 1,3-benzodiazole; benzoglyoxaline;  
                                      azindole; N,N'-methylenyl-o-phenylenediamine;  
     3-azaindole; o-benzimidazole; benzoimidazole; BZI;  
      1,3-diazaindene; 
Physical and Chemical Properties: 
Physical state    :  Slightly Beige Powder 
Melting point    :  172 °C 
Boiling point    :  360 °C 
Specific gravity        :  1 
Solubility in water   :  Slightly 
Auto ignition    :  538 °C 
Nfpa ratings    :  Health- 2 ; Flammability- 1; Reactivity- 0 
Flash point    :  143 °C 
Stability    :  Stable under normal temperatures and 
conditions 
1.13. Benzimidazole from Natural Sources 
 The most prominent benzimidazole compound in nature is N-ribosyl-
dimethylbenzimidazole, which serves as an axial ligand for cobalt in vitamin B12. 
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1.14. Preparation of Benz
 The synthetic pathway to the various benzimidazole usually proceeds 
through two steps; first the construction of benzene ring containing the desired 
substituents and 1-2 diamine grouping followed by the ring closer of the 1
diaminobenzene (o-phenylenediamine) derivative to construct the imidazole ring. In 
many cases this ring closure is the final step in the synthesis of the desired 
benzimidazole. However in the other instances this ring closure is followed by 
extensive derivatization of th
 The usual synthesis involves condensation of
phenylenediamine with
N
N
By altering the carboxylic acid used, this 
substituted benzimidazoles.
NH2
NH2
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 Generally, the synthesis of benzimidazoles involves the treatment of 1,2-
phenylenediamine either with carboxylic acids under strongly acidic conditions or 
with aldehydes under oxidative conditions.21,22 
NH2
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 Synthetic approaches to 2-substituted benzimidazoles from 2-nitroanilines as 
starting material have been reported. 
NO2
NH2
SnCl2. 2H2O
R2CO2H
N
N
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R1 R1
 
1.15. Chromene 
 
Among the widespread heterocyclic compounds, oxygen heterocycles occupy 
a distinct position because of their wide natural abundance and broad biological as 
well as pharmaceutical significance23. In these particular classes of O-heterocycles, 
‘chromene’ heterocyclic scaffolds represent a privileged structural motif well-
distributed in natural products with a broad spectrum of potent biological activities. 
The word chromones is derived from the Greek word chroma, meaning “color”, 
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which indicates that many chromone derivatives exhibit a broad variation of colors.  
The compound in which benzene ring is fused to a 4H pyran ring is known as 4H-
chromene (4H-l -benzopyran). Chromene constitute the basic backbone of various 
types of polyphenols and widely found in natural alkaloids, tocopherols, flavonoids, 
and anthocyanins.  The benzopyran nucleus include some structural skeletons such as 
chromane, 2H-chromene and 4H-chromene (figure 1.4) 
 
Figure 1.4. Structural skeletons of chromene 
1.16. Natural occurrence and pharmacological activity of chromone and its 
derivatives 
  Chromones are a group of naturally occurring compounds that are ubiquitous 
in nature, especially in plants, such as flavones and isoflavones. Flavones and 
isoflavones have been of interest for many years, as they have shown a broad range of 
biological activities, which are not limited to antioxidant24, anti-inflammatory25 and 
antiviral effects26. Figure 1.5 shows natural and synthetic chromone heterocyclic 
compounds. On the other hand, chromen ring acts as an essential chromophore in 
recent drug discovery. 
Chromone was obtained from the flower of Wisteria sinensis that exhibit 
organoleptic property. An additional naturally occurring chromone was uvafzlelin that 
isolated from the stems of Uvaria ufielii which shows broad spectrum of antimicrobial 
activity against gram-positive and acid-fast bacteria.  Vitamin E was an evident 
example for the naturally occurring chromone, which possess antioxidant activity. 
Conrauinone A was a naturally occurring fused ring chromone, has been isolated from 
Chapter 1 Introduction 
 
Dept. of Pharmaceutical chemistry, JKKNCP.  
 
Page | 25
the bark of the tree Millettia conraui and potentially utilized for the treatment of 
intestinal parasites. Another natural compound was Erysenegalensein C which has 
been extracted from the bark of Erythrina senegalensis and found potential use in the 
treatment of stomach pain, female infertility and gonorrhea. A number of 
biologically-active chromones have been isolated from Piper gaudichaudianum and 
from P. aduncum and these chromones have been shown to exhibit anti-fungal and 
antitumor properties27. 
 
Figure 1.5. Natural and synthetic chromone containing heterocyclic compounds 
The rigid bicyclic chromone fragment has been classified as a privileged 
structure in drug discovery, due to its use in a wide variety of pharmacologically 
active compounds such as anticancer, anti-HIV, antibacterial and anti-inflammatory 
agents28. Presence of chromene-based structure in a molecule is often associated with 
its capacity to prevent diseases. Few naturally occurring chromene exhibit 
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antimicrobial, antitumor, antiviral and mutagenic, antiproliferative and central 
nervous system (CNS) activities29. Some chromones are sex pheromones. Numerous 
synthetic derivatives of naturally occurring chromene have found use in 
pharmaceuticals, particularly as antifungal and antimicrobial agents. Certain 2- amino 
chromene derivatives are used in cosmetics and pigments industry30. Several 
chromone derivatives have also been reported to act as kinase inhibitors, to bind to 
benzodiazepine receptors and as efficient agents in the treatment of cystic fibrosis31. 
Some chromene derivatives might prove useful synthetic intermediates for the 
synthesis of certain naturally occurring substances, such as Miroestrol32.  A key 
feature is that the lipophilic nature of the benzopyran derivatives helps to cross the 
cell membrane easily. Chromene derivatives are also plays important role in the 
production of highly effective fluorescent dyes for synthetic fibers, daylight 
fluorescent pigments and electro photographic and electroluminescent devices.  
1.17. Cancer 
Among various diseases, cancer has become a big threat to human beings 
globally.  Cancer is also known as a malignant tumor or malignant neoplasm, which is 
a group of diseases involving abnormal cell growth with the potential to invade or 
spread to other parts of the body33. Not all tumors are cancerous; benign tumors do 
not spread to other parts of the body. Cancer results from a series of molecular events 
that fundamentally alter the normal properties of cells. In cancer cells the normal 
control systems that prevent cell overgrowth and the invasion of other tissues are 
disabled. These altered cells divide and grow in the presence of signals that normally 
inhibit cell growth. Therefore they no longer require special signals to induce cell 
growth and division. As these cells grow they develop new characteristics, including 
changes in cell structure, decreased cell adhesion, and production of new enzymes. 
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These heritable changes allow the cell and its progeny to divide and grow, even in the 
presence of normal cells that typically inhibit the growth of nearby cells. Such 
changes allow the cancer cells to spread and invade other tissues34. 
Six characteristics of cancer have been proposed: 
o Self-sufficiency in growth signaling 
o Insensitivity to anti-growth signals 
o Evasion of apoptosis 
o Enabling of a limitless replicative potential 
o Induction and sustainment of angiogenesis 
o Activation of metastasis and invasion of tissue. 
Cancer is a leading cause of death group worldwide and accounted for 7.4 
million deaths (around 13% of all deaths) in 200435. More than 70% of all cancer 
deaths occurred in low- and middle-income countries. Deaths from cancer worldwide 
are projected to continue rising, with an estimated 11.5 million deaths in 203036. 
 Globally, the five most common cancers considered in both sexes such as 
• Lung (1,824,701; 13%),   
• Breast (1,676,633; 11.9%),   
• Colorectal (1,360,602; 9.7%),   
• Prostate (1,111,689; 7.9%), and  
• Cervix uteri (527,624; 3.7%). 
The estimated five most common cancers in men is listed below and death due to 
these cancers as 2,769,670. 
• Lung (16.7%),   
• Prostate (15%),  
• Colorectum (10%),  
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• Stomach (8.5%) and  
• Liver (7.5%)  
In women, the five most common cancers is listed below, and these cancers with a 
total of 3,721,266 cases. Death due to these cancers was 1,675,069.  
• Breast (25.2%),  
• Colorectum (9.2%),  
• Lung (8.8%),  
• Cervix uteri (7.9%), and  
• Corus uteri (4.8%)  
1.17.1. Lung cancer 
Lung cancer happens when the cells in lungs start to grow in an uncontrolled 
way and form tumors. Tumors are lumps of tissue made up of abnormal cells. Lung 
cancer that starts in the lung is called primary lung cancer; if the cancer started in 
another part of the body and metastasizes to the lung, it is called secondary lung 
cancer. 
1.17.2. Causes of Lung cancer 
Primary lung cancer is caused by the out-of-control growth of cells that do not 
die in the normal cell pattern. The cause of lung cancer may not always be known. 
Carcinogens are those things that can cause cancer. Normal cells in the lung can be 
affected by carcinogens in the environment, genetic factors, or a combination of those 
factors. Exposure to carcinogens may form molecules in the body called free radicals 
which damage cells and alter the DNA of the cell. This damage may cause cancer. 
Environmental factors include things such as smoking, secondhand smoke, radon gas, 
air pollutants, asbestos, heavy metals, and chronic dust exposure. Genetic factors may 
include an inherited (passed from parent to child) or a genetic mutation.  
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 Lung cancers are generally divided into five types, which are based on how it looks 
under the microscope.  
• Non-small cell lung cancer 
• Small cell lung cancer 
• Mesothelioma 
• Carcinoid 
• Sarcoma 
Among these NSCLC and SCLC represent about 96% of all lung cancers. 
These two types of lung cancer are I dentified by the size of abnormal cells and the 
way the cancer spreads in the body. 
  Small cell cancer (SCLC) tends to grow more quickly than non-small cell 
cancer. Because it grows more quickly, SCLC is often found when it has spread 
outside of the lung.  
1.17.3. Stages of small cell lung cancer 
Small cell lung cancer is staged as ‘limited’ or ‘extensive’. ‘Limited’ means 
that it is only in one lung. ‘Extensive’ means that is has spread to other parts of body. 
1.17.4. Stages of non-small cell lung cancer 
Non-small cell lung cancer has four stages – one to four. These tell how much 
it has spread to other parts of your body. Stage four is the most widely spread, or 
advanced. 
 
Stage 1 
The cancer is only in lungs and is not in any of lymph glands 
(part of the immune system which helps the body fight infection). 
Stage 2 
Stage 2A 
 
 
The cancer is small but cancer cells have spread to the lymph 
glands nearest to affected lung.  
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Stage 2B 
The cancer is slightly larger and has spread to the lymph glands 
nearest affected lungs. Or, the cancer cells have spread to another 
area such as chest wall. 
Stage 3 
 
Stage 3A 
 
 
 
Stage 3B 
 
Cancer cells have spread to the lymph glands furthest away from 
your affected lung. Or, the cancer is in the lymph glands nearest 
to your affected lung, and cancer cells have spread to either your 
chest wall or the middle of chest. 
The cancer cells have spread to the lymph glands in the other side 
of chest or to the lymph glands above collarbone. Or, there is 
more than one tumour in lung. Or, the tumor has grown into 
another area in chest such as heart or gullet. Or, there is fluid 
around lungs that contains cancer cells. 
 
Stage 4 The cancer has spread to another part of body such as liver or 
bones. 
The symptoms of lung cancer can include: 
o Coughing up blood 
o A persistent cough 
o Breathlessness 
o Wheezing 
o Hoarseness 
o Chest or shoulder pain 
o Tiredness 
o Weight loss 
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1.17.5. Treatment of Lung Cancer 
Possible treatments for lung cancer include surgery, chemotherapy, radiation 
therapy, targeted therapy or a combination of these. 
Lung cancer treatments fall into two 
Local therapy: Surgery and radiation therapy are local therapies. They remove or 
destroy cancer tumors in the lungs. If lung cancer has spread to other parts of the 
body, such as other organs or bones, the doctors may use one of these local therapies 
to control the disease in those specific areas as well. 
Systemic therapy: Chemotherapy and targeted therapies are systemic therapies. 
These drugs enter the bloodstream to destroy or control cancer everywhere in the 
body. Systemic therapy is taken by mouth or given through a vein in the arm or a port 
that is inserted in chest (intravenous). 
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2. REVIEW OF LITRATURE 
1. El-Sayed Ali et al., studied “Synthesis of some new 4-oxo-4H-chromene 
derivatives bearing nitrogen heterocyclic systems as antifungal agents”.37 
 
2. Batista et al., studied “Natural chromenes and chromene derivatives as 
potential anti-trypanosomal agents”. 38  
 
3. Dyrager et al., studied “Design, synthesis, and biological evaluation of 
chromone-based p38 MAP kinase inhibitors”.39 
 
4. Al-Said et al., studied “Dapson in heterocyclic chemistry, part VIII: synthesis, 
molecular docking and anticancer activity of some novel sulfonyl 
biscompounds carrying biologically active 1, 3-dihydropyridine, chromene 
and chromenopyridine moieties”40. 
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5. Azab et al., studied “Microwave-assisted synthesis of novel 2H-chromene 
derivatives bearing phenyl thiazolidinones and their biological activity 
assessment”.41 
 
6. Mohamed et al., studied “Green chemistry: new synthesis of substituted 
chromenes and benzochromenes via three-component reaction utilizing 
rochelle salt as novel green catalyst”.42 
 
7. Keri et al., describes the “Chromones as a privileged scaffold in drug 
discovery: A review”. The present review focuses on the pharmacological 
profile of chromone derivatives in the current literature with an update of 
recent research findings on this nucleus and the perspectives that they hold for 
future research.43 
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8. Vichai et al., studied on “Sulforhodamine B colorimetric assay for 
cytotoxicity Screening”. The sulforhodamine B (SRB) assay is used for cell 
density determination, based on the measurement of cellular protein content. 
The method described here has been optimized for the toxicity screening of 
compounds to adherent cells in a 96-well format. After an incubation period, 
cell monolayer are fixed with 10% (wt/vol) trichloroacetic acid and stained for 
30 min, after which the excess dye is removed by washing repeatedly with 1% 
(vol/vol) acetic acid. The protein-bound dye is dissolved in 10 mM Tris base 
solution for OD determination at 510 nm using a microplate reader. The 
results are linear over a 20-fold range of cell numbers and the sensitivity is 
comparable to those of fluorometric methods. The method not only allows a 
large number of samples to be tested within a few days, but also requires only 
simple equipment and inexpensive reagents. The SRB assay is therefore an 
efficient and highly cost-effective method for screening.44 
9. Mohamed et al., synthesized various (2- substituted phenyl) 
benzimidazoles45. 
N
N
N
R
R
X
 
R=CH3, CH2CH3, Ph 
10. Chari et al., reported the synthesis of benzimidazoles through the coupling of 
aldehydes with ortho phenylenediamine by using highly acidic nanoporous 
aluminosilicate with 3D structure and cage-type porous as the catalyst46. 
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11. Kamal et al., reported the synthesis of 2-aryl-1-aryl-methyl-1H-
benzimidazoles by using ceric(IV) ammonium nitrate as catalyst47. 
N
N
Ar
Ar
 
12. Salehi et al., synthesized 2-aryl-1-arylmethyl-1H-1, 3-benzimidazoles by 
using silica sulfuric acid as catalyst48. 
N
H
N
R2
R1
R1
 
13. Alajarin et al., reported the synthesis of pyrido [1, 2-a] benzimidazole 
derivatives42. 
N
N
Ar
H
R1 R2
 
14. Jesudason et al. synthesized N-Mannich bases of benzimidazole derivatives49. 
 
N
N
R2
R1
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R1 = H, CH3, -CH=CH-C6H5 
R2 = -N(CH3)2, -N(C2H5)2, -N(C6H5)2 
15. Pawar et al., Synthesized various N-alkyl and N-acyl derivatives of 2-(4-
thiazolyl)-1H-benzimidazoles and screened for their antifungal and 
antibacterial activities50. 
N
N
R
N
S
 
16. Yunhe et al., synthesized some benzimidazole derivatives and screened for 
antibacterial activity against Staphylococcus aureus and Escherichia coli51. 
 
 
 
 
 
 
 
17. Sivakumar et al. synthesized some novel 2-(6-fluorochroman-2-yl)-1-
alkyl/acyl/aroyl-1H-benzimidazoles and screened for antibacterial activity 
against Salmonella typhimurium53. 
 
N
N
O F
R
 
N
N
Cl
Cl
NH
R2R1N
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18. Ramya  et al., synthesized some novel 5-(nitro/bromo)-styryl-2-
benzimidazoles and screened in vitro anti-tubercular activity against 
Mycobacterium Tuberculosis  H37 Rv, anti-bacterial activity against 
Staphylococcus aureus, Escherichia coli, Enterococcus faecalis, Klebsiella 
pneumoniae bacterial strains and anti-fungal activity against Candida albicans 
and Asperigillus fumigatus fungal strains54. 
N
N
H
H
H
R
R1
 
19. David et al. synthesized some novel benzimidazole derivatives and screened 
for their in vitro (rat tunica muscularis mucosae) and in vivo tests (Bezold–
Jarisch reflex in rat and gastrointestinal motility and spontaneous motility in 
mice) 55. 
20. Maria et al. synthesized new benzimidazole-4-carboxamides and 
Carboxylates and screened for serotonergic 5-HT4 and 5-HT3 receptor 
antagonistic property56. 
N
NH
X
O
YR
 
R= H, Cl 
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3. AIM & OBJECTIVE 
Aim: 
The main aim of this proposed research work is to design and synthesize a 
novel class of (E)-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one 
derivatives and  characterization by using  IR, 1H NMR, 13C NMR, and mass 
spectroscopy. Further these novel set of compounds will be screened for various 
pharmacological activities. 
 Objective: 
• Design and synthesize (E)-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl) vinyl)-4H-
chromen-4-one derivatives. 
• Develop the efficient methodologies for accomplishing their synthesis. 
• Elucidate the structure of synthesized molecule by IR, 1H NMR, 13C NMR, 
and mass spectroscopy. 
• Perform the quantitative structure activity relationship (QSAR) of newly 
synthesized bioactive compounds. 
• Molecular docking studies for newly designed compounds using 
AUTODOCK software 
• Biological evaluation of newly synthesize compounds such as, In vitro Anti 
cancer activity 
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4. SCHEME OF THE WORK 
 
Step 1: 
 
 
 
 
 
Step 2: 
 
 
 
 
Step 3: 
 
 
(E)-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one Derivatives 
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Table 4.1: chemical structure of newly designed molecule 
 
 
Sl. No Compound code R 
1 R1 6-Cl 
2 R2 7-F 
3 R3 6-CH3 
4 R4 -H 
5 R5 6,7-Cl 
6 R6 6-F 
7 R7 6-OCH3 
8 R8 6-Br 
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5. EXPERIMENTAL SECTION 
5.1. Materials and methods 
All the chemicals were purchased from sigma Aldrich U.S.A. Analytical TLC 
was performed on Precoated sheets of silica gel G/UV-254 of 0.2mm thickness 
(Macherey-Nagel, Germany) using analytical grade solvent and visualized with iodine 
spray (10% w/w I2 in silica gel) or UV light. We also used bioinformatics tools, 
biological databases like PDB (Protein Data Bank) and software’s like Autodock and 
ACD ChemSketch. The PDB (Protein Data Bank) is the single worldwide archive of 
Structural data of Biological macromolecules, established in Brookhaven National 
Laboratories (BNL). It contains Structural information of the macromolecules 
determined by X-ray crystallographic, NMR methods etc. Auto Dock is an automated 
docking tool. It is designed to predict how small molecules, such as substrates, bind to 
a receptor of known 3D structures. Argus lab also one of the automated docking tool. 
5.2. Equipment and analytical instrument 
Melting point was determined in capillary tubes and is uncorrected. IR spectra 
were taken as KBr pellets for solids on Perkin Elmer Spectrum FT-IR. 1H NMR 
(400MHz) and 13C NMR (100 MHz) spectra were recorded in DMSO-d6 solution 
with TMS as an internal standard on Bruker instrument. Spin multiplicities are given 
as s (singlet), d (doublet), t (triplet) and m (multiplet). Coupling constant (J) is given 
in hertz. Mass spectra were recorded on a thermo Finnigan LCQ Advantage MAX 
6000 ESI spectrometer. 
5.3. General procedure for the synthesis of title compounds 
Step 1: Synthesis of 2-methyl-1H-benzo[d]imidazole 
 Place 5.43g of o-phenylene diamine, 20ml of water and 5.4g of acetic acid in 
RBF. 
 Reflux in a water bath for 45 minutes. 
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 Cool and add 10% ammonia solution slowly with constant shaking. 
 Filter the precipitated product. 
 Recrystallise it from 10% aqueous ethanol and activated charcoal. 
 
 
Step 2: 2-methyl-5-nitro-1H-benzo[d]imidazole 
 2-methyl-1H-benzo[d]imidazole adds 5 mL of Con. HNO3, 5 mL of Con 
H2SO4 and reflux for 30 mints. 
 After that pour the reaction mixture into cold water and shack vigorously. The 
yellow colour of 2-methyl-5-nitro-1H-benzo[d]imidazole was precipitated out. 
 
Step 3: (E)-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one 
Derivatives 
 1mmole of 2-methyl-1H-benzo[d]imidazole and add 1mmole of various 
substituted chromen 3 carboldehyde dissolved in ethanol. 
 Add 10 mL of Glacial Acetic acid and reflux for 1 hr.  
 The completion of reaction monitor by using TLC using ethyl acetate and 
petroleum ether (50:50) as mobile phase.  
 Upon completion of reaction, the reaction mixture was filtered, washed with 
acetic acid or ethanol and dry using vacuum. 
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(E)-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one Derivatives 
  
Sl. No Compound code R 
1 R1 6-Cl 
2 R2 7-F 
3 R3 6-CH3 
4 R4 -H 
5 R5 6,7-Cl 
6 R6 6-F 
7 R7 6-OCH3 
8 R8 6-Br 
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6. CHARECTERIZATION OF TITLE COMPOUNDS 
6.1. Spectral data for synthesized compound 
6.1.1. IR spectral data 
 
 
Figure.6.1. IR Spectra for compound R1 
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Figure.6.2. IR Spectra for compound R2 
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Figure.6.3. IR Spectra for compound R3 
 
Characterization of title compound 
 
Dept. of Pharmaceutical Chemistry, JKKNCP Page 38 
 
 
 
 
Figure.6.4. IR Spectra for compound R4 
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Figure.6.5. IR Spectra for compound R5 
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Figure.6.6. IR Spectra for compound R6 
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Figure.6.7. IR Spectra for compound R7 
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Figure.6.8. IR Spectra for compound R8 
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6.1.2. NMR spectral data 
 
 
 
 
 
Figure.6.9. 1H NMR spectrum of compound R1 
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Figure.6.10. 13C NMR spectrum of compound R1 
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Figure.6.11. 1H NMR spectrum of compound R7 
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Figure.6.12. 13C NMR spectrum of compound R7 
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6.1.3. Mass Spectra 
 
 
Figure 6.13: Mass Spectra of Compound R1 
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Figure 6.13: Mass Spectra of Compound R4 
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6.2. CHARACTERIZATION OF TITLE COMPOUNDS 
6.2.1. (E)-6-chloro-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one 
(R1) 
 
 
C18H10ClN3O4; MP: 218-2200C; Orange solid; 1H NMR (400 MHz, DMSO) δ 8.39 (s, 
1H), 8.07 (d, J = 7.1 Hz, 1H), 8.10 (m, 2H), 7.86 – 7.77 (m, 3H) 6.39 – 6.37 (d, 1H), 
6.65 (s, 1H), 5.0 (s, NH). 13NMR (101 MHz, DMSO) δ 178.5, 163.2, 155.3, 144.3, 145.0, 
141.5, 139.8, 136.4, 145.0, 130. 6, 129.0, 128.8, 125.5, 125.3, 119.6, 118.6, 116.1, 112.2. 
IR (KBr): 3158, 3095, 1634, 1644, 724; ESI-MS: m/z 367.74; Elemental Analysis: C, 
58.79; H, 2.74; Cl, 9.64; N, 11.43; O, 17.40.  
 
6.2.2. (E)-7-fluoro-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one 
(R2) 
 
 
 
C18H10FN3O4; MP: 210-2120C; Yellow solid; 1H NMR (400 MHz, DMSO) δ 8.39 (s, 
1H), 8.17 (d, J = 7.1 Hz, 1H), 8.10 (m, 2H), 7.56 – 7.67 (m, 3H) 6.36 – 6.31 (d, 1H), 
6.65 (s, 1H), 5.0 (s, NH). 13NMR (101 MHz, DMSO) δ 178.5, 163.2, 155.3, 144.3, 145.0, 
141.5, 139.8, 136.4, 145.0, 130. 6, 128.7, 128.8, 125.5, 125.3, 119.6, 117.6, 116.1, 111.2. 
IR (KBr): 3157, 3095, 1644, 1317, 1124, 824, 726; ESI-MS: m/z 351; Elemental 
Analysis: C, 61.54; H, 2.87; F, 5.41; N, 11.96; O, 18.22. 
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6.2.3. (E)-6-methyl-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-
one (R3) 
 
 
C19H13N3O4; MP: 200-2020C; Orange solid; 1H NMR (400 MHz, DMSO) δ 8.29 (s, 1H), 
8.07 (d, J = 7.1 Hz, 1H), 8.10 (m, 2H), 7.56 – 7.67 (m, 3H) 6.36 – 6.31 (d, 1H), 6.65 (s, 
1H), 5.0 (s, NH), 2.33 (T, 3H). 13NMR (101 MHz, DMSO) δ 178.5, 163.2, 155.3, 144.3, 
145.0, 141.5, 139.8, 136.4, 145.0, 130. 6, 128.7, 128.8, 125.5, 125.3, 119.6, 117.6, 116.1, 
111.2. 20.98 IR (KBr): 3158, 3095, 2940, 1644, 1435, 1374, 834, 637; ESI-MS: m/z 347; 
Elemental Analysis: C, 65.70; H, 3.77; N, 12.10; O, 18.43. 
 
6.2.4. (E)-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one (R4) 
 
 
C18H11N3O4; MP: 220-2220C; Orange solid; 1H NMR (400 MHz, DMSO) δ 8.29 (s, 2H), 
8.07 (d, J = 7.1 Hz, 2H), 8.10 (m, 2H), 7.67 (s, 1H), 7.56 – 7.47 (m, 4H),  6.36 – 6.31 (d, 
2H), 6.65 (s, 2H), 5.0 (s, NH),. 13NMR (101 MHz, DMSO) δ 178.5, 163.2, 155.3, 144.3, 
145.0, 141.5, 139.8, 136.4, 145.0, 130. 6, 128.7, 128.8, 125.5, 125.3, 119.6, 118.2, 
115.90, 111.2.IR (KBr): 3159, 1641, 1499, 1215, 824, 725, 637; ESI-MS: m/z 333; 
Elemental Analysis: C, 64.86; H, 3.33; N, 12.61; O, 19.20. 
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6.2.5. (E)-6,7-dichloro-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-
4-one (R5) 
 
 
C18H9Cl2N3O4; MP: 221-2230C; Orange solid; 1H NMR (400 MHz, DMSO) δ 8.49 (s, 2H), 
8.37 (d, J = 7.1 Hz, 2H), 8.14 (m, 2H), 7.77 (s, 1H), 7.46 – 7.37 (m, 3H),  6.36 – 6.31 (d, 
2H), 6.55 (s, 2H), 5.2 (s, NH),. 13NMR (101 MHz, DMSO) δ 178.5, 163.2, 155.3, 144.3, 
145.0, 141.5, 139.8, 136.4, 145.0, 130. 6, 128.7, 128.8, 125.5, 125.3, 119.6, 118.2, 
115.90, 115.2.IR (KBr): 1644, 1468, 1336, 824, 725, 637; ESI-MS: m/z 402; Elemental 
Analysis: C, 53.75; H, 2.26; Cl, 17.63; N, 10.45; O, 15.91. 
 
6.2.6. (E)-6-fluoro-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one 
(R6) 
 
 
C18H10FN3O4; MP: 210-2120C; Yellow solid; 1H NMR (400 MHz, DMSO) δ 8.39 (s, 
1H), 8.17 (d, J = 7.1 Hz, 1H), 8.10 (m, 2H), 7.56 – 7.67 (m, 3H) 6.36 – 6.31 (d, 1H), 
6.65 (s, 1H), 5.0 (s, NH). 13NMR (101 MHz, DMSO) δ 178.5, 163.2, 155.3, 144.3, 145.0, 
141.5, 139.8, 136.4, 145.0, 130. 6, 128.7, 128.8, 125.5, 125.3, 119.6, 117.6, 116.1, 111.2. 
IR (KBr): 3157, 3095, 1644, 1317, 1124, 824, 726; ESI-MS: m/z 351; Elemental 
Analysis: C, 61.54; H, 2.87; F, 5.41; N, 11.96; O, 18.22. 
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6.2.7. (E)-6-methoxy-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-
one (R7) 
 
 
C19H13N3O5: MP: 216-2180C; Orange solid; 1H NMR (400 MHz, DMSO) δ 8.39 (s, 1H), 
8.17 (d, J = 7.1 Hz, 1H), 8.10 (m, 2H), 7.56 – 7.67 (m, 3H) 6.36 – 6.31 (d, 1H), 6.65 (s, 
2H), 5.0 (s, NH) 3.90 (m, 3H). 13NMR (101 MHz, DMSO) δ 178.5, 163.2, 155.3, 144.3, 
145.0, 141.5, 139.8, 136.4, 145.0, 130. 6, 128.7, 128.8, 125.5, 125.3, 119.6, 117.6, 116.1, 
111.2. IR (KBr): 3157, 3011, 2980, 2927, 1644, 1574, 1156, 1317, 937, 637; ESI-MS: 
m/z 363; Elemental Analysis: C, 62.81; H, 3.61; N, 11.57; O, 22.02.  
 
6.2.8. (E)-6-bromo-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-
one (R8) 
 
 
C18H10BrN3O4; MP: 218-2200C; Orange solid; 1H NMR (400 MHz, DMSO) δ 8.49 (s, 
1H), 8.27 (d, J = 7.1 Hz, 1H), 8.20 (m, 2H), 7.56 – 7.67 (m, 3H) 6.36 – 6.31 (d, 1H), 
6.65 (s, 1H), 5.0 (s, NH). 13NMR (101 MHz, DMSO) δ 179.01, 163.2, 155.3, 144.3, 
145.0, 141.5, 139.8, 136.4, 145.0, 130. 6, 128.7, 128.8, 125.5, 125.3, 119.6, 117.6, 116.1, 
111.2. IR (KBr): 3157, 3095, 1644, 1317, 1124, 824, 726; ESI-MS: m/z 412; Elemental 
Analysis: C, 52.45; H, 2.45; Br, 19.39; N, 10.19; O, 15.53. 
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7. PRELIMINARY QSAR STUDIES 
Table.7.1. Physico-chemical properties of synthesized compound 
 
Com 
code Structure 
Molecular 
Formula 
Mol 
weight 
Melting 
point Appearance 
R1 
 
 
C18H10ClN3O4 367 218-2200C Orange solid 
R2 
 
C18H10FN3O4 351 
210-
2120C Yellow solid 
R3 
 
 
 
C19H13N3O4 347 
200-
2020C Orange solid 
R4 
 
 
 
C18H11N3O4 333 
220-
2220C Orange solid 
R5 
 
 
 
C18H9Cl2N3O4 402 220-2220C Orange solid 
R6 
 
 
 
C18H10FN3O4 351 
219-
2210C Orange solid 
R7 
 
 
 
C19H13N3O5 363 
216-
2180C Orange solid 
R8  C18H10BrN3O4 412 218- Orange solid 
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2200C 
Table.7.2. Solubility data of synthesized compounds 
 
 
Compound 
code Water Acetone Chloroform DMSO Ethanol Methanol 
Ethyl 
acetate 
R1 - ++ +++ +++ + ++ + 
R2 - ++ +++ +++ + ++ + 
R3 - ++ +++ +++ + ++ + 
R4 - ++ +++ +++ + ++ + 
R5 - ++ +++ +++ ++ ++ + 
R6 - ++ +++ +++ + ++ + 
R7 - ++ ++ +++ + ++ + 
R8 - ++ ++ +++ + ++ + 
 
+++ = Freely soluble; ++ = Soluble; + = Slightly soluble; - = Insoluble 
 
Table7.3. QSAR studies of synthesized compounds 
 
Compound 
Code 
Log P TPSA 
N 
atoms 
n ON 
N 
OHNH 
N 
Violation 
N rotb Volume 
R1 3.48 104.72 25 7 1 0 3 275.57 
R2 4.13 104.72 26 7 1 0 3 289.10 
R3 4.47 104.72 27 7 1 0 3 302.64 
R4 2.64 104.72 26 7 1 0 3 280.50 
R5 3.62 104.72 26 7 1 0 3 280.50 
R6 4.26 104.72 26 7 1 0 3 293.45 
R7 3.90 104.72 26 7 1 0 3 292.13 
R8 3.51 113.95 27 8 1 0 4 301.11 
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Table. 7.4. Lipinski rule for title compounds 
 
Compound 
code 
Molecular 
Weight 
No. of H 
bond 
donor 
No. of H 
bond 
Acceptor 
TPSA 
No. of 
Rotatable 
Bond 
Log P 
R1 367 0 7 104.72 3 3.48 
R2 351 0 7 104.72 3 4.13 
R3 347 0 7 104.72 3 4.47 
R4 333 0 7 104.72 3 2.64 
R5 402 0 7 104.72 3 3.62 
R6 351 0 7 104.72 3 4.26 
R7 363 0 8 104.72 3 3.90 
R8 412 0 7 113.95 4 3.51 
 
 
 
 
Table.7.5. Drug likeness score for title compounds 
 
Compound 
Code 
GPCR 
Ligand 
Ion 
channel 
modulator 
Kinase 
inhibitor 
Nuclear 
Receptor 
ligand 
Protease 
Inhibitor 
Enzyme 
Inhibitor 
R1 
-0.16 -0.32 -0.11 -0.22 -0.65 -0.07 
R2 -0.16 -0.32 -0.12 -0.23 -0.65 -0.10 
R3 -0.13 -0.25 -0.16 -0.18 -0.62 -0.07 
R4 -0.13 -0.32 -0.08 -0.18 -0.65 -0.07 
R5 -0.07 -0.27 -0.05 -0.22 -0.62 -0.06 
R6 -0.28 -0.42 -0.16 -0.36 -0.76 -0.16 
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R7 -0.20 -0.39 -0.16 -0.23 -0.68 -0.12 
R8 -0.19 -0.37 -0.12 -0.20 -0.67 -0.10 
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8. DOCKING STUDY 
8.1. Docking Studies of Synthesized Compound on Various Enzymes  
8.1.1. Introduction 
In the field of molecular modeling, docking is a method which predicts the 
preferred orientation of one molecule to second when bound to each other to form a 
stable complex and it is also key tool in structural molecular biology and computer 
assisted drug design. Docking is frequently used to predict the binding orientation of 
small molecule drug candidates to their protein targets in order to in turn predict the 
affinity and activity of the small molecule57. The small molecule, known as ligand 
usually fits within the proteins cavity which is predicted by search algorithm. These 
protein cavities become active when come in contact with any external compounds and 
are thus called as active sites. Hence docking plays an important role in the rational 
design in drugs58.  
Docking is a method which predicts the preferred orientation of one molecule to a 
second molecule when bound to each other to form a stable complex in three 
dimensional spaces. In cell biology, the function protein is a result of its interaction with 
other proteins as well as other molecule components. So if we could predict how protein 
interacts with other molecules, we could possibly inhibit the function. Thus the result of 
docking was extremely beneficial in finding drugs which are effective against particular 
disease. The knowledge of the preferred orientation in turn may be used to predict the 
strength of association or binding affinity between two molecules using scoring function. 
There is much commercially available docking software each using a different 
combination of searching method and algorithm and scoring function. These are 
• GOLD (Genetic Optimization for Ligand Docking) 
• Glide 
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• Drug Discovery 
• Auto dock 1.5.4 
Among these in my research work i have used auto dock software to calculate the free 
energy binding of ligand towards various target enzymes. 
  8.1.2. AUTODOCK 1.5.4 
Autodock is a software suite to develop in Scripps Research Institute. This 
software is used for modeling flexible small molecule such as drug molecule binding to 
receptor proteins. The current version of Autodcok uses genetic algorithm for the 
conformational search and is a suitable method for the docking studies. Scripps Research 
Institute has developed a Graphical User Interface (GUI) using Python 2.5 language, and 
it is called Autodock Tool (ADT). ADT is used to prepare, run and analyze the docking 
stimulation, in addition to its several features necessary for modeling studies.  
8.1.3. Major steps involved in molecular docking 
Step I – Building the receptor 
In this step the 3D structure of the receptor should be downloaded from PDB and 
modified. This should include removal of water molecules from the cavity, stabilizing 
charges, filling in the missing residue, generation of side chain etc., according to the 
parameters available. After modification the receptor should be biologically active and 
stable. 
Step II – Identification of active site 
After the receptor is build, the active site within the receptor should be identified. 
The receptor may have many active sites but the one of the interest should be selected.  
Step III – Ligand preparation  
Ligand can be obtain from various databases like ZINC, PubChem or can be 
sketched using tools like chemsketch. While selecting the ligand, the Lipinski rule of 5 
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should be applied.  The rule is very important for drug development where the 
pharmacologically active lead structure is optimized stepwise for increased activity and 
selectivity as well as drug like properties.  
 Step IV – Docking 
This is a last step, where the ligand is docked into receptor and the interaction are 
checked. The scoring function generates depending on which ligand with best fit was 
selected.  
8.2. MAP Kinase as target Enzyme 
Over the last decade, the pursuit of p38a MAP kinase inhibitors has received an 
extraordinary level of attention in the pharmaceutical industry and in the medicinal 
chemistry community. A unique combination of well-established pharmacology, clinical 
efficacy and the opportunity to utilize structure-based drug design has made this a highly 
attractive target for therapeutic intervention. There is overwhelming evidence indicating 
that p38a plays a dominant role in regulating the production of pro-inflammatory 
cytokines, such as tumor necrosis factor and interleukin-1. Blocking this kinase may 
offer an effective therapy for treating many inflammatory diseases. 
However great number of heterocyclic compounds display interesting anti-
inflammatory and anti-cancer especially benzimidazole and 4H–chromen–4–one 
derivatives having important role in this concern. Compounds containing benzimidazole 
rings, which are formed via the fusion of imidazole and benzene rings, have been used 
extensively for pharmaceutical purposes. 1H-Benzimidazole rings exhibit remarkable 
number of biologically activities due to their nitrogen content, which comprise the active 
substrate of several drugs. Benzimidazole derivatives possessing wide range biological 
activities like antibacterial, antifunga, anticancer, anti-HIV, anti-tubercular. Presence of 
chromene-based structure in a molecule is often associated with its capacity to prevent 
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diseases. Chromone containing compound exhibit anticancer, anti-HIV, antibacterial, 
anti-inflammatory agents, antimicrobial, antitumor, antiviral and mutagenic, anti-
proliferative and central nervous system activities. Both the derivatives produced various 
biological activities individually. Hence we are planned to incorporate both the nucleus 
by chemical reaction. The designed compound were evaluated for their molecular 
properties by the “Lipinski’s rule of 5” and further their ability to bind in the active site 
region of MAP Kinase identified using molecular docking approach. 
8.3. Molecular docking study  
In order to gain more insight on the binding mode of the compounds with MAP 
Kinase docking studies using Auto Dock 4.0.1 were carried out. Top scoring molecules 
from the largest cluster were considered for interaction studies. The crystallographic 
structure of MAP kinase, which is retrieved from the RCSB Protein Data Bank (PDB 
code 1CM8) serves as docking receptor, and all the designed compounds are selected as 
ligand molecules. Before docking the screened ligands in to the protein active site, the 
protein was prepared by deleting the substrate cofactor as well as the crystallographically 
observed water molecules and then protein was defined for generating the grid. All 
molecules were drawn using ChemDraw Ultra 8.0 tool and energy minimized using 
Chem 3D Ultra 8.0 software.  
8.5. Auto Dock 4.0.1 procedure 
Automated docking was used to locate the appropriate binding orientations and 
conformations of various inhibitors into the 1CM8 binding pocket. To perform the task, 
the powerful genetic algorithm method implemented in the program Auto Dock 4.0.1 
was employed. Grid maps were generated by AutoGrid program. Each grid was centered 
at the crystal structure of the corresponding 1G2A and 2GT1 separately. Lamarckian 
Genetic Algorithm was employed as the docking algorithm. The grid dimensions were 
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60 Å X 60 Å X 60 Å with points separated by 0.375 Å. For all ligands, random starting 
positions, random orientations and torsions were used. During docking, grid parameters 
were specified for x, y and z axes as 38.808, 30.946 and 42.249 respectively. The 
Docking parameters Number of Genetic Algorithm (GA) runs: 25, Population size: 150, 
Maximum number of evaluation: 2,500,000, Maximum number of generation: 27,000 
were used for this study. The structure with the lowest binding free energy and the most 
cluster members was chosen for the optimum docking conformation. 
Table 8.1: Energy minimization table of Ligand and MAP kinase 
Interaction 
Code 
Binding 
Energy 
(Kcal/mol) 
 
Inhibition 
Constant 
Vdw. 
Desolvation 
Energy 
Intermol 
Energy 
Ligand 
efficiency 
Electrostatic 
Energy 
Total 
internal 
R1 -7.79 2.04 -7.66 -8.96 -0.31 -1.3 1.19 
R2 -7.95 6.75 -7.83 -8.25 -0.27 -0.42 0.32 
R3 -7.28 6.42 -6.95 -8.28 -0.26 -1.33 -0.44 
R4 -6.41 20.04 -7.48 -7.6 -0.25 -0.12 -.044 
R5 -7.19 5.36 -8.71 -8.38 -0.28 -0.32 -0.42 
R6 -7.76 2.05 -7.73 -8.95 -0.3 -1.23 -0.41 
R7 -7.35 4.1 -8.71 -8.54 -0.28 0.17 -0.44 
R8 -6.58 14.98 -7.89 -8.07 -0.24 -0.19 -0.43 
Diclofenac -7.18 14.32 -8.98 -9.02 -0.32 -0.18 -0.32 
Imatinib  -7.27 53.99 -11.29 -11.65 -0.43 -0.19 -0.54 
 
8.6. Docking Analysis 
The newly designed molecules are energy minimized and the resulting molecules 
are considered for docking analysis using Auto Dock 4.0.1. Auto Dock is employed to 
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study the docking molecules within active site region of 1CM8 and the H-bond 
interaction. Docked scores of newly designed molecules along with inhibition constant, 
Vdw. Desolvation Energy, ligand efficacy and electrostatic energy and hydrogen bonds 
are represented in Table 8.1. and table 8.2. respectively. Among the studied compounds, 
compound R1 have highest binding score (-7.79 K Cal/mol with one hydrogen bond) 
when compared with standard drugs such as Diclofenac -7.18 K Cal/mol (for anti-
inflammatory) and Imatinib -7.27 K Cal/mol (for Anti-cancer) followed by compound 
R6 with score of -7.76 K Cal/mol with one hydrogen bond, compound R5 with score of  
-7.19 K Cal/mol with one hydrogen bond, compound R3 have score of –7.28 with two 
hydrogen bond and lastly compound R4 with score of -6.41 K Cal/mol with one 
hydrogen bond. The docked molecule with MAP Kinase was visualized in Chimara 
software and the docking pose of compounds showed in figure 2 – 5. Docking results 
show that all the designed molecules have similar orientations in the binding pocket of 
MAP Kinase enzyme.  
Table 8.2: Hydrogen bond and hydrophobic interaction of ligand against target enzyme 
MAP kinase 
 
Compound 
code 
No. of 
Hydrogen 
bonds formed 
Amino acid 
involved in H 
bond interaction 
H bond 
distance 
Amino acid 
involved in 
vander waals 
interaction 
R1 1 Agr 82 2.93 
His 80, His 83, Lys 
139, Arg 142, Tyr 
143, Val 323, Gln 
324 
R2 Nil Nil Nil 
Gly 117, Met 120, 
Pro 156, Gly 157, 
Glu 218, Gly 222. 
R3 2 1. Lys 118 2. Lys 121 
2.771 
2.753 
Gly 117, Lys 118, 
Met 120, Glu 218 
R4 1 Asn 119 2.836 
Leu 193, Leu 253, 
Phe 249, Apg 252, 
Leu 294 
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R5 1 THR 242 2.75 
His 80, Arg 82, 
His 83, Lys 139, 
Val 323, Gln 324 
R6 1 TYR 143 3.327 
His 80, Arg 82, 
His 83, Lys 139, 
Arg 142, Tyr 143, 
Val 323, Gln 324 
R7 Nil Nil Nil 
Arg 142, Phe 249, 
Met 120, Glu 218, 
Tyr 143, Val 323 
R8 1 Arg 252 2.67 
Leu 253, Phe 249, 
Apg 252, Gln 254, 
Leu 294. 
Diclofenac Nil Nil Nil Met 120, Glu 218, Val 323, Gln 324. 
Imatinib Nil Nil Nil 
His 80, Arg 82, 
Arg 142, Glu 218, 
Val 323, Gln 324 
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Figure 8.1: Docking pose of compound R1 against MAP Kinase as Target Enzyme 
 
 
Figure 8.2: Docking pose of compound R2 against MAP Kinase as Target Enzyme 
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Figure 8.3: Docking pose of compound R3 against MAP Kinase as Target Enzyme 
 
 
 
Figure 8.4: Docking pose of compound R4 against MAP Kinase as Target Enzyme 
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Figure 8.5: Docking pose of compound R5 against MAP Kinase as Target Enzyme 
 
 
 
Figure 8.6: Docking pose of compound R6 against MAP Kinase as Target Enzyme 
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Figure 8.7: Docking pose of compound R7 against MAP Kinase as Target Enzyme 
 
 
 
Figure 8.8: Docking pose of compound R8 against MAP Kinase as Target Enzyme 
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Figure 8.9: Docking pose of standard drug (Imatinib) against MAP Kinase as Target 
Enzyme 
 
 
 
Figure 8.10: Docking pose of standard drug (Diclofenac) against MAP Kinase as Target 
Enzyme 
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9. IN-VITRO ANTICANCER ACTIVITY 
9.1. Introduction  
Cancers are a large family of diseases which involve abnormal cell growth with 
the potential to invade or spread to other parts of the body. They form a subset of 
neoplasms. A neoplasm or tumor is a group of cells that have undergone unregulated 
growth, and will often form a mass or lump, but may be distributed diffusely. 
Six characteristics of cancer have been proposed: 
• Self-sufficiency in growth signaling 
• Insensitivity to anti-growth signals 
• Evasion of apoptosis 
• Enabling of a limitless replicative potential 
• Induction and sustainment of angiogenesis 
• Activation of metastasis and invasion of tissue. 
The progression from normal cells to cells that can form a discernible mass to 
outright cancer involves multiple steps known as malignant progression. 
The great majority of cancers, some 90–95% of cases, are due to environmental 
factors. The remaining 5–10% is due to inherited genetics. Environmental, as used by 
cancer researchers, means any cause that is not inherited genetically, such as lifestyle, 
economic and behavioral factors, and not merely pollution. Common environmental 
factors that contribute to cancer death include tobacco (25–30%), diet and obesity (30–
35%), infections (15–20%), radiation (both ionizing and non ionizing, up to 10%), stress, 
lack of physical activity, and environmental pollutants. 
 
 
9.2. Anticancer Drug Development 
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Around the world, tremendous resources are being invested in prevention, 
diagnosis, and treatment of cancer. Cancer is the second leading cause of death in Europe 
and North America. Discovery and development of anticancer agents are the key focus 
of several pharmaceutical companies as well as nonprofit government and non-
government organizations, like the National Cancer Institute (NCI) in the United States, 
the European Organization for Research and Treatment of Cancer (EORTC), and the 
British Cancer Research Campaign (CRC). 
Identification of cytotoxic compounds led the development of anticancer 
therapeutics for several decades. Advances in cancer treatment, however, continued to be 
limited by the identification of unique biochemical aspects of malignancies that could be 
exploited to selectively target tumor cells. Schwartsmann et al. noted in 1988 that of over 
600,000 compounds screened by then, less than 40 agents were routinely used in the 
clinic. The recent growth in molecular sciences and the advances in genomics and 
proteomics have generated several potential new drug targets, leading to changes in the 
paradigms of anticancer drug discovery toward molecularly targeted therapeutics. These 
shifting paradigms have not only resulted in the greater involvement of biological 
scientists in the drug discovery process but also required changes in the screening and 
clinical evaluation of drug candidates. Both small and large molecular compounds 
continue to be investigated as anticancer agents. 
The discovery and development of anticancer drugs, especially cytotoxic agents, 
differ significantly from the drug development process for any other indication. The 
unique challenges and opportunities in working with these agents are reflected in each 
stage of the drug development process. This chapter will highlight the unique aspects of 
anticancer drug discovery and development. 
9.3. In-Vitro Anticancer Activity by SRB Assay 
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In order to study the anti tumor activity of new compound, it is important to 
determine the cytotoxicity concentration of the compound. Cytotoxicity tests define the 
upper limit of the extract concentration, which is non toxic to the cell line. After the 
addition of the drug, cell death and cell viability was estimated. The result is confirmed 
by additional metabolic intervention experiment such as SRB assay. 
9.3.1. Materials Required SRB Assay 
1. Monolayer culture in log phase 
2. Drug extracts (different concentration) 
3. 0.45 filter 
4. 5mL sterile storage vials 
5. Tissue paper, Marker pen, Spirit, Cotton, and Gloves 
6. 1mL, 2mL pipettes, Micropipettes and tips 
7. Discarding Jar with 1% Hypochlorite solution 
9.3.2. SRB Assay introduction 
The sulforhodamine B (SRB) assay, which was developed in 1990, remains one 
of the most widely used methods for in vitro cytotoxicity screening. The assay relies on 
the ability of SRB to bind to protein components of cells that have been fixed to tissue 
culture plates by trichloroacetic acid (TCA). SRB is a bright-pink aminoxanthene dye 
with two sulfonic groups that bind to basic amino-acid residues under mild acidic 
conditions, and dissociate under basic conditions. As the binding of SRB is 
stoichiometric, the amount of dye extracted from stained cells is directly proportional to 
the cell mass. 
The strong intensity of SRB staining allows the assay to be carried out in a 96-
well format showed that the assay can detect densities as low as 1,000–2,000 cells per 
well. The SRB method has proven to be practical, because after the TCA-fixed and SRB-
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stained cell monolayers are dried they can be stored indefinitely. Color extracted from 
SRB-stained cells is also stable. With its high level of sensitivity, adaptability to the 96-
well format and endpoint stability, the SRB assay is well suited to large-scale screening 
applications, as well as research.  
This assay has been widely used for drug-toxicity testing against different types 
of cancerous and non-cancerous cell lines. Other cell-growth assays have been employed 
to assess drug efficacy against both intracellular pathogens and host cells simultaneously 
in co-cultures and it is possible to use the SRB method for this purpose. In addition, the 
SRB method has also been shown to be effective for in vitro testing of cancer cell 
sensitivity to radiation, and for the study of interactions between radiotherapy and 
chemotherapy, with sensitivity comparable to that of the standard clonogenic assay. 
The application of the SRB assay is limited to manual or semiautomatic 
screening due to the multiple washing and drying steps, which, at present, are not 
amenable to automation. This method nevertheless provides an efficient and sensitive 
tool for screening, especially for use in less well-equipped laboratories.  
Calculate the percentage of cell-growth inhibition using the formulae below. For primary 
screening, we use a threshold of 50% cell-growth inhibition as a cut-off for compound 
toxicity against cell lines. However, the threshold can be varied according to toxicity 
criteria defined by the investigators. For IC50 determination, plot a dose–response curve 
between the compound concentration and percent growth inhibition. IC50 values can be 
derived using curve-fitting methods with statistical analysis software or IC50 calculation 
software. 
 
9.3.3. EXPERIMENTAL PROCEDURE FOR SRB ASSAY 
• The cell lines were grown in RPMI 1640 medium containing 10% fetal bovine 
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serum and 2 mM L-glutamine. For present screening experiment, cells were 
inoculated into 96 well microtiter plates in 100 µL at plating densities as shown 
in the study details above, depending on the doubling time of individual cell 
lines. After cell inoculation, the microtiter plates were incubated at 37° C, 5 % 
CO2, 95 % air and 100 % relative humidity for 24 h prior to addition of 
experimental drugs.  
• Experimental drugs were initially solubilize in dimethyl sulfoxide at 100mg/ml 
and diluted to 1mg/ml using water and stored frozen prior to use. At the time of 
drug addition, an aliquote of frozen concentrate (1mg/ml) was thawed and diluted 
to 100 µg/ml, 200 µg/ml, 400 µg/ml and 800 µg/ml with complete medium 
containing test article. Aliquots of 10 µl of these different drug dilutions were 
added to the appropriate micro titer wells already containing 90 µl of medium, 
resulting in the required final drug concentrations i.e.10 µg/ml, 20 µg/ml, 40 
µg/ml, 80 µg/ml.  
• After compound addition, plates were incubated at standard conditions for 48 
hours and assay was terminated by the addition of cold TCA. Cells were fixed in 
situ by the gentle addition of 50 µl of cold 30 % (w/v) TCA (final concentration, 
10 % TCA) and incubated for 60 minutes at 4°C. The supernatant was discarded; 
the plates were washed five times with tap water and air dried. Sulforhodamine B 
(SRB) solution (50 µl) at 0.4 % (w/v) in 1 % acetic acid was added to each of the 
wells, and plates were incubated for 20 minutes at room temperature. After 
staining, unbound dye was recovered and the residual dye was removed by 
washing five times with 1 % acetic acid. The plates were air dried. Bound stain 
was subsequently eluted with 10 mM trizma base, and the absorbance was read 
on an plate reader at a wavelength of 540 nm with 690 nm reference wavelength.  
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• Percent growth was calculated on a plate-by-plate basis for test wells relative to 
control wells. Percent Growth was expressed as the ratio of average absorbance 
of the test well to the average absorbance of the control wells * 100.  
• Using the six absorbance measurements [time zero (Tz), control growth (C), and 
test growth in the presence of drug at the four concentration levels (Ti)], the 
percentage growth was calculated at each of the drug concentration levels. 
Percentage growth inhibition was calculated as:  
[Ti/C] x 100 % 
• In this study Adriamycin used as standard drug. The table 9.1 shows the SRB 
Assay of tested compounds against Human Lung Cancer Cell Line A-549. And 
the table 9.2 represents the LC50, TGI and GI50 values of the tested compound. 
• The Figure 9.2 represented the drug treated human cancer cell line A-549. 
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Table 9.1. The SRB Assay of tested compounds against Human Lung Cancer Cell Line 
A-549 
Code 
Human Lung Cancer Cell Line A-549 
% Control Growth 
 Drug Concentrations (µg/ml) 
Experiment 1 Experiment 2 Experiment 3 Average Values 
10 20 40 80 10 20 40 80 10 20 40 80 10 20 40 80 
R1 86.7 96.7 62.5 18.3 101.9 113.2 84.1 34.7 93.2 92.4 42.5 12.8 93.9 100.8 63.0 21.9 
R2 91.2 89.5 85.6 95.3 101.3 104.9 112.6 93.0 90.8 92.4 88.9 95.2 94.4 95.6 95.7 94.5 
R5 91.2 87.6 75.6 66.9 102.7 104.9 104.3 56.3 90.1 90.6 61.2 49.9 94.7 94.3 80.4 57.7 
R6  96.2 88.5 77.0 33.5 110.4 111.7 98.6 51.0 96.2 102.0 81.7 33.5 100.9 100.7 85.8 39.4 
R7 94.9 85.6 80.0 43.3 104.8 97.6 102.6 75.1 93.6 111.8 82.3 96.2 97.8 98.3 88.3 71.5 
ADR 10.0 5.1 -8.4 -1.2 8.4 5.0 10.4 6.1 4.7 2.6 -3.1 5.4 7.7 4.2 -0.4 3.4 
 
Table 9.2.  LC50, TGI and GI50 values of the tested compoun 
sample coode 
Drug concentrations (µg/ml) calculated from graph 
LC50 TGI GI50* 
R1 NE >80 55.1 
R2 NE >80 >80 
R5 NE >80 >80 
R6 NE >80 71.9 
R7 NE >80 >80 
ADR NE <10 <10 
 
Figure 9.2 Drug treated human cancer cell line A-549 
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10. RESULT AND DISCUSSION 
10.1. Synthetic methodology 
A series of novel class of (E)-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-
chromen-4-one Derivatives were synthesized by  using of 2-methyl-1H-
benzo[d]imidazole,   substituted chromone-3-carbaldehyde in presence of GAA. 
10.2. Characterization of synthesized compound 
 The purity of synthesized compounds was confirmed by Melting Point and TLC 
using Ethyl Acetate: Petroleum Ether (50:50) as solvent system. 
 The structures of synthesized compounds were confirmed by FT-IR, 1H-NMR, 
13C-NMR and Mass spectral analysis the result was correlated with the 
expected structure. 
10.3. Preliminary QSAR study: 
 The physic chemical character of title compounds were evaluated and given in 
the table 7.1. 
 Solubility parameters of synthesized compounds were tested, using various 
organic solvents and the result was tabulated in Table 7.2. 
 The synthesized compounds were subject to Preliminary QSAR studies by using 
MOLINSPIRATION software and the results are given in the Table7.3. All the 
synthesized compounds obey Lipinski rule of 5. 
10.4. Docking study 
 The docking study of the synthesized compound was carried out by using 
AUTODOCK software version 4.2 working system against target enzyme MAP 
Kinase as per the literature survey. 
 The docking result of the synthesized compounds showed binding score in active 
site of MAP Kinase between 7.0 and 7.90 K Cal/mol. 
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 Compounds R1, R2, R6, and R7 were found to have significant binding score 
against target enzyme MAP Kinase, compared to standard drugs such as 
Imatinib and Diclofenac.  
10.5. In vitro Anti-cancer Activity 
 Synthesized compounds R1, R2, R3, R6 and R7 were evaluated for 
anticancer activity by SRB assay method against Human Cancer Cell line 
A-549. 
 All tested compound exhibit moderate to good percentage of growth 
inhibition of Human Lung Cancer Cell Line A-549 when compared with 
the control drug Adriamycin.  
 
During the last twenty years, the study of the biological activities of chromene 
derivatives has been the aim of many scientists.59 Chromene-based natural and synthetic 
compounds have contributed substantially to the development of therapeutics as anti-
neoplastic agents against various human malignancies. Sesilin, tephrosin, calanone and 
acronycine are some of the chromene derivatives with a very good anti-cancer activity. 
An important breakthrough in the development of 4H-chromenes as anti-cancer agents 
was given by the discovery of MAP Kinase protein.  Imidazole and benzimidazole nuclei 
are the important and well known pharmacophores in drug discovery.60,61. There is a 
continual increase on the incidence of cancer and it is considered to be the leading cause 
of morbidity and mortality.62 Recently, considerable attention has been drawn on the 
search for novel anticancer drugs in order to improve survival rates and wellbeing. 
Benzimidazole derivatives are being explored in pharmaceutical industries and 
substituted benzimidazole derivatives have also been found in the diverse therapeutic 
applications such as in anti-ulcers, anti-hypertensives, anti-virals, anti-fungals, anti-
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cancers and anti-histaminics.63 On the other hand, such benzimidazole derivatives are 
condensed with other heterocycles like pyrazole, thiadiazole, triazole, thiazole, coumarin 
and 2-azetidinone moieties which have shown diverse pharmacological activities.64-71 
We targeted MAP Kinase protein for anticancer activity by benzimidazole containing 
4H- chromen-4-one Derivatives. We  designed some novel (E)-2-(2-(5-nitro-1H-
benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one Derivatives on the basis reaction 
between 2-methyl-1H-benzo[d]imidazole,   substituted chromone-3-carbaldehyde in 
presence of GAA and the synthesized compound were characterized by IR, 1H NMR, 13C 
NMR, Mass spectrometry and Elementary Analysis. The structures of the synthesized 
compounds were studied using Autodock software against different target enzymes. The 
docking results showed that Compounds R2, R3, R6, and R7 were found to have 
significant binding score against target enzyme MAP Kinase compared to standard drug 
Imatinib. Synthesized compound were evaluated for their in-vitro anti cancer activity by 
SRB assay method against Human Cancer Cell line A-549. From the result the 
compound R1 and R6 allowed only 21.9 and 39.4 of % cell growth at the concentration 
of 80µg/mL. Whereas other compounds has showed 57-94% 0f %cell growth. From the 
results the substitution on the Coumarin nucleus alter the biological activity. The un-
substituted (R4) and Flouro (R6) and Chloro (R1) substituted Coumarin derivatives were 
found to be potent by producing biological activity.  
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11. CONCLUSION 
 The present study deals with designing of some novel (E)-2-(2-(5-nitro-1H-
benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one Derivatives on the basis reaction 
between 2-methyl-1H-benzo[d]imidazole,   substituted chromone-3-carbaldehyde 
in presence of GAA. 
 The synthesized compound were characterized by IR, 1H NMR, 13C NMR, Mass 
spectrometry and Elementary Analysis. 
 Preliminary QSAR study was carried out for the synthesized compounds. All the 
compounds obey the Lipnski rule of 5. 
 Solubility characters of synthesized compounds were carried out by using various 
solvents. The tested compounds are freely soluble in DMSO, soluble in 
Chloroform and Methanol, slightly soluble in Acetone, Ethyl Acetate and Ethanol 
and Insoluble in Water. 
 The structures of the synthesized compounds were studied using Autodock 
software against different target enzymes. The docking results showed that 
Compounds R2, R3, R6, and R7 were found to have significant binding score 
against target enzyme MAP Kinase compared to standard drug Imatinib.  
 Synthesized compound were evaluated for their in-vitro anti cancer activity by SRB 
assay method against Human Cancer Cell line A-549. From the result the compound 
R1 and R6 allowed only 21.9 and 39.4 of % cell growth at the concentration of 
80µg/mL. Whereas other compounds has showed 57-94% 0f %cell growth. 
 From the above, it may conclude that the substitution on the Coumarin nucleus 
alter the biological activity. The un-substituted (R4) and Flouro (R6) and Chloro 
(R1) substituted Coumarin derivatives were found to be potent by producing 
biological activity.        
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1.  INTRODUCTION 
1.1. Heterocyclic compounds 
Heterocycles are an important class of compounds, making up more than half 
of all known organic compounds1. Heterocycles are present in a wide variety of drugs, 
most vitamins, many natural products, biomolecules, and biologically active 
compounds, including antitumor, antibiotic, anti-inflammatory, antidepressant, 
antimalarial, anti-HIV, antimicrobial, antibacterial, antifungal, antiviral, antidiabetic, 
herbicidal, fungicidal, and insecticidal agents. Also, they have been frequently found 
as a key structural unit in synthetic pharmaceuticals and agrochemicals2. Some of 
these compounds exhibit a significant solvatochromic, photochromic, and biochemi-
luminescence properties.  
Most of the heterocycles possess important applications in materials science 
such as dyestuff, fluorescent sensor, brightening agents, information storage, plastics, 
and analytical reagents. In addition, they have applications in supra molecular and 
polymer chemistry, especially in conjugated polymers. 
The medicinal chemists, the true utility of heterocyclic structures is the ability 
to synthesize one library based on one core scaffold and to screen it against a variety 
of different receptors, yielding several active compounds. Almost unlimited 
combinations of fused heterocyclic structures can be designed, resulting in novel 
polycyclic frameworks with the most diverse physical, chemical and biological 
properties.  
Therefore, efficient methodologies resulting in polycyclic structures from 
biologically active heterocyclic templates are always of interest to both organic and 
medicinal chemists3. The primary objective of medicinal chemistry is the design and 
discovery of new drug compounds. 
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1.2. Drug discovery and development process 
Drug discovery and development process (figure 1.1) is one of the most 
challenging and difficult process because this process is often a matter of life and 
death for patients; their cures are in the hands of scientists and clinicians who 
discover, develop, and administer medications for prevention, management, and cure 
of disease, injuries, and other disorders4. But it takes about 12 - 15 years from 
discovery to the approved medication and requires an investment of about billion 
dollars.  
From more than a million screened molecules only few compounds is 
investigated in late stage clinical trials and is finally made available for patients4. 
There are several stages involved in the drug discovery process. They are 
• Target identification and validation 
• Assay development 
• Lead identification 
• Lead optimization 
• Preclinical development 
• Clinical development 
o Phase I 
o Phase II 
o Phase III 
• Regulatory approval 
• Life cycle management  
Chapter 1 Introduction 
 
Dept. of Pharmaceutical chemistry, JKKNCP.  
 
Page | 13
 
Figure 1.1: Drug discovery and development process 
1.5. Quantitative Structure Activity Relationship 
QSAR involves the derivation of mathematical formulae which relates the 
biological activities of a group of compounds to their measurable physiochemical 
parameters. These parameters have major influence on the drugs activity. QSAR 
derived equation take the general form: 
Biological activity = function 
(parameters) 
 Activity is expressed as log (1/c). C is the minimum concentration required 
to cause defined biological response. Activities used in QSAR include chemical 
measurements and biological assays. Quantitative structure-activity relationships have 
long been considered a vital component of drug discovery and development, providing 
insight into the role of molecular properties in the biological activity of similar and 
unrelated compounds. QSAR includes all statistical methods, by which biological 
activities (most often expressed by logarithms of equipotent molar activities) are 
related with structural elements (Free Wilson analysis), physicochemical properties 
(Hansch analysis), or fields (3D QSAR). The CoMFA analyses provided a number of 
insights into the mechanism of agonist binding5,6. 
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1.5.1. Molecular Descriptors used in QSAR 
Molecular descriptors can be defined as a numerical representation of 
chemical information encoded within a molecular structure via mathematical 
procedure. This mathematical representation has to be invariant to the molecule’s size 
and number of atoms to allow model building with statistical methods7. 
The information content of structure descriptors depends on two major factors: 
(1) The molecular representation of compounds. 
(2) The algorithm which is used for the calculation of the descriptor. 
There are various molecular descriptors used in QSAR, these are 
1. Hydrophobic parameter 
o Partition coefficient ; log P 
o Hansch’s substitution constant; π 
o Hydrophobic fragmental constant; f, f’ 
o Distribution coefficient; log D 
o Apparent log P 
o Capacity factor in HPLC; log k’ , log k’W 
o Solubility parameter; log S  
• Electronic parameter 
o Hammett constant; σ, σ +, σ - 
o Taft’s inductive (polar) constant; σ* 
o Swain and Lupton field parameter 
o Ionization constant; pKa , ∆pKa 
o Chemical shifts: IR, NMR 
• Steric parameter 
o Taft’s steric parameter; Es 
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o Molar volume; MV 
o Van der waals radius 
o Van der waals volume 
o Molar refractivity; MR 
o Parachor 
o Sterimol 
• Quantum chemical descriptors 
o Atomic net charge; Qσ, Qπ 
o Superdelocalizability 
o Energy of highest occupied molecular orbital; EHOMO 
o Energy of lowest unoccupied molecular orbital; ELUMO 
1.5.2. 3D-QSAR 
Three-dimensional quantitative structure-activity relationships (3D-QSAR) 
involve the analysis of the quantitative relationship between the biological activity of 
a set of compounds and their three-dimensional properties using statistical correlation 
methods. 3D-QSAR uses probe-based sampling within a molecular lattice to 
determine three-dimensional properties of molecules (particularly steric and 
electrostatic values) and can then correlate these 3D descriptors with biological 
activity. 
1.6. Physiochemical parameter 
The term physicochemical properties refers to the influence of the organic 
functional groups within a molecule on its acid-base properties, water solubility, 
partition coefficient, crystal structure, stereochemistry, ionization constant (pKa), 
lipophilicity and chemical stability. All these properties influence the absorption, 
distribution, metabolism excretion (ADME) and toxicity of the molecule. To design 
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better medicinal agents, the medicinal chemist needs to understand the relative 
contributions that each functional group makes to the overall physicochemical 
properties of the molecule. Studies of this type involve modification of the molecule 
in a systematic fashion and determination of how these changes affect biological 
activity. 
The physicochemical properties of a drug molecule are dependent not only on 
what functional groups are present in the molecule but also on the spatial arrangement 
of these groups. This becomes an especially important factor when a molecule is 
subjected to an asymmetric environment, such as the human body. Because proteins 
and other biological macromolecules are asymmetric in nature, how a particular drug 
molecule interacts with these macromolecules is determined by the three-dimensional 
orientation of the organic functional groups that are present. If crucial functional 
groups are not occupying the proper spatial region surrounding the molecule, then 
productive bonding interactions with the biological macromolecule (receptor) will not 
be possible, potentially negating the desired pharmacological effect. If however, these 
functional groups are in the proper three-dimensional orientation, the drug can 
produce a very strong interaction with its receptor. It therefore is very important for 
the medicinal chemist developing a new molecular entity for therapeutic use8,9. 
1.7. Molecular Docking10 - 13 
 When the structure of the target is known (available), usually from X-ray 
crystallography, the most commonly used virtual screening method is molecular 
docking. Molecular docking can also be used to test possible hypotheses before 
conducting costly laboratory experiments. Molecular docking programs try to predict 
how a drug candidate binds to a protein target without performing a laboratory 
experiment. Molecular docking software consists of two core components. 
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 A search algorithm (sometimes called an optimization algorithm). The 
search algorithm is responsible for finding the best conformations of the 
ligand3 and protein system. A conformation is the position and orientation 
of the ligand relative to the protein. In flexible docking a conformation 
also contains information about the internal flexible structure of the ligand 
– and in some cases about the internal flexible structure of the protein. 
Since the number of possible conformations is extremely large, it is not 
possible to test all of them, therefore sophisticated search techniques have 
to be applied. Examples of some commonly used methods are Genetic 
Algorithms and Monte Carlo simulations. 
 An evaluation function (sometimes called a score function). This is a 
function providing a measure of how strongly a given ligand will interact 
with a particular protein. Energy force fields are often used as evaluation 
functions. These force fields calculate the energy contribution from 
different terms such as the known electrostatic forces between the atoms 
in the ligand and in the protein, forces arising from deformation of the 
ligand, pure electron-shell repulsion between atoms and effect from the 
solvent in which the interaction takes place. 
 
An example of a drug candidate ( grey color) binding to a target (black color). The 
small filled circles represent solvent (water) molecules. 
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1.8. Molecular Docking Softwares 
 Molecular docking programs are widely used modeling tools for predicting 
ligand binding modes and structure based virtual screening.14 
 DOCK - University of California San Francisco. 
 AUTODOCK - Scripps Research Institute.  
 MOLEGRO VIRTUAL DOCKER  - Molegro APS, University of Aarhus, 
Denmark. 
 GRAMM - Centre of Bioinformatics, University of Kansas, USA. 
 HEX - University of Aberdeen, UK. 
1.9. Lipinski's Rule of Five 
 Lipinski's Rule of Five is a rule of thumb to evaluate drug likeness, or 
determine if a chemical compound with a certain pharmacological or biological 
activity has properties that would make it a likely orally active drug in humans. The 
rule was formulated by Christopher A. Lipinski in 1997, based on the observation that 
most medication drugs are relatively small and lipophilic molecules.15 
 The rule describes molecular properties important for a drug's 
pharmacokinetics in the human body, including their absorption, distribution, 
metabolism, and excretion ("ADME").  
 The rule is important for drug development where a pharmacologically active 
lead structure is optimized step-wise for increased activity and selectivity, as well as 
drug-like properties as described by Lipinski's rule. The modification of the molecular 
structure often leads to drugs with higher molecular weight, more rings, more 
rotatable bonds, and a higher lipophilicity.  
 The ‘Rule of 5’ 16 states that poor absorption or permeation of orally 
administered drugs are more likely when. 
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1) There are more than 5 H-bond donors (expressed as the sum of OHs 
and NHs) 
2) The Molecular Weight is over 500 Daltons 
3) The Log P is over 5 (or MLogP is over 4.15) 
4) There are more than 10 H-bond acceptors (expressed as the sum of Ns 
and Os) 
5) Compound classes that are substrates for biological transporters are 
exceptions to the rule. 
To evaluate drug likeness better, the rules have spawned many extensions 
• Partition coefficient log P in -0.4 to +5.6 range 
• Molar refractivity from 40 to 130 
• Molecular weight from 160 to 500 
• Number of atoms from 20 to 70 includes H-bond donors [e.g.OHs and 
NHs] and H-bond acceptors [e.g.; Ns and Os]. 
• Polar surface area no greater than 140 Ǻ 
Exception to the ‘Rule of 5’: 
Compound classes that are substrates for biological transporters: 
 Antibiotics 
 Fungicides-Protozoacides -antiseptics 
 Vitamins 
 Cardiac glycosides. 
1.10. Nitorgen Based Heterocycles 
 The nitrogen based heterocycles were involved at the very beginning of life 
in the genesis of DNA and plays an essential role in many living systems. The nucleic 
acid based adenine; guanine, cytosine and thymine are derivatives of the aromatic  
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nitrogen heterocycles.  
1.11. Benzimidazole 
 Benzimidazole is a heterocyclic aromatic organic compound. This bicyclic 
compound consists of the fusion of benzene and imidazole. Benzimidazole, in an 
extension of the well-elaborated imidazole system, has been used as carbon skeletons 
for  N-heterocyclic carbenes. The NHCs are usually used as ligands for transition 
metal complexes. They are often prepared by deprotonating an N,N'-disubstituted 
benzimidazolium salt at the 2-position with a base.17 
  Benzimidazole, as the name implies is a bicyclic ring system in which 
benzene has been fused to the 4 and 5 position of the hetero cycle (imidazole). A basis 
for interest in the benzimidazole ring system as a nucleus from which to develop 
potential chemotherapeutic agents was established in the 1950’s when it was found 
that 5,6,-dimethyl-l-(alpha-D-ribofuranosyl) benzimidazole was an integral part of the 
structure of the vitamin B12.18 
1.12. Chemistry of Benzimidazoles 
 Benzimidazole is a white to slightly beige solid; melting at 172 °C, boils at 
360 °C, slightly soluble in water, soluble in ethanol. It is a dicyclic compound having 
imidazole ring (containing two nitrogen atoms at nonadjacent positions) fused to 
benzene. Benzimidazole and its derivatives are used in organic synthesis and 
vermicides or fungicides as they inhibit the action of certain microorganisms. 
Examples of benzimidazole class fungicides include benomyl, carbendazim, 
chlorfenazole, cypendazole, debacarb, fuberidazole, furophanate, mecarbinzid, 
rabenzazole, thiabendazole, thiophanate. Benzimidazole structure is the nucleus in 
some drugs such as proton pump inhibitors and anthelmintic agents. 
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Product Identification: 
 CAS NO :  51-17-2 
       EINECS NO :  200-081-4 
       FORMULA :  C7H6N2 
       MOL WT :  118.14 
       SYNONYMS :  1H-Benzimidazole; 1,3-benzodiazole; benzoglyoxaline;  
                                      azindole; N,N'-methylenyl-o-phenylenediamine;  
     3-azaindole; o-benzimidazole; benzoimidazole; BZI;  
      1,3-diazaindene; 
Physical and Chemical Properties: 
Physical state    :  Slightly Beige Powder 
Melting point    :  172 °C 
Boiling point    :  360 °C 
Specific gravity        :  1 
Solubility in water   :  Slightly 
Auto ignition    :  538 °C 
Nfpa ratings    :  Health- 2 ; Flammability- 1; Reactivity- 0 
Flash point    :  143 °C 
Stability    :  Stable under normal temperatures and 
conditions 
1.13. Benzimidazole from Natural Sources 
 The most prominent benzimidazole compound in nature is N-ribosyl-
dimethylbenzimidazole, which serves as an axial ligand for cobalt in vitamin B12. 
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1.14. Preparation of Benz
 The synthetic pathway to the various benzimidazole usually proceeds 
through two steps; first the construction of benzene ring containing the desired 
substituents and 1-2 diamine grouping followed by the ring closer of the 1
diaminobenzene (o-phenylenediamine) derivative to construct the imidazole ring. In 
many cases this ring closure is the final step in the synthesis of the desired 
benzimidazole. However in the other instances this ring closure is followed by 
extensive derivatization of th
 The usual synthesis involves condensation of
phenylenediamine with
N
N
By altering the carboxylic acid used, this 
substituted benzimidazoles.
NH2
NH2
 
 
Vitamin B12 
imidazole 
e ring system of the existing exocyclic substituents.
 formic acid or the equivalent trimethyl orthoformate
H2
H2
HCO2H
∆
method is generally able to afford 2
20 
RCOOH
∆
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 Generally, the synthesis of benzimidazoles involves the treatment of 1,2-
phenylenediamine either with carboxylic acids under strongly acidic conditions or 
with aldehydes under oxidative conditions.21,22 
NH2
NH2
N
N
H N
N
H
Us
ing
 
ca
rbo
xy
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 aldehydes
under
 oxidative
 conditions
 
 Synthetic approaches to 2-substituted benzimidazoles from 2-nitroanilines as 
starting material have been reported. 
NO2
NH2
SnCl2. 2H2O
R2CO2H
N
N
H
R2
R1 R1
 
1.15. Chromene 
 
Among the widespread heterocyclic compounds, oxygen heterocycles occupy 
a distinct position because of their wide natural abundance and broad biological as 
well as pharmaceutical significance23. In these particular classes of O-heterocycles, 
‘chromene’ heterocyclic scaffolds represent a privileged structural motif well-
distributed in natural products with a broad spectrum of potent biological activities. 
The word chromones is derived from the Greek word chroma, meaning “color”, 
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which indicates that many chromone derivatives exhibit a broad variation of colors.  
The compound in which benzene ring is fused to a 4H pyran ring is known as 4H-
chromene (4H-l -benzopyran). Chromene constitute the basic backbone of various 
types of polyphenols and widely found in natural alkaloids, tocopherols, flavonoids, 
and anthocyanins.  The benzopyran nucleus include some structural skeletons such as 
chromane, 2H-chromene and 4H-chromene (figure 1.4) 
 
Figure 1.4. Structural skeletons of chromene 
1.16. Natural occurrence and pharmacological activity of chromone and its 
derivatives 
  Chromones are a group of naturally occurring compounds that are ubiquitous 
in nature, especially in plants, such as flavones and isoflavones. Flavones and 
isoflavones have been of interest for many years, as they have shown a broad range of 
biological activities, which are not limited to antioxidant24, anti-inflammatory25 and 
antiviral effects26. Figure 1.5 shows natural and synthetic chromone heterocyclic 
compounds. On the other hand, chromen ring acts as an essential chromophore in 
recent drug discovery. 
Chromone was obtained from the flower of Wisteria sinensis that exhibit 
organoleptic property. An additional naturally occurring chromone was uvafzlelin that 
isolated from the stems of Uvaria ufielii which shows broad spectrum of antimicrobial 
activity against gram-positive and acid-fast bacteria.  Vitamin E was an evident 
example for the naturally occurring chromone, which possess antioxidant activity. 
Conrauinone A was a naturally occurring fused ring chromone, has been isolated from 
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the bark of the tree Millettia conraui and potentially utilized for the treatment of 
intestinal parasites. Another natural compound was Erysenegalensein C which has 
been extracted from the bark of Erythrina senegalensis and found potential use in the 
treatment of stomach pain, female infertility and gonorrhea. A number of 
biologically-active chromones have been isolated from Piper gaudichaudianum and 
from P. aduncum and these chromones have been shown to exhibit anti-fungal and 
antitumor properties27. 
 
Figure 1.5. Natural and synthetic chromone containing heterocyclic compounds 
The rigid bicyclic chromone fragment has been classified as a privileged 
structure in drug discovery, due to its use in a wide variety of pharmacologically 
active compounds such as anticancer, anti-HIV, antibacterial and anti-inflammatory 
agents28. Presence of chromene-based structure in a molecule is often associated with 
its capacity to prevent diseases. Few naturally occurring chromene exhibit 
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antimicrobial, antitumor, antiviral and mutagenic, antiproliferative and central 
nervous system (CNS) activities29. Some chromones are sex pheromones. Numerous 
synthetic derivatives of naturally occurring chromene have found use in 
pharmaceuticals, particularly as antifungal and antimicrobial agents. Certain 2- amino 
chromene derivatives are used in cosmetics and pigments industry30. Several 
chromone derivatives have also been reported to act as kinase inhibitors, to bind to 
benzodiazepine receptors and as efficient agents in the treatment of cystic fibrosis31. 
Some chromene derivatives might prove useful synthetic intermediates for the 
synthesis of certain naturally occurring substances, such as Miroestrol32.  A key 
feature is that the lipophilic nature of the benzopyran derivatives helps to cross the 
cell membrane easily. Chromene derivatives are also plays important role in the 
production of highly effective fluorescent dyes for synthetic fibers, daylight 
fluorescent pigments and electro photographic and electroluminescent devices.  
1.17. Cancer 
Among various diseases, cancer has become a big threat to human beings 
globally.  Cancer is also known as a malignant tumor or malignant neoplasm, which is 
a group of diseases involving abnormal cell growth with the potential to invade or 
spread to other parts of the body33. Not all tumors are cancerous; benign tumors do 
not spread to other parts of the body. Cancer results from a series of molecular events 
that fundamentally alter the normal properties of cells. In cancer cells the normal 
control systems that prevent cell overgrowth and the invasion of other tissues are 
disabled. These altered cells divide and grow in the presence of signals that normally 
inhibit cell growth. Therefore they no longer require special signals to induce cell 
growth and division. As these cells grow they develop new characteristics, including 
changes in cell structure, decreased cell adhesion, and production of new enzymes. 
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These heritable changes allow the cell and its progeny to divide and grow, even in the 
presence of normal cells that typically inhibit the growth of nearby cells. Such 
changes allow the cancer cells to spread and invade other tissues34. 
Six characteristics of cancer have been proposed: 
o Self-sufficiency in growth signaling 
o Insensitivity to anti-growth signals 
o Evasion of apoptosis 
o Enabling of a limitless replicative potential 
o Induction and sustainment of angiogenesis 
o Activation of metastasis and invasion of tissue. 
Cancer is a leading cause of death group worldwide and accounted for 7.4 
million deaths (around 13% of all deaths) in 200435. More than 70% of all cancer 
deaths occurred in low- and middle-income countries. Deaths from cancer worldwide 
are projected to continue rising, with an estimated 11.5 million deaths in 203036. 
 Globally, the five most common cancers considered in both sexes such as 
• Lung (1,824,701; 13%),   
• Breast (1,676,633; 11.9%),   
• Colorectal (1,360,602; 9.7%),   
• Prostate (1,111,689; 7.9%), and  
• Cervix uteri (527,624; 3.7%). 
The estimated five most common cancers in men is listed below and death due to 
these cancers as 2,769,670. 
• Lung (16.7%),   
• Prostate (15%),  
• Colorectum (10%),  
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• Stomach (8.5%) and  
• Liver (7.5%)  
In women, the five most common cancers is listed below, and these cancers with a 
total of 3,721,266 cases. Death due to these cancers was 1,675,069.  
• Breast (25.2%),  
• Colorectum (9.2%),  
• Lung (8.8%),  
• Cervix uteri (7.9%), and  
• Corus uteri (4.8%)  
1.17.1. Lung cancer 
Lung cancer happens when the cells in lungs start to grow in an uncontrolled 
way and form tumors. Tumors are lumps of tissue made up of abnormal cells. Lung 
cancer that starts in the lung is called primary lung cancer; if the cancer started in 
another part of the body and metastasizes to the lung, it is called secondary lung 
cancer. 
1.17.2. Causes of Lung cancer 
Primary lung cancer is caused by the out-of-control growth of cells that do not 
die in the normal cell pattern. The cause of lung cancer may not always be known. 
Carcinogens are those things that can cause cancer. Normal cells in the lung can be 
affected by carcinogens in the environment, genetic factors, or a combination of those 
factors. Exposure to carcinogens may form molecules in the body called free radicals 
which damage cells and alter the DNA of the cell. This damage may cause cancer. 
Environmental factors include things such as smoking, secondhand smoke, radon gas, 
air pollutants, asbestos, heavy metals, and chronic dust exposure. Genetic factors may 
include an inherited (passed from parent to child) or a genetic mutation.  
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 Lung cancers are generally divided into five types, which are based on how it looks 
under the microscope.  
• Non-small cell lung cancer 
• Small cell lung cancer 
• Mesothelioma 
• Carcinoid 
• Sarcoma 
Among these NSCLC and SCLC represent about 96% of all lung cancers. 
These two types of lung cancer are I dentified by the size of abnormal cells and the 
way the cancer spreads in the body. 
  Small cell cancer (SCLC) tends to grow more quickly than non-small cell 
cancer. Because it grows more quickly, SCLC is often found when it has spread 
outside of the lung.  
1.17.3. Stages of small cell lung cancer 
Small cell lung cancer is staged as ‘limited’ or ‘extensive’. ‘Limited’ means 
that it is only in one lung. ‘Extensive’ means that is has spread to other parts of body. 
1.17.4. Stages of non-small cell lung cancer 
Non-small cell lung cancer has four stages – one to four. These tell how much 
it has spread to other parts of your body. Stage four is the most widely spread, or 
advanced. 
 
Stage 1 
The cancer is only in lungs and is not in any of lymph glands 
(part of the immune system which helps the body fight infection). 
Stage 2 
Stage 2A 
 
 
The cancer is small but cancer cells have spread to the lymph 
glands nearest to affected lung.  
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Stage 2B 
The cancer is slightly larger and has spread to the lymph glands 
nearest affected lungs. Or, the cancer cells have spread to another 
area such as chest wall. 
Stage 3 
 
Stage 3A 
 
 
 
Stage 3B 
 
Cancer cells have spread to the lymph glands furthest away from 
your affected lung. Or, the cancer is in the lymph glands nearest 
to your affected lung, and cancer cells have spread to either your 
chest wall or the middle of chest. 
The cancer cells have spread to the lymph glands in the other side 
of chest or to the lymph glands above collarbone. Or, there is 
more than one tumour in lung. Or, the tumor has grown into 
another area in chest such as heart or gullet. Or, there is fluid 
around lungs that contains cancer cells. 
 
Stage 4 The cancer has spread to another part of body such as liver or 
bones. 
The symptoms of lung cancer can include: 
o Coughing up blood 
o A persistent cough 
o Breathlessness 
o Wheezing 
o Hoarseness 
o Chest or shoulder pain 
o Tiredness 
o Weight loss 
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1.17.5. Treatment of Lung Cancer 
Possible treatments for lung cancer include surgery, chemotherapy, radiation 
therapy, targeted therapy or a combination of these. 
Lung cancer treatments fall into two 
Local therapy: Surgery and radiation therapy are local therapies. They remove or 
destroy cancer tumors in the lungs. If lung cancer has spread to other parts of the 
body, such as other organs or bones, the doctors may use one of these local therapies 
to control the disease in those specific areas as well. 
Systemic therapy: Chemotherapy and targeted therapies are systemic therapies. 
These drugs enter the bloodstream to destroy or control cancer everywhere in the 
body. Systemic therapy is taken by mouth or given through a vein in the arm or a port 
that is inserted in chest (intravenous). 
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2. REVIEW OF LITRATURE 
1. El-Sayed Ali et al., studied “Synthesis of some new 4-oxo-4H-chromene 
derivatives bearing nitrogen heterocyclic systems as antifungal agents”.37 
 
2. Batista et al., studied “Natural chromenes and chromene derivatives as 
potential anti-trypanosomal agents”. 38  
 
3. Dyrager et al., studied “Design, synthesis, and biological evaluation of 
chromone-based p38 MAP kinase inhibitors”.39 
 
4. Al-Said et al., studied “Dapson in heterocyclic chemistry, part VIII: synthesis, 
molecular docking and anticancer activity of some novel sulfonyl 
biscompounds carrying biologically active 1, 3-dihydropyridine, chromene 
and chromenopyridine moieties”40. 
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5. Azab et al., studied “Microwave-assisted synthesis of novel 2H-chromene 
derivatives bearing phenyl thiazolidinones and their biological activity 
assessment”.41 
 
6. Mohamed et al., studied “Green chemistry: new synthesis of substituted 
chromenes and benzochromenes via three-component reaction utilizing 
rochelle salt as novel green catalyst”.42 
 
7. Keri et al., describes the “Chromones as a privileged scaffold in drug 
discovery: A review”. The present review focuses on the pharmacological 
profile of chromone derivatives in the current literature with an update of 
recent research findings on this nucleus and the perspectives that they hold for 
future research.43 
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8. Vichai et al., studied on “Sulforhodamine B colorimetric assay for 
cytotoxicity Screening”. The sulforhodamine B (SRB) assay is used for cell 
density determination, based on the measurement of cellular protein content. 
The method described here has been optimized for the toxicity screening of 
compounds to adherent cells in a 96-well format. After an incubation period, 
cell monolayer are fixed with 10% (wt/vol) trichloroacetic acid and stained for 
30 min, after which the excess dye is removed by washing repeatedly with 1% 
(vol/vol) acetic acid. The protein-bound dye is dissolved in 10 mM Tris base 
solution for OD determination at 510 nm using a microplate reader. The 
results are linear over a 20-fold range of cell numbers and the sensitivity is 
comparable to those of fluorometric methods. The method not only allows a 
large number of samples to be tested within a few days, but also requires only 
simple equipment and inexpensive reagents. The SRB assay is therefore an 
efficient and highly cost-effective method for screening.44 
9. Mohamed et al., synthesized various (2- substituted phenyl) 
benzimidazoles45. 
N
N
N
R
R
X
 
R=CH3, CH2CH3, Ph 
10. Chari et al., reported the synthesis of benzimidazoles through the coupling of 
aldehydes with ortho phenylenediamine by using highly acidic nanoporous 
aluminosilicate with 3D structure and cage-type porous as the catalyst46. 
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N
H
N
Ar
 
11. Kamal et al., reported the synthesis of 2-aryl-1-aryl-methyl-1H-
benzimidazoles by using ceric(IV) ammonium nitrate as catalyst47. 
N
N
Ar
Ar
 
12. Salehi et al., synthesized 2-aryl-1-arylmethyl-1H-1, 3-benzimidazoles by 
using silica sulfuric acid as catalyst48. 
N
H
N
R2
R1
R1
 
13. Alajarin et al., reported the synthesis of pyrido [1, 2-a] benzimidazole 
derivatives42. 
N
N
Ar
H
R1 R2
 
14. Jesudason et al. synthesized N-Mannich bases of benzimidazole derivatives49. 
 
N
N
R2
R1
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R1 = H, CH3, -CH=CH-C6H5 
R2 = -N(CH3)2, -N(C2H5)2, -N(C6H5)2 
15. Pawar et al., Synthesized various N-alkyl and N-acyl derivatives of 2-(4-
thiazolyl)-1H-benzimidazoles and screened for their antifungal and 
antibacterial activities50. 
N
N
R
N
S
 
16. Yunhe et al., synthesized some benzimidazole derivatives and screened for 
antibacterial activity against Staphylococcus aureus and Escherichia coli51. 
 
 
 
 
 
 
 
17. Sivakumar et al. synthesized some novel 2-(6-fluorochroman-2-yl)-1-
alkyl/acyl/aroyl-1H-benzimidazoles and screened for antibacterial activity 
against Salmonella typhimurium53. 
 
N
N
O F
R
 
N
N
Cl
Cl
NH
R2R1N
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18. Ramya  et al., synthesized some novel 5-(nitro/bromo)-styryl-2-
benzimidazoles and screened in vitro anti-tubercular activity against 
Mycobacterium Tuberculosis  H37 Rv, anti-bacterial activity against 
Staphylococcus aureus, Escherichia coli, Enterococcus faecalis, Klebsiella 
pneumoniae bacterial strains and anti-fungal activity against Candida albicans 
and Asperigillus fumigatus fungal strains54. 
N
N
H
H
H
R
R1
 
19. David et al. synthesized some novel benzimidazole derivatives and screened 
for their in vitro (rat tunica muscularis mucosae) and in vivo tests (Bezold–
Jarisch reflex in rat and gastrointestinal motility and spontaneous motility in 
mice) 55. 
20. Maria et al. synthesized new benzimidazole-4-carboxamides and 
Carboxylates and screened for serotonergic 5-HT4 and 5-HT3 receptor 
antagonistic property56. 
N
NH
X
O
YR
 
R= H, Cl 
 
 
Chapter 3 Aim and Objective 
Dept. of Pharmaceutical chemistry, JKKNCP.  
 
Page | 28
3. AIM & OBJECTIVE 
Aim: 
The main aim of this proposed research work is to design and synthesize a 
novel class of (E)-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one 
derivatives and  characterization by using  IR, 1H NMR, 13C NMR, and mass 
spectroscopy. Further these novel set of compounds will be screened for various 
pharmacological activities. 
 Objective: 
• Design and synthesize (E)-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl) vinyl)-4H-
chromen-4-one derivatives. 
• Develop the efficient methodologies for accomplishing their synthesis. 
• Elucidate the structure of synthesized molecule by IR, 1H NMR, 13C NMR, 
and mass spectroscopy. 
• Perform the quantitative structure activity relationship (QSAR) of newly 
synthesized bioactive compounds. 
• Molecular docking studies for newly designed compounds using 
AUTODOCK software 
• Biological evaluation of newly synthesize compounds such as, In vitro Anti 
cancer activity 
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4. SCHEME OF THE WORK 
 
Step 1: 
 
 
 
 
 
Step 2: 
 
 
 
 
Step 3: 
 
 
(E)-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one Derivatives 
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Table 4.1: chemical structure of newly designed molecule 
 
 
Sl. No Compound code R 
1 R1 6-Cl 
2 R2 7-F 
3 R3 6-CH3 
4 R4 -H 
5 R5 6,7-Cl 
6 R6 6-F 
7 R7 6-OCH3 
8 R8 6-Br 
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5. EXPERIMENTAL SECTION 
5.1. Materials and methods 
All the chemicals were purchased from sigma Aldrich U.S.A. Analytical TLC 
was performed on Precoated sheets of silica gel G/UV-254 of 0.2mm thickness 
(Macherey-Nagel, Germany) using analytical grade solvent and visualized with iodine 
spray (10% w/w I2 in silica gel) or UV light. We also used bioinformatics tools, 
biological databases like PDB (Protein Data Bank) and software’s like Autodock and 
ACD ChemSketch. The PDB (Protein Data Bank) is the single worldwide archive of 
Structural data of Biological macromolecules, established in Brookhaven National 
Laboratories (BNL). It contains Structural information of the macromolecules 
determined by X-ray crystallographic, NMR methods etc. Auto Dock is an automated 
docking tool. It is designed to predict how small molecules, such as substrates, bind to 
a receptor of known 3D structures. Argus lab also one of the automated docking tool. 
5.2. Equipment and analytical instrument 
Melting point was determined in capillary tubes and is uncorrected. IR spectra 
were taken as KBr pellets for solids on Perkin Elmer Spectrum FT-IR. 1H NMR 
(400MHz) and 13C NMR (100 MHz) spectra were recorded in DMSO-d6 solution 
with TMS as an internal standard on Bruker instrument. Spin multiplicities are given 
as s (singlet), d (doublet), t (triplet) and m (multiplet). Coupling constant (J) is given 
in hertz. Mass spectra were recorded on a thermo Finnigan LCQ Advantage MAX 
6000 ESI spectrometer. 
5.3. General procedure for the synthesis of title compounds 
Step 1: Synthesis of 2-methyl-1H-benzo[d]imidazole 
 Place 5.43g of o-phenylene diamine, 20ml of water and 5.4g of acetic acid in 
RBF. 
 Reflux in a water bath for 45 minutes. 
Chapter 5  Experimental Section 
Dept. of Pharmaceutical chemistry, JKKNCP.  
 
Page | 32
 Cool and add 10% ammonia solution slowly with constant shaking. 
 Filter the precipitated product. 
 Recrystallise it from 10% aqueous ethanol and activated charcoal. 
 
 
Step 2: 2-methyl-5-nitro-1H-benzo[d]imidazole 
 2-methyl-1H-benzo[d]imidazole adds 5 mL of Con. HNO3, 5 mL of Con 
H2SO4 and reflux for 30 mints. 
 After that pour the reaction mixture into cold water and shack vigorously. The 
yellow colour of 2-methyl-5-nitro-1H-benzo[d]imidazole was precipitated out. 
 
Step 3: (E)-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one 
Derivatives 
 1mmole of 2-methyl-1H-benzo[d]imidazole and add 1mmole of various 
substituted chromen 3 carboldehyde dissolved in ethanol. 
 Add 10 mL of Glacial Acetic acid and reflux for 1 hr.  
 The completion of reaction monitor by using TLC using ethyl acetate and 
petroleum ether (50:50) as mobile phase.  
 Upon completion of reaction, the reaction mixture was filtered, washed with 
acetic acid or ethanol and dry using vacuum. 
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(E)-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one Derivatives 
  
Sl. No Compound code R 
1 R1 6-Cl 
2 R2 7-F 
3 R3 6-CH3 
4 R4 -H 
5 R5 6,7-Cl 
6 R6 6-F 
7 R7 6-OCH3 
8 R8 6-Br 
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6. CHARECTERIZATION OF TITLE COMPOUNDS 
6.1. Spectral data for synthesized compound 
6.1.1. IR spectral data 
 
 
Figure.6.1. IR Spectra for compound R1 
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Figure.6.2. IR Spectra for compound R2 
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Figure.6.3. IR Spectra for compound R3 
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Figure.6.4. IR Spectra for compound R4 
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Figure.6.5. IR Spectra for compound R5 
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Figure.6.6. IR Spectra for compound R6 
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Figure.6.7. IR Spectra for compound R7 
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Figure.6.8. IR Spectra for compound R8 
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6.1.2. NMR spectral data 
 
 
 
 
 
Figure.6.9. 1H NMR spectrum of compound R1 
 
 
 
 
 
 
Characterization of title compound 
 
Dept. of Pharmaceutical Chemistry, JKKNCP Page 44 
 
 
 
 
 
 
Figure.6.10. 13C NMR spectrum of compound R1 
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Figure.6.11. 1H NMR spectrum of compound R7 
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Figure.6.12. 13C NMR spectrum of compound R7 
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6.1.3. Mass Spectra 
 
 
Figure 6.13: Mass Spectra of Compound R1 
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Figure 6.13: Mass Spectra of Compound R4 
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6.2. CHARACTERIZATION OF TITLE COMPOUNDS 
6.2.1. (E)-6-chloro-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one 
(R1) 
 
 
C18H10ClN3O4; MP: 218-2200C; Orange solid; 1H NMR (400 MHz, DMSO) δ 8.39 (s, 
1H), 8.07 (d, J = 7.1 Hz, 1H), 8.10 (m, 2H), 7.86 – 7.77 (m, 3H) 6.39 – 6.37 (d, 1H), 
6.65 (s, 1H), 5.0 (s, NH). 13NMR (101 MHz, DMSO) δ 178.5, 163.2, 155.3, 144.3, 145.0, 
141.5, 139.8, 136.4, 145.0, 130. 6, 129.0, 128.8, 125.5, 125.3, 119.6, 118.6, 116.1, 112.2. 
IR (KBr): 3158, 3095, 1634, 1644, 724; ESI-MS: m/z 367.74; Elemental Analysis: C, 
58.79; H, 2.74; Cl, 9.64; N, 11.43; O, 17.40.  
 
6.2.2. (E)-7-fluoro-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one 
(R2) 
 
 
 
C18H10FN3O4; MP: 210-2120C; Yellow solid; 1H NMR (400 MHz, DMSO) δ 8.39 (s, 
1H), 8.17 (d, J = 7.1 Hz, 1H), 8.10 (m, 2H), 7.56 – 7.67 (m, 3H) 6.36 – 6.31 (d, 1H), 
6.65 (s, 1H), 5.0 (s, NH). 13NMR (101 MHz, DMSO) δ 178.5, 163.2, 155.3, 144.3, 145.0, 
141.5, 139.8, 136.4, 145.0, 130. 6, 128.7, 128.8, 125.5, 125.3, 119.6, 117.6, 116.1, 111.2. 
IR (KBr): 3157, 3095, 1644, 1317, 1124, 824, 726; ESI-MS: m/z 351; Elemental 
Analysis: C, 61.54; H, 2.87; F, 5.41; N, 11.96; O, 18.22. 
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6.2.3. (E)-6-methyl-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-
one (R3) 
 
 
C19H13N3O4; MP: 200-2020C; Orange solid; 1H NMR (400 MHz, DMSO) δ 8.29 (s, 1H), 
8.07 (d, J = 7.1 Hz, 1H), 8.10 (m, 2H), 7.56 – 7.67 (m, 3H) 6.36 – 6.31 (d, 1H), 6.65 (s, 
1H), 5.0 (s, NH), 2.33 (T, 3H). 13NMR (101 MHz, DMSO) δ 178.5, 163.2, 155.3, 144.3, 
145.0, 141.5, 139.8, 136.4, 145.0, 130. 6, 128.7, 128.8, 125.5, 125.3, 119.6, 117.6, 116.1, 
111.2. 20.98 IR (KBr): 3158, 3095, 2940, 1644, 1435, 1374, 834, 637; ESI-MS: m/z 347; 
Elemental Analysis: C, 65.70; H, 3.77; N, 12.10; O, 18.43. 
 
6.2.4. (E)-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one (R4) 
 
 
C18H11N3O4; MP: 220-2220C; Orange solid; 1H NMR (400 MHz, DMSO) δ 8.29 (s, 2H), 
8.07 (d, J = 7.1 Hz, 2H), 8.10 (m, 2H), 7.67 (s, 1H), 7.56 – 7.47 (m, 4H),  6.36 – 6.31 (d, 
2H), 6.65 (s, 2H), 5.0 (s, NH),. 13NMR (101 MHz, DMSO) δ 178.5, 163.2, 155.3, 144.3, 
145.0, 141.5, 139.8, 136.4, 145.0, 130. 6, 128.7, 128.8, 125.5, 125.3, 119.6, 118.2, 
115.90, 111.2.IR (KBr): 3159, 1641, 1499, 1215, 824, 725, 637; ESI-MS: m/z 333; 
Elemental Analysis: C, 64.86; H, 3.33; N, 12.61; O, 19.20. 
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6.2.5. (E)-6,7-dichloro-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-
4-one (R5) 
 
 
C18H9Cl2N3O4; MP: 221-2230C; Orange solid; 1H NMR (400 MHz, DMSO) δ 8.49 (s, 2H), 
8.37 (d, J = 7.1 Hz, 2H), 8.14 (m, 2H), 7.77 (s, 1H), 7.46 – 7.37 (m, 3H),  6.36 – 6.31 (d, 
2H), 6.55 (s, 2H), 5.2 (s, NH),. 13NMR (101 MHz, DMSO) δ 178.5, 163.2, 155.3, 144.3, 
145.0, 141.5, 139.8, 136.4, 145.0, 130. 6, 128.7, 128.8, 125.5, 125.3, 119.6, 118.2, 
115.90, 115.2.IR (KBr): 1644, 1468, 1336, 824, 725, 637; ESI-MS: m/z 402; Elemental 
Analysis: C, 53.75; H, 2.26; Cl, 17.63; N, 10.45; O, 15.91. 
 
6.2.6. (E)-6-fluoro-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one 
(R6) 
 
 
C18H10FN3O4; MP: 210-2120C; Yellow solid; 1H NMR (400 MHz, DMSO) δ 8.39 (s, 
1H), 8.17 (d, J = 7.1 Hz, 1H), 8.10 (m, 2H), 7.56 – 7.67 (m, 3H) 6.36 – 6.31 (d, 1H), 
6.65 (s, 1H), 5.0 (s, NH). 13NMR (101 MHz, DMSO) δ 178.5, 163.2, 155.3, 144.3, 145.0, 
141.5, 139.8, 136.4, 145.0, 130. 6, 128.7, 128.8, 125.5, 125.3, 119.6, 117.6, 116.1, 111.2. 
IR (KBr): 3157, 3095, 1644, 1317, 1124, 824, 726; ESI-MS: m/z 351; Elemental 
Analysis: C, 61.54; H, 2.87; F, 5.41; N, 11.96; O, 18.22. 
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6.2.7. (E)-6-methoxy-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-
one (R7) 
 
 
C19H13N3O5: MP: 216-2180C; Orange solid; 1H NMR (400 MHz, DMSO) δ 8.39 (s, 1H), 
8.17 (d, J = 7.1 Hz, 1H), 8.10 (m, 2H), 7.56 – 7.67 (m, 3H) 6.36 – 6.31 (d, 1H), 6.65 (s, 
2H), 5.0 (s, NH) 3.90 (m, 3H). 13NMR (101 MHz, DMSO) δ 178.5, 163.2, 155.3, 144.3, 
145.0, 141.5, 139.8, 136.4, 145.0, 130. 6, 128.7, 128.8, 125.5, 125.3, 119.6, 117.6, 116.1, 
111.2. IR (KBr): 3157, 3011, 2980, 2927, 1644, 1574, 1156, 1317, 937, 637; ESI-MS: 
m/z 363; Elemental Analysis: C, 62.81; H, 3.61; N, 11.57; O, 22.02.  
 
6.2.8. (E)-6-bromo-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-
one (R8) 
 
 
C18H10BrN3O4; MP: 218-2200C; Orange solid; 1H NMR (400 MHz, DMSO) δ 8.49 (s, 
1H), 8.27 (d, J = 7.1 Hz, 1H), 8.20 (m, 2H), 7.56 – 7.67 (m, 3H) 6.36 – 6.31 (d, 1H), 
6.65 (s, 1H), 5.0 (s, NH). 13NMR (101 MHz, DMSO) δ 179.01, 163.2, 155.3, 144.3, 
145.0, 141.5, 139.8, 136.4, 145.0, 130. 6, 128.7, 128.8, 125.5, 125.3, 119.6, 117.6, 116.1, 
111.2. IR (KBr): 3157, 3095, 1644, 1317, 1124, 824, 726; ESI-MS: m/z 412; Elemental 
Analysis: C, 52.45; H, 2.45; Br, 19.39; N, 10.19; O, 15.53. 
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7. PRELIMINARY QSAR STUDIES 
Table.7.1. Physico-chemical properties of synthesized compound 
 
Com 
code Structure 
Molecular 
Formula 
Mol 
weight 
Melting 
point Appearance 
R1 
 
 
C18H10ClN3O4 367 218-2200C Orange solid 
R2 
 
C18H10FN3O4 351 
210-
2120C Yellow solid 
R3 
 
 
 
C19H13N3O4 347 
200-
2020C Orange solid 
R4 
 
 
 
C18H11N3O4 333 
220-
2220C Orange solid 
R5 
 
 
 
C18H9Cl2N3O4 402 220-2220C Orange solid 
R6 
 
 
 
C18H10FN3O4 351 
219-
2210C Orange solid 
R7 
 
 
 
C19H13N3O5 363 
216-
2180C Orange solid 
R8  C18H10BrN3O4 412 218- Orange solid 
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2200C 
Table.7.2. Solubility data of synthesized compounds 
 
 
Compound 
code Water Acetone Chloroform DMSO Ethanol Methanol 
Ethyl 
acetate 
R1 - ++ +++ +++ + ++ + 
R2 - ++ +++ +++ + ++ + 
R3 - ++ +++ +++ + ++ + 
R4 - ++ +++ +++ + ++ + 
R5 - ++ +++ +++ ++ ++ + 
R6 - ++ +++ +++ + ++ + 
R7 - ++ ++ +++ + ++ + 
R8 - ++ ++ +++ + ++ + 
 
+++ = Freely soluble; ++ = Soluble; + = Slightly soluble; - = Insoluble 
 
Table7.3. QSAR studies of synthesized compounds 
 
Compound 
Code 
Log P TPSA 
N 
atoms 
n ON 
N 
OHNH 
N 
Violation 
N rotb Volume 
R1 3.48 104.72 25 7 1 0 3 275.57 
R2 4.13 104.72 26 7 1 0 3 289.10 
R3 4.47 104.72 27 7 1 0 3 302.64 
R4 2.64 104.72 26 7 1 0 3 280.50 
R5 3.62 104.72 26 7 1 0 3 280.50 
R6 4.26 104.72 26 7 1 0 3 293.45 
R7 3.90 104.72 26 7 1 0 3 292.13 
R8 3.51 113.95 27 8 1 0 4 301.11 
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Table. 7.4. Lipinski rule for title compounds 
 
Compound 
code 
Molecular 
Weight 
No. of H 
bond 
donor 
No. of H 
bond 
Acceptor 
TPSA 
No. of 
Rotatable 
Bond 
Log P 
R1 367 0 7 104.72 3 3.48 
R2 351 0 7 104.72 3 4.13 
R3 347 0 7 104.72 3 4.47 
R4 333 0 7 104.72 3 2.64 
R5 402 0 7 104.72 3 3.62 
R6 351 0 7 104.72 3 4.26 
R7 363 0 8 104.72 3 3.90 
R8 412 0 7 113.95 4 3.51 
 
 
 
 
Table.7.5. Drug likeness score for title compounds 
 
Compound 
Code 
GPCR 
Ligand 
Ion 
channel 
modulator 
Kinase 
inhibitor 
Nuclear 
Receptor 
ligand 
Protease 
Inhibitor 
Enzyme 
Inhibitor 
R1 
-0.16 -0.32 -0.11 -0.22 -0.65 -0.07 
R2 -0.16 -0.32 -0.12 -0.23 -0.65 -0.10 
R3 -0.13 -0.25 -0.16 -0.18 -0.62 -0.07 
R4 -0.13 -0.32 -0.08 -0.18 -0.65 -0.07 
R5 -0.07 -0.27 -0.05 -0.22 -0.62 -0.06 
R6 -0.28 -0.42 -0.16 -0.36 -0.76 -0.16 
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R7 -0.20 -0.39 -0.16 -0.23 -0.68 -0.12 
R8 -0.19 -0.37 -0.12 -0.20 -0.67 -0.10 
Chapter 7  Docking Studies 
Dept. of Pharmaceutical chemistry, JKKNCP. Page | 57
8. DOCKING STUDY 
8.1. Docking Studies of Synthesized Compound on Various Enzymes  
8.1.1. Introduction 
In the field of molecular modeling, docking is a method which predicts the 
preferred orientation of one molecule to second when bound to each other to form a 
stable complex and it is also key tool in structural molecular biology and computer 
assisted drug design. Docking is frequently used to predict the binding orientation of 
small molecule drug candidates to their protein targets in order to in turn predict the 
affinity and activity of the small molecule57. The small molecule, known as ligand 
usually fits within the proteins cavity which is predicted by search algorithm. These 
protein cavities become active when come in contact with any external compounds and 
are thus called as active sites. Hence docking plays an important role in the rational 
design in drugs58.  
Docking is a method which predicts the preferred orientation of one molecule to a 
second molecule when bound to each other to form a stable complex in three 
dimensional spaces. In cell biology, the function protein is a result of its interaction with 
other proteins as well as other molecule components. So if we could predict how protein 
interacts with other molecules, we could possibly inhibit the function. Thus the result of 
docking was extremely beneficial in finding drugs which are effective against particular 
disease. The knowledge of the preferred orientation in turn may be used to predict the 
strength of association or binding affinity between two molecules using scoring function. 
There is much commercially available docking software each using a different 
combination of searching method and algorithm and scoring function. These are 
• GOLD (Genetic Optimization for Ligand Docking) 
• Glide 
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• Drug Discovery 
• Auto dock 1.5.4 
Among these in my research work i have used auto dock software to calculate the free 
energy binding of ligand towards various target enzymes. 
  8.1.2. AUTODOCK 1.5.4 
Autodock is a software suite to develop in Scripps Research Institute. This 
software is used for modeling flexible small molecule such as drug molecule binding to 
receptor proteins. The current version of Autodcok uses genetic algorithm for the 
conformational search and is a suitable method for the docking studies. Scripps Research 
Institute has developed a Graphical User Interface (GUI) using Python 2.5 language, and 
it is called Autodock Tool (ADT). ADT is used to prepare, run and analyze the docking 
stimulation, in addition to its several features necessary for modeling studies.  
8.1.3. Major steps involved in molecular docking 
Step I – Building the receptor 
In this step the 3D structure of the receptor should be downloaded from PDB and 
modified. This should include removal of water molecules from the cavity, stabilizing 
charges, filling in the missing residue, generation of side chain etc., according to the 
parameters available. After modification the receptor should be biologically active and 
stable. 
Step II – Identification of active site 
After the receptor is build, the active site within the receptor should be identified. 
The receptor may have many active sites but the one of the interest should be selected.  
Step III – Ligand preparation  
Ligand can be obtain from various databases like ZINC, PubChem or can be 
sketched using tools like chemsketch. While selecting the ligand, the Lipinski rule of 5 
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should be applied.  The rule is very important for drug development where the 
pharmacologically active lead structure is optimized stepwise for increased activity and 
selectivity as well as drug like properties.  
 Step IV – Docking 
This is a last step, where the ligand is docked into receptor and the interaction are 
checked. The scoring function generates depending on which ligand with best fit was 
selected.  
8.2. MAP Kinase as target Enzyme 
Over the last decade, the pursuit of p38a MAP kinase inhibitors has received an 
extraordinary level of attention in the pharmaceutical industry and in the medicinal 
chemistry community. A unique combination of well-established pharmacology, clinical 
efficacy and the opportunity to utilize structure-based drug design has made this a highly 
attractive target for therapeutic intervention. There is overwhelming evidence indicating 
that p38a plays a dominant role in regulating the production of pro-inflammatory 
cytokines, such as tumor necrosis factor and interleukin-1. Blocking this kinase may 
offer an effective therapy for treating many inflammatory diseases. 
However great number of heterocyclic compounds display interesting anti-
inflammatory and anti-cancer especially benzimidazole and 4H–chromen–4–one 
derivatives having important role in this concern. Compounds containing benzimidazole 
rings, which are formed via the fusion of imidazole and benzene rings, have been used 
extensively for pharmaceutical purposes. 1H-Benzimidazole rings exhibit remarkable 
number of biologically activities due to their nitrogen content, which comprise the active 
substrate of several drugs. Benzimidazole derivatives possessing wide range biological 
activities like antibacterial, antifunga, anticancer, anti-HIV, anti-tubercular. Presence of 
chromene-based structure in a molecule is often associated with its capacity to prevent 
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diseases. Chromone containing compound exhibit anticancer, anti-HIV, antibacterial, 
anti-inflammatory agents, antimicrobial, antitumor, antiviral and mutagenic, anti-
proliferative and central nervous system activities. Both the derivatives produced various 
biological activities individually. Hence we are planned to incorporate both the nucleus 
by chemical reaction. The designed compound were evaluated for their molecular 
properties by the “Lipinski’s rule of 5” and further their ability to bind in the active site 
region of MAP Kinase identified using molecular docking approach. 
8.3. Molecular docking study  
In order to gain more insight on the binding mode of the compounds with MAP 
Kinase docking studies using Auto Dock 4.0.1 were carried out. Top scoring molecules 
from the largest cluster were considered for interaction studies. The crystallographic 
structure of MAP kinase, which is retrieved from the RCSB Protein Data Bank (PDB 
code 1CM8) serves as docking receptor, and all the designed compounds are selected as 
ligand molecules. Before docking the screened ligands in to the protein active site, the 
protein was prepared by deleting the substrate cofactor as well as the crystallographically 
observed water molecules and then protein was defined for generating the grid. All 
molecules were drawn using ChemDraw Ultra 8.0 tool and energy minimized using 
Chem 3D Ultra 8.0 software.  
8.5. Auto Dock 4.0.1 procedure 
Automated docking was used to locate the appropriate binding orientations and 
conformations of various inhibitors into the 1CM8 binding pocket. To perform the task, 
the powerful genetic algorithm method implemented in the program Auto Dock 4.0.1 
was employed. Grid maps were generated by AutoGrid program. Each grid was centered 
at the crystal structure of the corresponding 1G2A and 2GT1 separately. Lamarckian 
Genetic Algorithm was employed as the docking algorithm. The grid dimensions were 
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60 Å X 60 Å X 60 Å with points separated by 0.375 Å. For all ligands, random starting 
positions, random orientations and torsions were used. During docking, grid parameters 
were specified for x, y and z axes as 38.808, 30.946 and 42.249 respectively. The 
Docking parameters Number of Genetic Algorithm (GA) runs: 25, Population size: 150, 
Maximum number of evaluation: 2,500,000, Maximum number of generation: 27,000 
were used for this study. The structure with the lowest binding free energy and the most 
cluster members was chosen for the optimum docking conformation. 
Table 8.1: Energy minimization table of Ligand and MAP kinase 
Interaction 
Code 
Binding 
Energy 
(Kcal/mol) 
 
Inhibition 
Constant 
Vdw. 
Desolvation 
Energy 
Intermol 
Energy 
Ligand 
efficiency 
Electrostatic 
Energy 
Total 
internal 
R1 -7.79 2.04 -7.66 -8.96 -0.31 -1.3 1.19 
R2 -7.95 6.75 -7.83 -8.25 -0.27 -0.42 0.32 
R3 -7.28 6.42 -6.95 -8.28 -0.26 -1.33 -0.44 
R4 -6.41 20.04 -7.48 -7.6 -0.25 -0.12 -.044 
R5 -7.19 5.36 -8.71 -8.38 -0.28 -0.32 -0.42 
R6 -7.76 2.05 -7.73 -8.95 -0.3 -1.23 -0.41 
R7 -7.35 4.1 -8.71 -8.54 -0.28 0.17 -0.44 
R8 -6.58 14.98 -7.89 -8.07 -0.24 -0.19 -0.43 
Diclofenac -7.18 14.32 -8.98 -9.02 -0.32 -0.18 -0.32 
Imatinib  -7.27 53.99 -11.29 -11.65 -0.43 -0.19 -0.54 
 
8.6. Docking Analysis 
The newly designed molecules are energy minimized and the resulting molecules 
are considered for docking analysis using Auto Dock 4.0.1. Auto Dock is employed to 
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study the docking molecules within active site region of 1CM8 and the H-bond 
interaction. Docked scores of newly designed molecules along with inhibition constant, 
Vdw. Desolvation Energy, ligand efficacy and electrostatic energy and hydrogen bonds 
are represented in Table 8.1. and table 8.2. respectively. Among the studied compounds, 
compound R1 have highest binding score (-7.79 K Cal/mol with one hydrogen bond) 
when compared with standard drugs such as Diclofenac -7.18 K Cal/mol (for anti-
inflammatory) and Imatinib -7.27 K Cal/mol (for Anti-cancer) followed by compound 
R6 with score of -7.76 K Cal/mol with one hydrogen bond, compound R5 with score of  
-7.19 K Cal/mol with one hydrogen bond, compound R3 have score of –7.28 with two 
hydrogen bond and lastly compound R4 with score of -6.41 K Cal/mol with one 
hydrogen bond. The docked molecule with MAP Kinase was visualized in Chimara 
software and the docking pose of compounds showed in figure 2 – 5. Docking results 
show that all the designed molecules have similar orientations in the binding pocket of 
MAP Kinase enzyme.  
Table 8.2: Hydrogen bond and hydrophobic interaction of ligand against target enzyme 
MAP kinase 
 
Compound 
code 
No. of 
Hydrogen 
bonds formed 
Amino acid 
involved in H 
bond interaction 
H bond 
distance 
Amino acid 
involved in 
vander waals 
interaction 
R1 1 Agr 82 2.93 
His 80, His 83, Lys 
139, Arg 142, Tyr 
143, Val 323, Gln 
324 
R2 Nil Nil Nil 
Gly 117, Met 120, 
Pro 156, Gly 157, 
Glu 218, Gly 222. 
R3 2 1. Lys 118 2. Lys 121 
2.771 
2.753 
Gly 117, Lys 118, 
Met 120, Glu 218 
R4 1 Asn 119 2.836 
Leu 193, Leu 253, 
Phe 249, Apg 252, 
Leu 294 
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R5 1 THR 242 2.75 
His 80, Arg 82, 
His 83, Lys 139, 
Val 323, Gln 324 
R6 1 TYR 143 3.327 
His 80, Arg 82, 
His 83, Lys 139, 
Arg 142, Tyr 143, 
Val 323, Gln 324 
R7 Nil Nil Nil 
Arg 142, Phe 249, 
Met 120, Glu 218, 
Tyr 143, Val 323 
R8 1 Arg 252 2.67 
Leu 253, Phe 249, 
Apg 252, Gln 254, 
Leu 294. 
Diclofenac Nil Nil Nil Met 120, Glu 218, Val 323, Gln 324. 
Imatinib Nil Nil Nil 
His 80, Arg 82, 
Arg 142, Glu 218, 
Val 323, Gln 324 
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Figure 8.1: Docking pose of compound R1 against MAP Kinase as Target Enzyme 
 
 
Figure 8.2: Docking pose of compound R2 against MAP Kinase as Target Enzyme 
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Figure 8.3: Docking pose of compound R3 against MAP Kinase as Target Enzyme 
 
 
 
Figure 8.4: Docking pose of compound R4 against MAP Kinase as Target Enzyme 
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Figure 8.5: Docking pose of compound R5 against MAP Kinase as Target Enzyme 
 
 
 
Figure 8.6: Docking pose of compound R6 against MAP Kinase as Target Enzyme 
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Figure 8.7: Docking pose of compound R7 against MAP Kinase as Target Enzyme 
 
 
 
Figure 8.8: Docking pose of compound R8 against MAP Kinase as Target Enzyme 
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Figure 8.9: Docking pose of standard drug (Imatinib) against MAP Kinase as Target 
Enzyme 
 
 
 
Figure 8.10: Docking pose of standard drug (Diclofenac) against MAP Kinase as Target 
Enzyme 
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9. IN-VITRO ANTICANCER ACTIVITY 
9.1. Introduction  
Cancers are a large family of diseases which involve abnormal cell growth with 
the potential to invade or spread to other parts of the body. They form a subset of 
neoplasms. A neoplasm or tumor is a group of cells that have undergone unregulated 
growth, and will often form a mass or lump, but may be distributed diffusely. 
Six characteristics of cancer have been proposed: 
• Self-sufficiency in growth signaling 
• Insensitivity to anti-growth signals 
• Evasion of apoptosis 
• Enabling of a limitless replicative potential 
• Induction and sustainment of angiogenesis 
• Activation of metastasis and invasion of tissue. 
The progression from normal cells to cells that can form a discernible mass to 
outright cancer involves multiple steps known as malignant progression. 
The great majority of cancers, some 90–95% of cases, are due to environmental 
factors. The remaining 5–10% is due to inherited genetics. Environmental, as used by 
cancer researchers, means any cause that is not inherited genetically, such as lifestyle, 
economic and behavioral factors, and not merely pollution. Common environmental 
factors that contribute to cancer death include tobacco (25–30%), diet and obesity (30–
35%), infections (15–20%), radiation (both ionizing and non ionizing, up to 10%), stress, 
lack of physical activity, and environmental pollutants. 
 
 
9.2. Anticancer Drug Development 
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Around the world, tremendous resources are being invested in prevention, 
diagnosis, and treatment of cancer. Cancer is the second leading cause of death in Europe 
and North America. Discovery and development of anticancer agents are the key focus 
of several pharmaceutical companies as well as nonprofit government and non-
government organizations, like the National Cancer Institute (NCI) in the United States, 
the European Organization for Research and Treatment of Cancer (EORTC), and the 
British Cancer Research Campaign (CRC). 
Identification of cytotoxic compounds led the development of anticancer 
therapeutics for several decades. Advances in cancer treatment, however, continued to be 
limited by the identification of unique biochemical aspects of malignancies that could be 
exploited to selectively target tumor cells. Schwartsmann et al. noted in 1988 that of over 
600,000 compounds screened by then, less than 40 agents were routinely used in the 
clinic. The recent growth in molecular sciences and the advances in genomics and 
proteomics have generated several potential new drug targets, leading to changes in the 
paradigms of anticancer drug discovery toward molecularly targeted therapeutics. These 
shifting paradigms have not only resulted in the greater involvement of biological 
scientists in the drug discovery process but also required changes in the screening and 
clinical evaluation of drug candidates. Both small and large molecular compounds 
continue to be investigated as anticancer agents. 
The discovery and development of anticancer drugs, especially cytotoxic agents, 
differ significantly from the drug development process for any other indication. The 
unique challenges and opportunities in working with these agents are reflected in each 
stage of the drug development process. This chapter will highlight the unique aspects of 
anticancer drug discovery and development. 
9.3. In-Vitro Anticancer Activity by SRB Assay 
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In order to study the anti tumor activity of new compound, it is important to 
determine the cytotoxicity concentration of the compound. Cytotoxicity tests define the 
upper limit of the extract concentration, which is non toxic to the cell line. After the 
addition of the drug, cell death and cell viability was estimated. The result is confirmed 
by additional metabolic intervention experiment such as SRB assay. 
9.3.1. Materials Required SRB Assay 
1. Monolayer culture in log phase 
2. Drug extracts (different concentration) 
3. 0.45 filter 
4. 5mL sterile storage vials 
5. Tissue paper, Marker pen, Spirit, Cotton, and Gloves 
6. 1mL, 2mL pipettes, Micropipettes and tips 
7. Discarding Jar with 1% Hypochlorite solution 
9.3.2. SRB Assay introduction 
The sulforhodamine B (SRB) assay, which was developed in 1990, remains one 
of the most widely used methods for in vitro cytotoxicity screening. The assay relies on 
the ability of SRB to bind to protein components of cells that have been fixed to tissue 
culture plates by trichloroacetic acid (TCA). SRB is a bright-pink aminoxanthene dye 
with two sulfonic groups that bind to basic amino-acid residues under mild acidic 
conditions, and dissociate under basic conditions. As the binding of SRB is 
stoichiometric, the amount of dye extracted from stained cells is directly proportional to 
the cell mass. 
The strong intensity of SRB staining allows the assay to be carried out in a 96-
well format showed that the assay can detect densities as low as 1,000–2,000 cells per 
well. The SRB method has proven to be practical, because after the TCA-fixed and SRB-
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stained cell monolayers are dried they can be stored indefinitely. Color extracted from 
SRB-stained cells is also stable. With its high level of sensitivity, adaptability to the 96-
well format and endpoint stability, the SRB assay is well suited to large-scale screening 
applications, as well as research.  
This assay has been widely used for drug-toxicity testing against different types 
of cancerous and non-cancerous cell lines. Other cell-growth assays have been employed 
to assess drug efficacy against both intracellular pathogens and host cells simultaneously 
in co-cultures and it is possible to use the SRB method for this purpose. In addition, the 
SRB method has also been shown to be effective for in vitro testing of cancer cell 
sensitivity to radiation, and for the study of interactions between radiotherapy and 
chemotherapy, with sensitivity comparable to that of the standard clonogenic assay. 
The application of the SRB assay is limited to manual or semiautomatic 
screening due to the multiple washing and drying steps, which, at present, are not 
amenable to automation. This method nevertheless provides an efficient and sensitive 
tool for screening, especially for use in less well-equipped laboratories.  
Calculate the percentage of cell-growth inhibition using the formulae below. For primary 
screening, we use a threshold of 50% cell-growth inhibition as a cut-off for compound 
toxicity against cell lines. However, the threshold can be varied according to toxicity 
criteria defined by the investigators. For IC50 determination, plot a dose–response curve 
between the compound concentration and percent growth inhibition. IC50 values can be 
derived using curve-fitting methods with statistical analysis software or IC50 calculation 
software. 
 
9.3.3. EXPERIMENTAL PROCEDURE FOR SRB ASSAY 
• The cell lines were grown in RPMI 1640 medium containing 10% fetal bovine 
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serum and 2 mM L-glutamine. For present screening experiment, cells were 
inoculated into 96 well microtiter plates in 100 µL at plating densities as shown 
in the study details above, depending on the doubling time of individual cell 
lines. After cell inoculation, the microtiter plates were incubated at 37° C, 5 % 
CO2, 95 % air and 100 % relative humidity for 24 h prior to addition of 
experimental drugs.  
• Experimental drugs were initially solubilize in dimethyl sulfoxide at 100mg/ml 
and diluted to 1mg/ml using water and stored frozen prior to use. At the time of 
drug addition, an aliquote of frozen concentrate (1mg/ml) was thawed and diluted 
to 100 µg/ml, 200 µg/ml, 400 µg/ml and 800 µg/ml with complete medium 
containing test article. Aliquots of 10 µl of these different drug dilutions were 
added to the appropriate micro titer wells already containing 90 µl of medium, 
resulting in the required final drug concentrations i.e.10 µg/ml, 20 µg/ml, 40 
µg/ml, 80 µg/ml.  
• After compound addition, plates were incubated at standard conditions for 48 
hours and assay was terminated by the addition of cold TCA. Cells were fixed in 
situ by the gentle addition of 50 µl of cold 30 % (w/v) TCA (final concentration, 
10 % TCA) and incubated for 60 minutes at 4°C. The supernatant was discarded; 
the plates were washed five times with tap water and air dried. Sulforhodamine B 
(SRB) solution (50 µl) at 0.4 % (w/v) in 1 % acetic acid was added to each of the 
wells, and plates were incubated for 20 minutes at room temperature. After 
staining, unbound dye was recovered and the residual dye was removed by 
washing five times with 1 % acetic acid. The plates were air dried. Bound stain 
was subsequently eluted with 10 mM trizma base, and the absorbance was read 
on an plate reader at a wavelength of 540 nm with 690 nm reference wavelength.  
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• Percent growth was calculated on a plate-by-plate basis for test wells relative to 
control wells. Percent Growth was expressed as the ratio of average absorbance 
of the test well to the average absorbance of the control wells * 100.  
• Using the six absorbance measurements [time zero (Tz), control growth (C), and 
test growth in the presence of drug at the four concentration levels (Ti)], the 
percentage growth was calculated at each of the drug concentration levels. 
Percentage growth inhibition was calculated as:  
[Ti/C] x 100 % 
• In this study Adriamycin used as standard drug. The table 9.1 shows the SRB 
Assay of tested compounds against Human Lung Cancer Cell Line A-549. And 
the table 9.2 represents the LC50, TGI and GI50 values of the tested compound. 
• The Figure 9.2 represented the drug treated human cancer cell line A-549. 
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Table 9.1. The SRB Assay of tested compounds against Human Lung Cancer Cell Line 
A-549 
Code 
Human Lung Cancer Cell Line A-549 
% Control Growth 
 Drug Concentrations (µg/ml) 
Experiment 1 Experiment 2 Experiment 3 Average Values 
10 20 40 80 10 20 40 80 10 20 40 80 10 20 40 80 
R1 86.7 96.7 62.5 18.3 101.9 113.2 84.1 34.7 93.2 92.4 42.5 12.8 93.9 100.8 63.0 21.9 
R2 91.2 89.5 85.6 95.3 101.3 104.9 112.6 93.0 90.8 92.4 88.9 95.2 94.4 95.6 95.7 94.5 
R5 91.2 87.6 75.6 66.9 102.7 104.9 104.3 56.3 90.1 90.6 61.2 49.9 94.7 94.3 80.4 57.7 
R6  96.2 88.5 77.0 33.5 110.4 111.7 98.6 51.0 96.2 102.0 81.7 33.5 100.9 100.7 85.8 39.4 
R7 94.9 85.6 80.0 43.3 104.8 97.6 102.6 75.1 93.6 111.8 82.3 96.2 97.8 98.3 88.3 71.5 
ADR 10.0 5.1 -8.4 -1.2 8.4 5.0 10.4 6.1 4.7 2.6 -3.1 5.4 7.7 4.2 -0.4 3.4 
 
Table 9.2.  LC50, TGI and GI50 values of the tested compoun 
sample coode 
Drug concentrations (µg/ml) calculated from graph 
LC50 TGI GI50* 
R1 NE >80 55.1 
R2 NE >80 >80 
R5 NE >80 >80 
R6 NE >80 71.9 
R7 NE >80 >80 
ADR NE <10 <10 
 
Figure 9.2 Drug treated human cancer cell line A-549 
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10. RESULT AND DISCUSSION 
10.1. Synthetic methodology 
A series of novel class of (E)-2-(2-(5-nitro-1H-benzo[d]imidazol-2-yl)vinyl)-4H-
chromen-4-one Derivatives were synthesized by  using of 2-methyl-1H-
benzo[d]imidazole,   substituted chromone-3-carbaldehyde in presence of GAA. 
10.2. Characterization of synthesized compound 
 The purity of synthesized compounds was confirmed by Melting Point and TLC 
using Ethyl Acetate: Petroleum Ether (50:50) as solvent system. 
 The structures of synthesized compounds were confirmed by FT-IR, 1H-NMR, 
13C-NMR and Mass spectral analysis the result was correlated with the 
expected structure. 
10.3. Preliminary QSAR study: 
 The physic chemical character of title compounds were evaluated and given in 
the table 7.1. 
 Solubility parameters of synthesized compounds were tested, using various 
organic solvents and the result was tabulated in Table 7.2. 
 The synthesized compounds were subject to Preliminary QSAR studies by using 
MOLINSPIRATION software and the results are given in the Table7.3. All the 
synthesized compounds obey Lipinski rule of 5. 
10.4. Docking study 
 The docking study of the synthesized compound was carried out by using 
AUTODOCK software version 4.2 working system against target enzyme MAP 
Kinase as per the literature survey. 
 The docking result of the synthesized compounds showed binding score in active 
site of MAP Kinase between 7.0 and 7.90 K Cal/mol. 
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 Compounds R1, R2, R6, and R7 were found to have significant binding score 
against target enzyme MAP Kinase, compared to standard drugs such as 
Imatinib and Diclofenac.  
10.5. In vitro Anti-cancer Activity 
 Synthesized compounds R1, R2, R3, R6 and R7 were evaluated for 
anticancer activity by SRB assay method against Human Cancer Cell line 
A-549. 
 All tested compound exhibit moderate to good percentage of growth 
inhibition of Human Lung Cancer Cell Line A-549 when compared with 
the control drug Adriamycin.  
 
During the last twenty years, the study of the biological activities of chromene 
derivatives has been the aim of many scientists.59 Chromene-based natural and synthetic 
compounds have contributed substantially to the development of therapeutics as anti-
neoplastic agents against various human malignancies. Sesilin, tephrosin, calanone and 
acronycine are some of the chromene derivatives with a very good anti-cancer activity. 
An important breakthrough in the development of 4H-chromenes as anti-cancer agents 
was given by the discovery of MAP Kinase protein.  Imidazole and benzimidazole nuclei 
are the important and well known pharmacophores in drug discovery.60,61. There is a 
continual increase on the incidence of cancer and it is considered to be the leading cause 
of morbidity and mortality.62 Recently, considerable attention has been drawn on the 
search for novel anticancer drugs in order to improve survival rates and wellbeing. 
Benzimidazole derivatives are being explored in pharmaceutical industries and 
substituted benzimidazole derivatives have also been found in the diverse therapeutic 
applications such as in anti-ulcers, anti-hypertensives, anti-virals, anti-fungals, anti-
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cancers and anti-histaminics.63 On the other hand, such benzimidazole derivatives are 
condensed with other heterocycles like pyrazole, thiadiazole, triazole, thiazole, coumarin 
and 2-azetidinone moieties which have shown diverse pharmacological activities.64-71 
We targeted MAP Kinase protein for anticancer activity by benzimidazole containing 
4H- chromen-4-one Derivatives. We  designed some novel (E)-2-(2-(5-nitro-1H-
benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one Derivatives on the basis reaction 
between 2-methyl-1H-benzo[d]imidazole,   substituted chromone-3-carbaldehyde in 
presence of GAA and the synthesized compound were characterized by IR, 1H NMR, 13C 
NMR, Mass spectrometry and Elementary Analysis. The structures of the synthesized 
compounds were studied using Autodock software against different target enzymes. The 
docking results showed that Compounds R2, R3, R6, and R7 were found to have 
significant binding score against target enzyme MAP Kinase compared to standard drug 
Imatinib. Synthesized compound were evaluated for their in-vitro anti cancer activity by 
SRB assay method against Human Cancer Cell line A-549. From the result the 
compound R1 and R6 allowed only 21.9 and 39.4 of % cell growth at the concentration 
of 80µg/mL. Whereas other compounds has showed 57-94% 0f %cell growth. From the 
results the substitution on the Coumarin nucleus alter the biological activity. The un-
substituted (R4) and Flouro (R6) and Chloro (R1) substituted Coumarin derivatives were 
found to be potent by producing biological activity.  
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11. CONCLUSION 
 The present study deals with designing of some novel (E)-2-(2-(5-nitro-1H-
benzo[d]imidazol-2-yl)vinyl)-4H-chromen-4-one Derivatives on the basis reaction 
between 2-methyl-1H-benzo[d]imidazole,   substituted chromone-3-carbaldehyde 
in presence of GAA. 
 The synthesized compound were characterized by IR, 1H NMR, 13C NMR, Mass 
spectrometry and Elementary Analysis. 
 Preliminary QSAR study was carried out for the synthesized compounds. All the 
compounds obey the Lipnski rule of 5. 
 Solubility characters of synthesized compounds were carried out by using various 
solvents. The tested compounds are freely soluble in DMSO, soluble in 
Chloroform and Methanol, slightly soluble in Acetone, Ethyl Acetate and Ethanol 
and Insoluble in Water. 
 The structures of the synthesized compounds were studied using Autodock 
software against different target enzymes. The docking results showed that 
Compounds R2, R3, R6, and R7 were found to have significant binding score 
against target enzyme MAP Kinase compared to standard drug Imatinib.  
 Synthesized compound were evaluated for their in-vitro anti cancer activity by SRB 
assay method against Human Cancer Cell line A-549. From the result the compound 
R1 and R6 allowed only 21.9 and 39.4 of % cell growth at the concentration of 
80µg/mL. Whereas other compounds has showed 57-94% 0f %cell growth. 
 From the above, it may conclude that the substitution on the Coumarin nucleus 
alter the biological activity. The un-substituted (R4) and Flouro (R6) and Chloro 
(R1) substituted Coumarin derivatives were found to be potent by producing 
biological activity.        
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